PDF download Download full issue

ORIGINAL RESEARCH

Analysis of the Federal State Information System for Drug Traceability in the Republic of Adygea Abdokov I.A. (Russia, Maykop), Mamsirova S.K. (Russia, Maykop) P. 7

Specific characteristics of chronic obstructive pulmonary disease in patients with frequent exacerbations Aznabaeva Yu.G. (Russia, Ufa), Zulkarneev Sh.R. (Russia, Ufa), Korytina G.F. (Russia, Ufa), Zagidullin N.Sh. (Russia, Ufa) P. 12

Detection of biomarkers in biological fluids in ricin poisoning Barsegyan S.S. (Russia, Moscow), Kаlekin R.A. (Russia, Moscow), Vоlkova A.A. (Russia, Moscow), Orlova A.M. (Russia, Moscow) P. 22

Brain Parcellation as a tool for standardization of preoperative assessment of mass effect in glial tumors: A pilot MRI-based study Djuraeva N.M. (Uzbekistan, Tashkent), Ikramov A.I. (Uzbekistan, Tashkent), Abdukhalimova Kh.V. (Uzbekistan, Tashkent), Batalov A.I. (Russia, Moscow), Lebedenko A.V. (Russia, Moscow) P. 30

Association between clinical symptoms and laboratory parameters of calcium, magnesium, and phosphorus metabolism in patients with widespread musculoskeletal pain Zhilyaev G.E. (Russia, Moscow), Zhilyaev E.V. (Russia, Moscow), Kargaeva T.N. (Russia, Moscow), Gorshkov S.V. (Russia, Moscow), Malikova M.E. (Russia, Moscow), Sadikova D.R. (Russia, Moscow), Kucherenko A.I. (Russia, Moscow), Klimenko A.A. (Russia, Moscow) P. 41

Phytochemical composition of extracts obtained from the herb of Oxytropis pilosa and their effect on the growth of bacterial populations Karavaeva L.V (Russia, Saratov), Shapoval O.G. (Russia, Saratov), Matvienko U.A. (Russia, Saratov), Kulshan T.A. (Russia, Saratov), Durnova N.A. (Russia, Moscow) P. 50

Digital transformation of pharmaceutical supply: From challenges to regional solutions Mamsirova S.K. (Russia, Maykop), Umarov S.Z. (Russia, Saint Petersburg), Abdokov I.A. (Russia, Maykop) P. 60

Immune system status during vaccination in post-COVID-19 children Mullaeva L.Dzh.Gafarova F.M. (Uzbekistan, Tashkent), Mukhamedova S.Kh. (Uzbekistan, Tashkent) P. 66

Inflammatory markers associated with myocardial remodeling in patients with myocardial infarction Mushikhina N.A. (Russia, Tyumen), Tuzmukhametova O.Kh. (Russia, Tyumen), Gorbatenko E.A. (Russia, Tyumen), Shirokov N.E. (Russia, Tyumen), Tuzmukhametov O.Kh. (Russia, Tyumen), Dremina N.V. (Russia, Tyumen), Laggar O.N. (Russia, Tyumen) P. 72

Development of a gel formulation containing a liquid extract of jujube leaves and evaluation of its wound-healing activity Nikiforova E.B. (Russia, Moscow), Shevchenko A.I. (Russia, Krasnodar), Davitavyan N.A. (Russia, Krasnodar), Krylova I.N. (Russia, Moscow), Martirosyan L.K. (Russia, Krasnodar), Krivenkova O.V. (Russia, Moscow), Barannikova G.A. (Russia, Moscow) P. 81

Changes in interleukin-6 levels during atorvastatin and pitavastatin therapy in patients with ST-segment elevation acute coronary syndrome after percutaneous coronary intervention Nurieva L.M. (Russia, Kazan), Kim Z.F. (Russia, Kazan), Zakirova I.I. (Russia, Kazan), Abdullina R.R. (Russia, Kazan), Sharifullina G.Sh. (Russia, Kazan) P. 89

Relationship between oral health indicators, inflammatory markers in saliva, and cardiac pathology Ozden K.A. (Russia, Moscow), Galimova S.Sh. (Russia, Ufa), Vedenkin A.Yu. (Russia, Moscow),  Galimov K.Sh. (Russia, Ufa), Zhadan N.A. (Russia, Moscow), Kyarova L.Z. (Russia, Moscow), Galimova E.F. (Russia, Ufa) P. 95

Renal dysfunction in patients with myocardial infarction and various phenotypes of concomitant chronic obstructive pulmonary disease Prokofieva T.V. (Russia, Astrakhan), Polunin A.A. (Russia, Astrakhan), Belyakova I.S. (Russia, Astrakhan), Perova N.Y. (Russia, Astrakhan) P. 101

REVIEWS

Inula helenium L. as a source of active pharmaceutical substances: A review of recent advances in pharmacology Matvienko U.A. (Russia, Saratov), Karavaeva L.V. (Russia, Saratov), Kalyuta T.Yu. (Russia, Saratov), Phedonnikov A.S. (Russia, Saratov) P. 109

Dyslipidemia in pregnant women as a risk factor for gestational complications Molostvova A.F. (Russia, Kazan), Kim Z.F. (Russia, Kazan), Gabidullina R.I. (Russia, Kazan) P. 121

A review of the microbiota of the male urogenital tract in health and disease Fuzeynikov A.A. (Russia, Samara), Kanaev E.I. (Russia, Samara), Boriaev E.A. (Russia, Samara), Alekseev D.V (Russia, Samara) P. 131

Burden and phenotype of extrasystoles as determinants of prognosis Chepurnenko S.A. (Russia, Rostov-on-Don), Burtseva N.V. (Russia, Moscow), Shavkuta G.V. (Russia, Rostov-on-Don), Chepurnenko M.S. (Russia, Rostov-on-Don) P. 139

Infusion therapy in adult patients with sepsis and sepsis-associated acute respiratory distress syndrome: A systematic review of current strategies and an ultrasound-guided approach Sharipova V.Kh. (Uzbekistan, Tashkent), Rosstalnaya A.L. (Uzbekistan, Tashkent), Yuldosheva Sh.A. (Uzbekistan, Tashkent), Narimova M.I. (Uzbekistan, Tashkent) P. 146

Pharmacopuncture in stroke patients: An integrative approach to recovery and rehabilitation Ergasheva N.O. (Uzbekistan, Tashkent), Reyimberdiyeva K.I. (Uzbekistan, Tashkent), Maxamadxodjaeva M.A. (Uzbekistan, Tashkent), Sobirova S.K. (Uzbekistan, Tashkent), Alixonov S.A. (Uzbekistan, Tashkent), Mardonova X.J. (Uzbekistan, Tashkent), Abduqodirov E.I. (Uzbekistan, Tashkent) P. 157

PRACTICAL EXPERIENCE

Endoscopic management of choledocholithiasis in altered anatomy and topography of the major duodenal papilla: From technical limitations to functional outcomes Saifutdinov I.M. (Russia, Kazan) P. 163

___

ORIGINAL RESEARCH

УДК: 614.2:615.1

DOI: 10.20969/VSKM.2026.19(5 ).7-11

PDF download Analysis of the Federal State Information System for Drug Traceability in the Republic of Adygea

Inal A. Abdokov1, Svetlana K. Mamsirova2

1State Unitary Enterprise of the Republic of Adygea “Aptechnaya Baza” (Pharmaceutical Depot), 5a Zagorodnaya str., 385000 Maykop, Russia

2Maykop State Technological University, 191 Pervomayskaya str., 385000 Maykop, Russia

Abstract. Introduction. Federal State Information System for Drug Traceability (FSIS DT) has been deployed nationwide across the Russian Federation; however, its effectiveness at the regional level varies considerably. Aim. To conduct a systematic analysis of the implementation and operation of the Federal State Information System for Drug Traceability in the Republic of Adygea and to develop practical recommendations for improving the efficiency of preferential (social) drug provision. Material and Methods. We analyzed data from Rosstat (Federal State Statistics Service of Russia), TFOMI (Territorial Fund of Obligatory Medical Insurance), and Roszdravnadzor (Russian Federal Service for Surveillance in Healthcare) for the Republic of Adygea for the year 2025. We analyzed the documentary workflow and performed a technical assessment of the Federal State Information System for Drug Traceability operational schemes across 14 social pharmacies in the region. Descriptive statistical methods were applied, including calculating the arithmetic means, percentage ratios, and absolute values. Results and Discussion. It was established that 314 pharmacies serve 500.7 thousand people in the region. However, only 14 pharmacies (4.5%) participate in subsidized drug dispensing, creating a significant social burden: 35,766 beneficiaries per authorized pharmacy on average. In 4 out of 14 social pharmacies, outdated disposal registrars are still unsupported by the automatic DataMatrix code scanning. This leads to entering data manually, increasing by 7 minutes the average service time per reimbursed prescription, and elevating technical error rates to up to 5% of the total dispensing quantities. Implementation of a centralized drug delivery schedule from the warehouse of the State Unitary Enterprise of the Republic of Adygea “Aptechnaya Baza” (Pharmaceutical Depot) with fixed delivery frequencies (Monday, Wednesday, and Friday in Maykop; Tuesday in 4 districts; Thursday in 2 districts; and CITO (urgent) orders to be processed on the same day) reduced the average waiting time for subsidized medications from 12 down to 4 days – a threefold improvement, which significantly enhanced patient access to drug therapy. Consequently, the number of substantiated complaints to Roszdravnadzor decreased by 37% (from 215 in 2024 down to 135 in 2025), while the amounts of drug returns within the subsidized dispensing scheme fell by 28%. These outcomes confirm the increased efficiency of logistical processes and improved beneficiary satisfaction with drug supply organization. Nevertheless, persisting technical and organizational barriers necessitate further digitalization of inventory management and synchronization of the Federal State Information System for Drug Traceability data with the regional procurement system. Conclusions. Federal State Information System for Drug Traceability has demonstrated its effectiveness as a public oversight instrument. It is advisable to adjust procurement planning approaches and strengthen monitoring of executing the defer red prescriptions.

Keywords: Federal State Information System for Drug Traceability, FSIS DT, Republic of Adygea, subsidized drug dispensing, deferred prescriptions, reverse acceptance.

For citation: Abdokov, I.A.; Mamsirova, S.K. Analysis of the Federal State Information System for Drug Traceability in the Republic of Adygea. The Bulletin of Contemporary Clinical Medicine. 2026, 19 (5), 7-11. DOI: 10.20969/VSKM.2026.19(5).7-11.

REFERENCES

1. Постановление Правительства РФ от 14.12.2018 № 1556 (ред. от 24.04.2025) «Об утверждении Положения о системе мониторинга движения лекарственных препаратов для медицинского применения» // Собрание законодательства РФ. – 2018. – № 52. – Ст . 8284. Postanovlenie Pravitel’stva RF ot 14.12.2018 № 1556 (red. ot 24.04.2025) «Ob utverzhdenii Polozheniya o sisteme monitoringa dvizheniya lekarstvennykh preparatov dlya meditsinskogo primeneniya» [Decree of the Government of the Russian Federation No. 1556 dated December 14, 2018 (as amended on April 24, 2025) “On Approval of the Regulations on the System for Monitoring the Movement of Medicines for Medical Use”]. Sobranie zakonodatel’stva RF [Collecti on of Legislation of the Russian Federation]. 2018; (52): Art 8284. (In Russ.)

2. Баглей Д.В. Матрица фарммаркировки 2.0.2.0. Производство и импорт лекарственных препаратов: практическое пособие / под ред. Г.Б. Иноземцева. – Москва: Издательский дом «Бионика», 2020. – 320 с. Bagley DV. Matritsa farmmarkirovki 2.0.2.0; Proizvodstvo i import lekarstvennykh preparatov: prakticheskoye posobiye; pod redakciey GB Inozemtseva [Pharmaceutical Labeling Matrix 2.0.2.0; Production and Import of Medicines: A Practical Guide; edited by G.B. Inozemtsev]. Moskva: Izdatel’skiy dom «Bionika» [Moscow: Bionika Publishing House]. 2020; 320 p. (In Russ.)

3. Гацан В.В. Теоретические и методологические основы разработки системы территориального лекарственного обеспечения населения на примере Северо-Кавказского района: автореф. дис. д-ра фармац. наук : 15.00.01. – Пятигорск, 2002. – 42 с. Gatsan VV. Teoreticheskie i metodologicheskie osnovy razrabotki sistemy territorial’nogo lekarstvennogo obespecheniya naseleniya na primere Severo-Kavkazskogo rayona : avtoreferat dissertatsii na soiskaniye stepeni doktora farmatsevticheskikh nauk [Theoretical and methodological foundations for developing a system of territorial drug provision for the population using the example of the North Caucasus region: Abstract of the dissertation of the Doctor of Pharmaceutical Sciences]. Pyatigorsk [Pyatigorsk]. 2002; 42 p. (In Russ.)

4. Назарова В.В., Борисенкова К.А. Оценка эффективности системы здравоохранения в России // Народонаселение. – 2017. – № 4. – С. 119-134. Nazarova VV, Borisenkova KA. Otsenka effektivnosti sistemy zdravookhraneniya v Rossii [Evaluation of the healthcare system efficiency in Russia]. Narodonaselenie [Population]. 2017; (4): 119-134. (In Russ.) DOI: 10.26653/1561-7785-2017-4-9

5. Федеральная служба государственной статистики. Данные по Республике Адыгея на 01.01.2025. Форма № 1-здрав. – Москва: Росстат , 2025. Federal’naya sluzhba gosudarstvennoy statistiki [Federal State Statistics Service]. Dannye po Respublike Adygeya na 01.01.2025. Forma № 1-zdrav [Data on the Republic of Adygeya as of 01.01.2025. Form No. 1-zdrav]. Moskva: Rosstat [Moscow: Rosstat]. 2025. (In Russ.)

6. Территориальный фонд обязательного медицинского страхования Республики Адыгея. Отчёт о деятельности за 2024 год. – Майкоп: ТФОМС РА, 2025. Territorial’nyy fond obyazatel’nogo meditsinskogo strakhovaniya Respubliki Adygeya [Territorial Compulsory Medical Insurance Fund of the Republic of Adygeya]. Otchet o deyatel’nosti za 2024 god [Report on activities for 2024]. Maykop: TFOMS RA [Maykop: TFOMS RA]. 2025. (In Russ.)

7. Федеральный закон от 17.07.1999 № 178-ФЗ (ред. от 28.12.2024) «О государственной социальной помощи» // Собрание законодательства РФ. – 1999. – № 29. – Ст . 3699. Federal’nyy zakon ot 17.07.1999 № 178-FZ (red. ot 28.12.2024) «O gosudarstvennoy sotsial’noy pomoshchi» [Federal Law No. 178-FZ dated July 17, 1999 (as amended on December 28, 2024) “On State Social Assistance”]. Sobranie zakonodatel’stva RF [Collection of Legislation of the Russian Federation]. 1999; (29): Art 3699. (In Russ.)

8. Гражданкина А.А., Каракулова Е.В. Анализ факторов, влияющих на затраты в системе льготного лекарственного обеспечения детей с сахарным диабетом 1 типа // Фармакоэкономика: теория и практика. – 2025. – Т .13. – № 3. – С.5-12. Grazhdankina AA, Karakulova EV. Analiz faktorov, vliyayushchikh na zatraty v sisteme l’gotnogo lekarstvennogo obespecheniya detey s sakharnym diabetom 1 tipa [Analysis of factors affecting costs in the preferential drug provision system for children with type 1 diabetes mellitus]. Farmakoekonomika: teoriya i praktika [Pharmacoeconomics: Theory and Practice]. 2025; 13(3): 5-12. (In Russ.) DOI: 10.30809/phe.3.2025.1

9. Совместный приказ Министерства здравоохранения Республики Адыгея и Территориального фонда обязательного медицинского страхования Республики Адыгея от 01.10.2025 № 829а/108-ОД «Об утверждении Порядка взаимодействия участников обязательного медицинского страхования». Sovmestnyy prikaz Ministerstva zdravookhraneniya Respubliki Adygeya i Territorial’nogo fonda obyazatel’nogo meditsinskogo strakhovaniya Respubliki Adygeya ot 01/10/2025 № 829a/108-OD «Ob utverzhdenii Poryadka vzaimodeystviya uchastnikov obyazatel’nogo meditsinskogo strakhovaniya» [Joint Order of the Ministry of Health of the Republic of Adygeya and the Territorial Compulsory Health Insurance Fund of the Republic of Adygeya No 829a/108-OD dated October 1, 2025 “On Approval of the Procedure for Interaction of Participants in Compulsory Health Insurance”]. 2025. (In Russ.)

10. Методические рекомендации по работе участников оборота лекарственных препаратов в период действия уведомительного режима работы ФГИС МДЛП / ООО «Оператор-ЦРПТ». – Москва, 2020. – 11 с. Metodicheskie rekomendatsii po rabote uchastnikov oborota lekarstvennykh preparatov v period deystviya uvedomitel’nogo rezhima raboty FGIS MDLP [Methodological  recommendations for participants in the circulation of medicinal products during the notification mode of the FSIS MDP]. Moscow: Operator-CRPT [Moscow: LLC “Operator-CRPT”]. 2020; 11 p. (In Russ.)

11. Каракозова В.В., Кныш О.И., Каракозов С.В. Организационно-методическое решение проблемы регистрации выбытия из оборота маркированных лекарственных средств в аптеке медицинской организации // Современные проблемы здравоохранения и медицинской статистики. – 2021. – № 4. – С.23-37. Karakozova VV, Knysh OI, Karakozov SV. Organizatsionno-metodicheskoe reshenie problemy registratsii vybytiya iz oborota markirovannykh lekarstvennykh sredstv v apteke meditsinskoy organizatsii [Organizational and methodological solution to the problem of recording the disposal of labeled medicines in a pharmacy of a medical organization]. Sovremennye problemy zdravookhraneniya i meditsinskoy statistiki [Modern problems of health care and medical statistics]. 2021; (4): 23-37. (In Russ.)

12. Об обратном порядке акцептования при ввозе лекарственных препаратов в Российскую Федерацию: разъяснения PharmaTrace [Электронный ресурс] // Фармацевтический вестник. – 10 сентября, 2020. Ob obratnom poryadke aktseptovaniya pri vvoze lekarstvennykh preparatov v Rossiyskuyu Federatsiyu: raz”yasneniya PharmaTrace [On the reverse acceptance procedure for the import of medicinal products into the Russian Federation: explanations from PharmaTrace]. Farmatsevticheskiy vestnik [Pharmaceutical Bulletin]. 2020. (In Russ.) Режим доступа [Available from]: https://pharmvestnik.ru/content/news/V-PharmaTrace-obyasnili-pryamuu-rabotu-obratnogo-poryadka.html

13. Загузова Е.В., Глембоцкая Г.Т ., Абросимова Н.В. Территориально-отраслевая дифференциация социальных предприятий в отечественной медицине и фармации // Современные проблемы здравоохранения и медицинской статистики. – 2025. – № 5. – С.18-30. Zaguzova EV, Glembotskaya GT, Abrosimova NV. Territorial’no-otraslevaya differentsiatsiya sotsial’nykh  predpriyatiy v otechestvennoy meditsine i farmatsii [Territorial-sectoral differentiation of social enterprises in domestic medicine and pharmacy]. Sovremennye problemy zdravookhraneniya i meditsinskoy statistiki [Modern problems of health care and medical statistics]. 2025; (5): 18-30. (In Russ.)

14. Сушкова М.С. Пути оптимизации отбора и адаптации персонала аптечных организаций : автореф. дис. ... канд. фарм. наук. – Пермь, 2023. – 24 с. Sushkova MS. Puti optimizatsii otbora i adaptatsii personala aptechnykh organizatsiy : avtoreferat dissertatsii na soiskaniye stepeni kandidata farmatsevticheskikh nauk [Ways to optimize the selection and adaptation of personnel for pharmacy organizations: abstract of the dissertation of the Candidate of Pharmaceutical Sciences]. Perm [Perm]. 2023; 24 p. (In Russ.)

15. Сидорчук Р.Р ., Глазкова О.С. Маркетинговый аспект маркировки лекарств в странах Европейского союза и Российской Федерации // Международный научно-исследовательский журнал. – 2021. – № 4 (106). – С. 43-47. Sidorchuk RR, Glazkova OS. Marketingovyy aspekt markirovki lekarstv v stranakh Yevropeyskogo soyuza i Rossiyskoy Federatsii [Marketing aspect of medicines labeling in European Union countries and Russian Federation]. Mezhdunarodnyy nauchno-issledovatel’skiy zhurnal [International Research Journal]. 2021; 4(106): 43-47. (In Russ.)

 

 

УДК: 616.24-007.63

DOI: 10.20969/VSKM.2026.19(5).12-21

PDF download Specific characteristics of chronic obstructive pulmonary disease in patients with frequent exacerbations

Yulia G. Aznabaeva1, Shamil R. Zulkarneev1, Gulnaz F. Korytina1,2, Naufal Sh. Zagidullin1

1 Bashkir State Medical University, 3 Lenin str., 450000 Ufa, Russia

2 Institute of Biochemistry and Genetics – Subdivision of the Ufa Federal Research Centre of the Russian Academy of Sciences, 71 Oktyabr Ave., 450054 Ufa, Russia

Abstract. Introduction. Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition characterized by persistent respiratory symptoms, recurrent exacerbations, and progressive airflow limitation. Globally, COPD ranks as the third leading cause of mortality. The frequent exacerbator COPD phenotype is associated with an accelerated decline in lung function, impaired health-related quality of life, and increased mortality, underscoring the need for both molecular-genetic investigations and comprehensive clinical characterization of this specific patient subgroup. Aim. To provide a comprehensive clinical characterization of the frequent exacerbator COPD phenotype, incorporating previously obtained data on the phenotype-associated genetic markers of the disease. Materials and Methods. A total of 200 patients were enrolled, comprising 150 individuals with the frequent exacerbator phenotype and 50 with the non-frequent exacerbator phenotype. The assessment included anamnestic, clinical, and spirometric data, comorbidity profiles, and baseline inhalation therapy for COPD. Statistical analysis was performed using non-parametric methods, such as Mann–Whitney U test and Chi-square test. Results and Discussion. Patients with frequent exacerbations exhibited significantly greater symptom burden: median mMRC score was 3 [3; 4] versus 3 [2; 3] in the infrequent exacerbations group (p < 0.001); median CAT score was 23 [19; 26] versus 17 [13.7; 23.2], respectively (p < 0.001). Greater obstructive ventilatory impairment was also observed in the frequent exacerbator group: median Forced Vital Capacity was 74.9% [62.0; 89.6] versus 85.2% [72.8; 93.1] (p = 0.016); median Forced Expiratory Volume in one second was 39.8% [29.8; 49.0] versus 55.8% [40.6; 66.6] (p < 0.001); median of Forced Expiratory Volume in one second and Forced Vital Capacity ratio was 44.5% [36.9; 53.9] versus 54.1% [46.2; 62.5] (p < 0.001). More frequent applying of Inhaled corticosteroids as part of combination therapy was reported in the frequent exacerbator group: 72/150 (48%) versus 8/50 (16%) (p < 0.001). A markedly higher rate of disability certification due to any cause was observed among frequent exacerbators: 112/150 (74.7%) versus 24/50 (48%) (p < 0.001). No statistically significant differences were found between groups in the average age of patients at the time of diagnosis of the disease, smoking index (pack-years), smoking status, Charlson Comorbidity Index or body mass index. Conclusions. The frequent exacerbator phenotype of COPD is characterized by more severe respiratory symptoms, greater airflow obstruction, frequent use of inhaled corticosteroids in baseline therapy, and a high rate of disability. These clinical features correlate with the previously observed downregulation of inflammatory response molecule expression in this patient subgroup.

Keywords: chronic obstructive pulmonary disease, phenotype, exacerbations, obstruction severity, genotypic characteristics, comorbidity.

For citation: Aznabaeva Y.G., Zulkarneev Sh.R., Korytina G.F., Zagiddullin N.Sh. Specific characteristics of chronic obstructive pulmonary disease in patients with frequent exacerbations. The Bulletin of Contemporary Clinical Medicine. 2026, 19(5), 12-21. DOI: 10.20969/VSKM.2026.19(5).12-21.

REFERENCES

1. Celli B, Fabbri L, Criner G, et al. Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its Revision. Am J Respir Crit Care Med. 2022; 206 (11): 1317-25. DOI: 10.1164/rccm.202204-0671PP

2. Global Strategy for Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (updated 2024) [Электронный ресурс] / Global Initiative for Chronic Obstructive Lung Disease. – 2024. URL: https://goldcopd.org/wp-content/uploads/2024/01/GOLD-2024_v1.2-11Jan24_WMV-1.pdf

3. Global Strategy for Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (updated 2026) [Электронный ресурс] / Global Initiative for Chronic Obstructive Lung Disease. – 2025. URL: https://goldcopd.org/wp-content/uploads/2026/01/GOLD-REPORT-2026-v1.3-8Dec2025_WMV2.pdf

4. Авдеев С.Н., Лещенко И.В., Айсанов З.Р. Хроническая обструктивная болезнь легких (ХОБЛ 2024). Клинические рек омендации (кратк ая версия) // Респираторная медицина. – 2025. – Т. 1, вып. 2. – С. 5–16. Avdeev SN, Leshchenko IV, Aisanov ZR. Khronicheskaya obstruktivnaya bolezn’ legkikh (KhOBL 2024). Klinicheskie rekomendatsii (kratkaya versiya) [Chronic obstructive pulmonary disease (COPD 2024). Clinical guidelines (short version)]. Respiratornaya meditsina [Journal of Respiratory Medicine]. 2025; 1 (2): 5–16. (In Russ.) DOI: 10.17116/respmed202510215

5. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010; 182 (5): 598–604. DOI: 10.1164/rccm.200912-1843CC

6. Pavord ID, Jones PW, Burgel PR, Rabe KF. Exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2016; 11 (Spec Iss): 21–30. DOI: 10.2147/COPD.S85978

7. Le Rouzic O, Roche N, Cortot AB, et al. Defining the “frequent exacerbator” phenotype in COPD: a hypothesis-free approach. Chest. 2018; 153: 1106–1115. DOI: 10.1016/j.chest.2017.10.009

8. McGarvey L, Lee AJ, Roberts J, et al. Characterisation of the frequent exacerbator phenotype in COPD patients in a large UK primary care population. Respir Med. 2015; 109: 228–237. DOI: 10.1016/j. rmed.2014.12.00611

9. Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respiratory Research. 2010; 11 (1): 122. DOI: 10.1186/1465-9921-11-122

10. Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012; 67 (11): 957-963. DOI: 10.1136/thoraxjnl-2011-201518

11. Couper D, LaVange LM, Han M, et al. Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). Thorax. 2014; 69 (5): 491-494. DOI: 10.1136/thoraxjnl-2013-203897

12. Song Q, Lin L, Cheng W, et al. Clinical-functional characteristics and risk of exacerbation and mortality among more symptomatic patients with chronic obstructive pulmonary disease: a retrospective cohort study. BMJ Open. 2023; 13 (3): e065625. DOI:10.1136/bmjopen-2022-065625

13. Корытина Г.Ф., Ахмадишина Л.З., Кочетова О.В., [и др.]. Исследование ассоциации полиморфных вариантов генов С-реактивного белка (CRP), рецептора CD14, провоспалительных цитокинов и их рецепторов (TNFA, LTA, TNFRSF1A, TNFRSF1B, IL1B, IL6) с развитием хронической обструктивной болезни легких // Генетика. – 2020. – Т . 56, вып. 8. – С. 953–963. Korytina GF, Akhmadishina LZ, Kochetova OV, et al. Issledovanie assotsiatsii polimorfnykh variantov genov S-reaktivnogo belka (CRP), retseptora CD14, provospalitel’nykh tsitokinov i ikh retseptorov (TNFA, LTA, TNFRSF1A, TNFRSF1B, IL1B, IL6) s razvitiem khronicheskoy obstruktivnoy bolezni legkikh [Study of the association of polymorphic variants of C-reactive protein (CRP) genes, CD14 receptor, proinflammatory cytokines and their receptors (TNFA, LTA, TNFRSF1A, TNFRSF1B, IL1B, IL6) with the development of chronic obstructive pulmonary disease]. Genetika [Genetics]. 2020; 56 (8): 953–963. (In Russ.) DOI: 10.31857/S0016675820080081

14. Корытина Г.Ф., Азнабаева Ю.Г ., Темнов М.Ю., [и др.]. Молекулярные механизмы фенотипической гетерогенности хронической обструктивной болезни легких: роль JAK/STAT-, NFKB1-сигнального пути и молекул иммунного ответа // Медицинская генетика. – 2020. – Т . 19 (217), вып. 8. – С. 100–104. Korytina GF, Aznabaeva YuG, Temnov MYu, et al. Molekulyarnye mekhanizmy fenotipicheskoy geterogennosti khronicheskoy obstruktivnoy bolezni legkikh: rol’ JAK/STAT-, NFKB1-signal’nogo puti i molekul immunnogo otveta [Molecular mechanisms of phenotypic heterogeneity of chronic obstructive pulmonary disease: the role of JAK/STAT-, NFKB1-signaling pathway and immune response molecules]. Meditsinskaya genetika [Medical Genetics]. 2020; 19 (217) (8): 100–104. (In Russ.) DOI: 10.25557/2073-7998.2020.08.100-104

15. Корытина Г.Ф., Маркелов В.А., Ахмадишина Л.З., [и др.]. Вклад генов НАД-зависимых деацетилаз семейства сиртуинов в фенотипическую гетерогенность хронической обструктивной болезни легких // Якутский медицинский журнал. – 2023. – Т. 83, вып. 3. – С. 14–18. Korytina GF, Markelov VA, Akhmadishina LZ, et al. Vklad genov NAD-zavisimykh deatsetilaz semeystva sirtuinov v fenotipicheskuyu geterogennost’ khronicheskoy obstruktivnoy bolezni legkikh [Contribution of NAD-dependent deacetylase sirtuin family genes to the phenotypic heterogeneity of chronic obstructive pulmonary disease]. Yakutskiy meditsinskiy zhurnal [Yakut Medical Journal]. 2023; 83 (3): 14–18. (In Russ.) DOI: 10.25789/YMJ.2023.83.03

16. Маркелов В.А., Ахмадишина Л.З., Насибуллин Т.Р ., [и др.]. Вклад генов транскрипционных факторов семейства FOXO (FOXO1, FOXO3) в развитие хронической обструктивной болезни легких // Вавиловский журнал генетики и селекции. – 2025. – Т . 29, вып. 6. – С. 828–837. Markelov VA, Akhmadishina LZ, Nasibullin TR, et al. Vklad genov transkriptсionnykh faktorov semeystva FOXO (FOXO1, FOXO3) v razvitie khronicheskoy obstruktivnoy bolezni legkikh [Contribution of transcription factor genes of the FOXO family (FOXO1, FOXO3) to the development of chronic obstructive pulmonary disease]. Vavilovskiy zhurnal genetiki i selektsii [Vavilov Journal of Genetics and Breeding]. 2025; 29 (6): 828–837. (In Russ.) DOI: 10.18699/vjgb-25-90

17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40 (5): 373-383. DOI: 10.1016/0021-9681(87)90171-8

18. Pavord ID, Jones PW, Burgel PR, Rabe KF. Exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2016; 11 (Spec Iss): 21–30. DOI: 10.2147/COPD.S85978

19. Wu YK, Su WL, Yang MC et al. Characterization Associated with the Frequent Severe Exacerbator Phenotype in COPD Patients. Int J Chron Obstruct Pulmon Dis. 2021; 16: 2475-2485. DOI: 10.2147/COPD.S317177

20. Reilev M, Pottegård A, Lykkegaard J, et al. Increased risk of major adverse cardiac events following the onset of acute exacerbations of COPD. Respirology. 2019; 24 (12): 1183-1190. DOI: 10.1111/resp.13620

21. Wallström O, Stridsman C, Lindberg A, et al. Exacerbation History and Risk of Myocardial Infarction and Pulmonary Embolism in COPD. Chest. 2024; 166 (6): 1347-1359. DOI: 10.1016/j.chest.2024.07.150

22. Hou D, Liu Z, Li X, et al. Impacts of COPD exacerbation history on mortality and severe cardiovascular events among patients with COPD in China: a retrospective cohort study. Respir Res. 2025; 26 (1): 252. DOI: 10.1186/s12931-025-03316-4

23. Hong YJ, Kim Y, Moon JY, et al. Associations between depression and anxiety index and frequency of acute exacerbation in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2023; 17: 17534666231216591. DOI: 10.1177/17534666231216591

24. Wen-Tao D, Xue-Xiu C, Zun-Jiang C, et al. The Relationship Between Hospitalization Frequency of Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Anxiety and Depression. Front Genet. 2022; 13: 817727. DOI: 10.3389/fgene.2022.817727

25. Chen SY, Ya IL, Chen PR, et al. Impact of dynapenia, presarcopenia and sarcopenia in chronic obstructive pulmonary disease: a prospective cohort study. BMJ Open Respir Res. 2025; 12 (1): e002667. DOI: 10.1136/bmjresp-2024-002667

26. Baldomero AK, Wendt CH, Petersen A, et al. Impact of gastroesophageal reflux on longitudinal lung function and quantitative computed tomography in the COPDGene cohort. Respir Res. 2020; 21 (1): 203. DOI: 10.1186/s12931-020-01469-y

27. Huang C, Liu Y, Shi G. A systematic review with meta-analysis of gastroesophageal reflux disease and exacerbations of chronic obstructive pulmonary disease. BMC Pulm Med. 2020; 20 (1): 2. DOI: 10.1186/s12890-019-1027-z

28. Корытина Г.Ф., Маркелов В.А., Азнабаева Ю.Г ., [и др.]. Профиль экспрессии генов метаболизма свободных радикалов и антиоксидантной защиты при хронической обструктивной болезни легких // Биомика. – 2023. – Т . 15, № 1. – С. 26–32. Korytina GF, Markelov VA, Aznabaeva YuG, et al. Profil’ ekspressii genov metabolizma svobodnykh radikalov i antioksidantnoy zashchity pri khronicheskoy obstruktivnoy bolezni legkikh [Profile of gene expression of free radical metabolism and antioxidant defense in chronic obstructive pulmonary disease]. Biomica [Biomics]. 2023; 15 (1): 26–32. (In Russ.). DOI: 10.31301/2221-6197.bmcs.2023-4

29. Sadatsafavi M, McCormack J, Petkau J, Lynd LD, Lee TY, Sin DD. Should the number of acute exacerbations in the previous year be used to guide treatments in COPD? Eur Respir J. 2021 Feb;57(2):2002122. DOI: 10.1183/13993003.02122-2020

 

 

УДК 615.917

DOI: 10.20969/VSKM.2026.19(5).22-29

PDF download Detection of biomarkers in biological fluids in ricin poisoning

Samvel S. Barsegyan1, Roman A. Kаlekin1,2, Alla A. Vоlkova1,2, Alevtina M. Orlova1

1 Russian Center of Forensic Examinations, 12/13 Polikarpov str., 125284 Moscow, Russia

2 Peoples’ Friendship University of Russia, 6 Miklukho-Maklay str., 117198 Moscow, Russia

Abstract. Introduction. Ricin is an extremely poisonous substance found in the seeds of the castor plant (Ricinus communis). Humans can be poisoned by consuming just 4–8 castor seeds. Due to the relatively simple method of obtaining ricin, as compared to other toxic agents, it can be used both for criminal purposes and as a potential tool in terrorist attacks. Many forensic chemical laboratories experience lack of equipment and methodological basis to identify biomolecules, such as ricin or its metabolites. Aim. To develop a quick-detection technique designed to identify marker compounds of ricin use. Materials and Methods. Ricinus communis extract that contains ricinin and ricinolic acid, as well as castor oil, was used as a reference sample. The objects studied were the blood and urine of individuals who allegedly consumed castor oil components. Chromatography-mass spectrometry was used for the analysis. Results and Discussion. This paper describes an original express technique to detect ricinin and ricinolic acid, which requires only 200 μl of biological fluid. The paper presents the results of the development and optimization of technology for the extraction of ricin and its derivatives from biological samples, ensuring their subsequent analysis by modern chromatographic methods, such as HPLC/MS/MS and GC/MS/MS. Conclusions. A quick and easy technique to detect the toxin in blood, urine, castor seeds, and castor oil was developed, characterized by the minimal volume of the test fluid and a high speed of sample preparation. Specific parameters were identified for the detection of ricinine and ricinoleic acid; these are relevant for forensic chemical and chemical-toxicological examinations. The technique developed is applicable for the diagnosis of poisoning in clinical and forensic practice.

Keywords: ricin; ricinin; ricinolic acid; poisoning; marker compounds

For citation: Barseghyan S.S., Kalekin R.A., Volkova A.A., Orlova A.M. Detection of biomarkers in biological fluids in ricin poisoning. The Bulletin of Contemporary Clinical Medicine. 2026; 19(5):22-29. DOI: 10.20969/VSKM.2026.19(5).22-29.

REFERENCES

1. Калёкин Р.А., Волкова А.А., Орлова А.М., Акимова В.Д., Барсегян С.С. Судебно-химическое и химико-токсикологическое исследование методом ВЭЖХ-МС/МС при отравлении рицином. Судебно-медицинская экспертиза. – 2023. – 66(3). – С. 34–39. Kalekin RA, Volkova AA, Orlova AM, Akimova VD, Barseghyan SS. Sudebno-himicheskoe i himiko-toksikologicheskoe issledovanie metodom VEZHKH-MS/MS pri otravlenii ricinom [Forensic chemical and chemical-toxicological examination by HPLC-MS/MS in ricin poisoning]. Sudebno-medicinskaya ekspertiza [Forensic medical examination]. 2023;66(3):34-39. (in Russ.) DOI: 10.17116/sudmed20236603134

2. Савоченко А.И., Филькова К.И. Действие рицина на организм. Известия Российской военно-медицинской академии. – 2018. – 37(1 S1-2). – С. 187–190. Savochenko AI, Filkova KI. Dejstvie ricina na organizm [The effect of ricin on the body]. Izvestiya Rossijskoj voenno-medicinskoj akademii [Proceedings of the Russian Military Medical Academy]. 2018;37(1 S1-2):187-190. (in Russ.) DOI: 10.17816/rmmar711054

3. Чепур С.В., Аль-Шехадат Р.И., Гоголевский А.С., Пугач В.А., Мясников В.А., Анисенкова Е.В., Левчук Е.В., Тюнин М.А. Молекулярные аспекты цитотоксичности рицина. Medline.ru. Российский биомедицинский журнал. – 2021. – 22. – С. 271–292. Chepur SV, Al-Shekhadat RI, Gogolevsky AS, Pugach VA, Myasnikov VA, Anisenkova EV, Levchuk EV, Tyunin MA. Molekulyarnye aspekty citotoksichnosti ricina [Molecular aspects of cytotoxicity of ricin]. Medline.ru. Rossijskij biomedicinskij zhurnal [Russian Biomedical Journal]. 2021;22:271-292. (in Russ.)

4. Привалова Е.Г ., Мирович В.И. Основы фитотоксикологии. Обзор растительных объектов. Элементы фитохимического анализа: учебное пособие / ФГБОУ ВО ИГМУ Минздрава России, Кафедра фармакогнозии и фармацевтической технологии. – Иркутск: ИГМУ , 2018. – 102 с. Privalova EG, Mirovich VI. Osnovy fitotoksikologii. Obzor rastitel’nyh ob”ektov. Elementy fitohimicheskogo analiza: uchebnoe posobie [Fundamentals of phytotoxicology. Overview of plant objects. Elements of phytochemical analysis: textbook]. Irkutsk: IGMU; 2018. 102 p. (in Russ.)

5. Арстамян О.М., Ткачишин В.С., Алексейчук А.Ю. Современные ядовитые вещества в качестве террористической угрозы обществу. Медицина неотложных состояний. – 2016. – 2(73). – С.  11–20. Arstamyan OM, Tkachishin VS, Alekseychuk AY. Sovremennye yadovitye veshchestva v kachestve terroristicheskoj ugrozy obshchestvu [Modern toxic substances as a terrorist threat to society]. Medicina neotlozhnyh sostoyanij [Emergency Medicine]. 2016;2(73):11-20. (in Russ.) DOI: 10.22141/2224-0586.2.73.2016.74730

6. Мельниченко О.Г. Рицин как возможное биотеррористическое оружие и его влияние на сердечно-сосудистую систему. Студенческий вестник. – 2022. – 10-3(202). – С. 24–25. Melnichenko OG. Ricin kak vozmozhnoe bioterroristicheskoe oruzhie i ego vliyanie na serdechno-sosudistuyu sistemu [Ricin as a possible bioterrorist weapon and its effect on the cardiovascular system]. Studencheskij vestnik [Student Bulletin]. 2022;10-3(202):24-25. (in Russ.)

7. Одинец С.И. Биометрический анализ семядольных листьев проростков клещевины. Научно-технический бюллетень Института масличных культур НААН. – 2018. – 26. – С. 60–71. Odinets SI. Biometricheskij analiz semyadol’nyh list’ev prorostkov kleshcheviny [Biometric analysis of cotyledon leaves of castor seedlings]. Nauchno-tekhnicheskij byulleten’ Instituta maslichnyh kul’tur NAAN [Scientific and Technical Bulletin of the Institute of Oilseed Crops of NAAS]. 2018;26:60-71. (in Russ.)

8. ГОСТ 18102-95. Масло касторовое медицинское. Технические условия. Межгосударственный стандарт . Castor oil for medical purposes. Specifications. Дата введения 1997-01-01. GOST 18102-95. Maslo kastorovoe medicinskoe. Tekhnicheskie usloviya [Castor oil for medical purposes. Specifications]. Interstate standard. Date of introduction: 1997-01-01. (in Russ.)

9. Волкова А.А., Калёкин Р.А., Орлова А.М. Обнаружение клобазама и его метаболита в моче методом высокоэффективной жидкостной хроматографии с тандемным масс-спектрометрическим детектированием при отравлении. Судебная медицина. – 2022. – 8(4). – С. 47–55. Volkova AA, Kalekin RA, Orlova AM. Obnaruzhenie klobazama i ego metabolita v moche metodom vysokoeffektivnoj zhidkostnoj hromatografii s tandemnym mass-spektrometricheskim detektirovaniem pri otravlenii [Detection of clobazam and its metabolite in urine by high-performance liquid chromatography with tandem mass spectrometric detection in poisoning]. Sudebnaya medicina [Forensic Medicine]. 2022;8(4):47-55. (in Russ.) DOI: 10.17816/fm705

10. Калекин Р.А., Москалева Н.Е., Волкова А.А., Орлова А.М., Маркин П.А., Невмятова С.Р ., Апполонова С.А. Определение залеплона и клобазама методом высокоэффективной жидкостной хроматографии – тандемной масс-спектрометрии с высоким разрешением с использованием технологии Orbitrap. Судебно-медицинская экспертиза. – 2022. – 65(2). – С. 24–28. Kalekin RA, Moskaleva NE, Volkova AA, Orlova AM, Markin PA, Nevmyatova SR, Appolonova SA. Opredelenie zaleplona i klobazama metodom vysokoeffektivnoj zhidkostnoj hromatografii – tandemnoj mass-spektrometrii s vysokim razresheniem s ispol’zovaniem tekhnologii Orbitrap [Determination of zaleplon and clobazam by high-performance liquid chromatography – high-resolution tandem mass spectrometry using Orbitrap technology]. Sudebno-medicinskaya ekspertiza [Forensic Medical Expertise]. 2022;65(2):24-28. (in Russ.) DOI: 10.17116/sudmed20226502124

11. Саломатин Е.М., Калекин Р.А., Орлова А.М., Валуева М.И. Особенности и перспективы исследования птомаинов для целей судебно-химического анализа. Судебно-медицинская экспертиза. – 2015. – 58(6). – С. 49–52. Salomatin EM, Kalekin RA, Orlova AM, Valueva MI. Osobennosti i perspektivy issledovaniya ptomainov dlya celej sudebno-himicheskogo analiza [Features and prospects of ptomaine research for the purposes of forensic chemical analysis]. Sudebno-medicinskaya ekspertiza [Forensic Medical Expertise]. 2015;58(6):49-52. (in Russ.)

 

 

УДК: 616.831-006-073.756.8:611.813.1

DOI: 10.20969/VSKM.2026.19(5).30-40

PDF download Brain Parcellation as a tool for standardization of preoperative assessment of mass effect in glial tumors: A pilot MRI-based study

Nigora M. Djuraeva1, Adkham I. Ikramov , Khanum V. Abdukhalimova1,Artem I. Batalov3, Alisa V. Lebedenko3

1 Republican Specialized Scientific and Practical Medical Center of Surgery named after Academician V. Vakhidov, 10 Kichik Khalka Yuli Street, Chilanzar District, 100115 Tashkent, Uzbekistan

2 Center for the Development of Professional Qualifications of Medical Professionals, 51 Parkentskaya str., 100000 Tashkent, Uzbekistan

3 N. N. Burdenko National Medical Research Center of Neurosurgery, 16 4th Tverskaya-Yamskaya str., 125047 Moscow, Russia

Abstract. Introduction. Intracerebral glial tumors are associated with mass effect, midline displacement, and changes in the ventricular system configuration. Use of the automated Brain Parcellation technology based on 3D T1-weighted magnetic resonance imaging data allows quantitatively assessing the ventricular and cerebrospinal fluid volumes. Aim. To evaluate the influence of tumor localization and size on ventricular volumes, using preoperative magnetic resonance imaging data processed with the Brain Parcellation technology. Materials and Methods. The study included 64 patients with histologically confirmed glial tumors. All patients underwent preoperative MRI with unenhanced 3D T1-weighted images (slice thickness 1 mm). The tumors were located in the right and left hemispheres, predominantly in the frontal, parietal, and temporal lobes, and less frequently in the occipital lobes, lateral and medial regions, with moderate to severe perifocal edema. Tumor diameters ranged from 2.0 to 5.6 cm. Using еру Brain Parcellation technology, the volumes of the right and left lateral ventricles, the third and fourth ventricles, the total cerebrospinal fluid volume, and the lateral ventricular asymmetry index were automatically calculated. Results and Discussion. According to Brain Parcellation, the volumes of the right lateral (Me 5.11→6.29 ml; p=0.03), IIIth (0.80→0.87 ml; p=0.03) and IVth ventricles (1.80→2.00 ml; p<0.05) significantly increased after the surgery, with no significant changes in the left lateral (p=0.06), Asym IDX (p=0.27), or total CSF (p=0.38). For frontal tumors, the average diameter was 3.79±1.23 cm (with edema sized 4.77±1.43 cm); the relationship being strong between the lesion size and the edema (r=0.85; p<0.001). Small tumors (≤3 cm) did not affect ventricular volumes, whereas large medial tumors with significant edema (>5 cm) were associated with decreased ventricular and CSF volumes postoperatively (p<0.001); the changes were more pronounced in men. Conclusions. Automated Brain Parcellation based on three-dimensional T1-weighted magnetic resonance imaging enables an objective quantification of ventricular and cerebrospinal fluid volumes, revealing postoperative enlargement of the right lateral, third, and fourth ventricles without any changes in the total cerebrospinal fluid volume or asymmetry index, and should be used alongside visual magnetic resonance imaging assessment to standardize reporting and improve stratification of mass effect and dislocation risk.

Keywords: magnetic resonance imaging, intracerebral glial tumors, Brain Parcellation, ventricular system, cerebrospinal fluid, asymmetry index.

For citation: Djuraeva, N.M.; Ikramov, A.I.; Abdukhalimova, Kh.V.; et al. Brain parcellation as a tool for standardization of preoperative assessment of mass effect in glial tumors: A pilot MRI-based study. The Bulletin of Contemporary Clinical Medicine. 2026, 19(5), 30-40. DOI: 10.20969/VSKM.2026.19(5). 30-40.

REFERENCES

1. Dorfner FJ, Patel JB, Kalpathy-Cramer J, Gerstner ER, Bridge CP. A review of deep learning for brain tumor analysis in MRI. J Precision Oncology. 2025;9(1): 2. DOI: 10.1038/s41698-024-00789-2

2. Satushe V, Vyas V, Metkar S, Singh DP. AI in MRI brain tumor diagnosis: A systematic review of machine learning and deep learning advances (2010–2025). J Chemometrics and Intelligent Laboratory Systems. 2025; 263:105-14. DOI: 10.1016/j.chemolab.2025.105414

3. Lee M, Kim JH, Choi W, Lee KH. AI-assisted Segmentation Tool for Brain Tumor MR Image Analysis. Journal of Imaging Informatics in Medicine. 2025; 38(1):74–83. DOI: 10.1007/s10278-024-01187-7

4. Evangelou K, et al. Artificial Intelligence in the Diagnosis and Treatment of Brain Gliomas. J Biomedicines. 2025; 13(9): 2285. DOI: 10.3390/biomedicines13092285

5. Al-Rahbi A, Al-Habsi T, Al-Suli A, Al-Saadi T. Artificial intelligence use in diagnosis, grading, and segmentation of neuro-oncology: a narrative review. Egyptian Journal of Neurology, Psychiatry and Neurosurgery. 2025; 61(1): 54. DOI: 10.1186/s41983-025-00980-7

6. Ullah F, Nadeem M, Abrar M, et al. Brain Tumor Segmentation from MRI Images Using Handcrafted Convolutional Neural Network. Diagnostics (Basel). 2023;13(16):2650. DOI: 10.3390/diagnostics13162650

7. Huang J, et al. Brain tumor segmentation using deep learning: high performance with minimized MRI data. J Frontiers in Radiology. 2025; 5. DOI: 10.3389/fradi.2025.1616293

8. Bhandari A, Koppen J, Agzarian M. Convolutional neural networks for brain tumour segmentation. J nsights Imaging. 2020; 11(1): P. 77. DOI: 10.1186/s13244-020-00869-4

9. Xiong Z. ResSAXU-Net for multimodal brain tumor segmentation from brain MRI. Sci Rep.2025; 15: 241-79. DOI:org/10.1038/s41598-025-09539-1

10. Rosenstock P, et al. Association between tumor size and peritumoral brain edema in patients with convexity and parasagittal meningiomas. J PLOS ONE. 2021; 16 (6). P. e025-45. DOI: 10.1371/journal.pone.0252945

11. Thammaroj J, Wongwichit N, Boonrod A. Evaluation of Perienhancing Area in Differentiation between Glioblastoma and Solitary Brain Metastasis. Asian Pacific Journal of Cancer Prevention. 2020; 21(9): 2525–2530. DOI: 10.31557/APJCP.2020.21.9.2525

12. Tsygankov VA, et al. Modern approaches to segmentation and analysis of brain structures: problems and solutions. Doctor and Information Technologies. 2025; 1: 42–57. DOI: 10.25881/18110193_2025_1_42

13. Ranjbarzadeh R, Zarbakhsh P, Caputo A, et al. Brain tumor segmentation based on optimized convolutional neural network and improved chimp optimization algorithm. Comput Biol Med. 2024; 168:107723. DOI: 10.1016/j.compbiomed.2023.107723

14. Wu W, Li D, Du J, et al. An Intelligent Diagnosis Method of Brain MRI Tumor Segmentation Using Deep Convolutional Neural Network and SVM Algorithm. Comput Math Methods Med. 2020; 2020:6789306 DOI: 10.1155/2020/6789306. PMID: 32733596; PMCID: PMC7376410.

15. Cui S, Mao L, Jiang J, et al. Automatic Semantic Segmentation of Brain Gliomas from MRI Images Using a Deep Cascaded Neural Network. J Healthc Eng. 2018; 2018:4940593. DOI: 10.1155/2018/4940593

 

 

УДК: 616-008.9

DOI: 10.20969/VSKM.2026.19(5).41-49

PDF download Association between clinical symptoms and laboratory parameters of calcium, magnesium, and phosphorus metabolism in patients with widespread musculoskeletal pain

Gennadiy E. Zhilyaev1,2, Evgeny V. Zhilyaev1,3,4, Tatyana N. Kargaeva1,5, Stanislav V. Gorshkov5, Malika E. Malikova5, Diana R. Sadikova5, Alexander I. Kucherenko5, Alesya A. Klimenko1

1 Pirogov Russian National Research Medical University, 1 Ostrovitianov str., 117513 Moscow, Russia

2 AudioMed Medical Center, Istok Audio Trading, Ltd., 27 Tsentralnaya str., 141190 Fryazino, Moscow Oblast, Russia

3 Russian Medical Academy of Continuous Professional Education, 2/1 Barrikadnaya str., Bldg. 1, 125993 Moscow, Russia

4 European Medical Center, 35 SKhepkin str., 129090 Moscow, Russia

5 Moscow City Clinical Hospital No. 1 named after N.I. Pirogov, 8 Lenin Ave., 119049 Moscow, Russia

Abstract. Introduction. Widespread musculoskeletal pain is the main symptom of fibromyalgia and occurs with a frequency of 10% to 15% in the population Occurrence of this symptom, among other reasons, may be associated with metabolic disorders, such as magnesium/calcium deficiencies, as evidenced by the results of recent studies. Aim. To study the association of various clinical symptoms with laboratory parameters reflecting calcium, magnesium, and phosphorus metabolism in a patient with widespread musculoskeletal pain. Materials and Methods. The study included adult outpatients with widespread musculoskeletal pain according to the ACR (1990) criteria. The techniques used were Spearman and Kendall rank correlation methods, the chi-square test, Mann-Whitney and Kruskal-Wallis tests, and generalized linear modeling. Results and Discussion. Patients with lower concentrations of ionized calcium had the following clinical manifestations: Burning pain; burning sensation of various localizations; episodes of palpitations for no apparent reason, tenderness of the small pectoral muscles; and greater spread and severity of pain. Lower magnesium concentrations in serum were associated with stabbing pain; numbness of the upper extremities at rest; episodes of feeling short of air for no apparent reason; unstable stool; burning sensation of various localizations; and nodules on the tendons of the flexors of the fingers. In patients with 2 or more mutually independent clinical manifestations associated with low levels of ionized calcium in blood, ionized calcium ranged within 0.86–1.22 mmol/l. In patients with 2 mutually independent clinical signs of hypomagnesemia, the level of magnesium in blood serum ranged within 0.61–0.85  mmol/L. Conclusions. There is a significant association between laboratory parameters and clinical symptoms. Mutually independent clinical signs of calcium deficiency in patients with widespread musculoskeletal pain include burning pain, widespread pain (index of widespread pain >7), and episodes of palpitations for no apparent reason. Mutually independent clinical signs of magnesium deficiency in patients with widespread musculoskeletal pain may include numbness of the upper extremities at rest and episodes of feeling short of air for no apparent reason.

Keywords: hypocalcemia, hypomagnesemia, hypocalciuria, hypomagnesuria, widespread musculoskeletal pain

For citation: Zhilyaev, G.E.; Zhilyaev, E.V.; Kargaeva, T.N.; et al. Association between clinical symptoms and laboratory parameters of calcium, magnesium, and phosphorus metabolism in patients with widespread musculoskeletal pain. The Bulletin of Contemporary Clinical Medicine. 2026, 19 (5), 41-49. DOI: 10.20969/VSKM.2026.19(5).41-49.

REFERENCES

1. Mansfield KE, Sim J, Jordan JL, Jordan KP. A systematic review and meta-analysis of the prevalence of chronic widespread pain in the general population. Pain. 2016;157(1):55-64. DOI: 10.1097/j.pain.0000000000000314

2. Boulis M, Boulis M, Clauw D. Magnesium and Fibromyalgia: A Literature Review. J Prim Care Community Health. 2021; 12: 21501327211038433. DOI: 10.1177/21501327211038433

3. Macian N, Dualé C, Voute M, et al. Short-Term Magnesium Therapy Alleviates Moderate Stress in Patients with Fibromyalgia: A Randomized Double-Blind Clinical Trial. Nutrients. 2022;14(10):2088. Published 2022 May 17. DOI: 10.3390/nu14102088

4. Makrani AH, Afshari M, Ghajar M, et al.Vitamin D and fibromyalgia: a meta-analysis. Korean J Pain. 2017;30(4):250-257. DOI: 10.3344/kjp.2017.30.4.250

5. Ahmad J, Tagoe CE. Fibromyalgia and chronic widespread pain in autoimmune thyroid disease. Clin Rheumatol. 2014;33(7):885-891. DOI: 10.1007/s10067-014-2490-9

6. Pappu R, Jabbour SA, Reginato AM, Reginato AJ. Musculoskeletal manifestations of primary hyperparathyroidism. Clin Rheumatol. 2016;35(12):3081-3087. DOI: 10.1007/s10067-016-3450-3

7. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33(2):160-172. DOI: 10.1002/art.1780330203

8. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken).

2010;62(5):600-610. DOI: 10.1002/acr.20140

9. Амиpджанова В. Н., Горячев Д. В., Коршунов Н. И., [и др.]. Популяционные показатели качества жизни по опроснику SF-36 (результаты многоцентрового исследования качества жизни «МИРАЖ») // Научно-практическая ревматология. – 2008. – Т . 46, № 1. – С. 36–48. Amirdjanova VN, Goryachev DV, Korshunov NI, et al. Populyacionnye pokazateli kachestva zhizni po oprosniku SF-36 (rezul’taty mnogocentrovogo issledovaniya kachestva zhizni (results of the multicenter quality of life study “MIRAGE”)]. Nauchno-Prakticheskaya Revmatologiya [Scientific and Practical Rheumatology]. 2008;46(1):36-48. (In Russ.) DOI: 10.14412/1995-4484-2008-852

10. Морозова М.А., Потанин С.С., Бениашвили А.Г ., [и др.]. Валидация русскоязычной версии Госпитальной шкалы тревоги и депрессии в общей популяции // Профилактическая медицина. – 2023. – Т . 26, вып. 4. – С.7-14. Morozova MA, Potanin SS, Beniashvili AG, [et al.]. Validaciya russkoyazychnoj versii Gospital’noj shkaly trevogi i depressii v obshchej populyacii [Validation of the Hospital anxiety and depression scale russian-language version in the general population]. Profilakticheskaya Meditsina [Preventive Medicine]. 2023; 26 (4): 7-14. (In Russ.) DOI: 10.17116/profmed2023260417

11. Bagis S, Karabiber M, As I, et al. Is magnesium citrate treatment effective on pain, clinical parameters and functional status in patients with fibromyalgia? Rheumatol Int. 2013;33(1):167-172. DOI: 10.1007/s00296-011-2334-8

12. Reginato AJ, Falasca GF, Pappu R, et al. Musculoskeletal manifestations of osteomalacia: report of 26 cases and literature review. Semin Arthritis Rheum. 1999;28(5):287-304. DOI: 10.1016/s0049-0172(99)80013-4

13. Pepe J, Colangelo L, Biamonte F, et al. Diagnosis and management of hypocalcemia. Endocrine. 2020;69(3):485-495. DOI: 10.1007/s12020-020-02324-2

14. Costello RB, Elin RJ, Rosanoff A, et al. Perspective: The Case for an Evidence-Based Reference Interval for Serum Magnesium: The Time Has Come. Adv Nutr. 2016;7(6):977-993. DOI:10.3945/an.116.012765

 

 

УДК 615.322:615.076.7:615.017

DOI: 10.20969/VSKM.2026.19(5).50-59

PDF download Phytochemical composition of extracts obtained from the herb of Oxytropis pilosa and their effect on the growth of bacterial populations

Ludmila V. Karavaeva1, Olga G. Shapoval1, Uliana A. Matvienko1, Tatiana A. Kulshan 1, Natalya A. Durnova1,2

1 Saratov State Medical University named after V.I. Razumovsky, 112 B Kazachya str., 410012 Saratov, Russia

2 I. M. Sechenov Moscow State Medical University (Sechenov University), 8 Trubetskaya str., 119991 Moscow, Russia

Abstract. Introduction. Herbal medicines, due to various groups of biologically active substances (BAS) contained in them, can provide an antimicrobial effect through simultaneously targeting different sites within the microbial cell. Oxytropis pilosa (L.) DC. contains alkaloids, steroids, phenolcarboxylic acids, coumarins, and flavonoids, such as quercetin, kaempferol and quercetin mono- and diglycosides, and astragalin, which potentially indicates an antimicrobial effect of its extracts. Aim. To conduct a phytochemical analysis of aqueous and alcoholic extracts of O. pilosa and evaluate their effect on the growth of bacterial populations. Materials and Methods. The study objects were aqueous and alcoholic extracts (ethanol concentrations of 40%, 70%, and 95%) prepared from O. pilosa herb. Main BAS groups were screened using qualitative chemical reactions and thin-layer chromatography (TLC). The total flavonoid contents in the extracts were identified by differential spectrophotometry, calculated as rutin equivalents. Antimicrobial activity of the extracts against standard strains of Pseudomonas aeruginosa ATCC 27853, Escherichia coli ATCC 25922, and a clinical strain of Staphylococcus aureus 2963 was studied using the broth microdilution method in Mueller-Hinton broth with a microbial load of 5×10 CFU/mL at extract concentrations ranging from 50 to 3.125 mg/mL. Growth of bacterial populations was assessed by measuring their optical density immediately and at the 2-, 7-, and 20-hour post-inoculation. Results and Discussion. Phytochemical screening revealed the presence of tannins and flavonoids in all extracts. Coumarins were detected exclusively in the alcoholic extracts, while triterpene saponins were found in the aqueous extracts and in the 40%- and 70%-ethanol extracts. TLC analysis identified the phenolic profiles of the extracts, confirming the presence of rutin and cynaroside in all samples. The total flavonoid contents varied: The maximum values were observed in the 40%- and 70%-ethanol extracts (8.76±0.30% and 8.74±0.32%, respectively), while the minimum was recorded for the 95%-ethanol extract (5.27±0.14%). Aqueous extract exhibited a flavonoid content of 6.81±0.19%. Aqueous and alcoholic extracts of O. pilosa at the concentrations of 50–3.125 mg/mL provided a bacteriostatic effect against the test strains of E. coli, P. aeruginosa, and S. aureus. Regarding Staphylococcus, this effect was more pronounced in the alcoholic extracts and less pronounced in the aqueous extract. Conclusions. The findings indicate the potential of developing an antimicrobial preparation of the O. pilosa herb. However, this requires a further, more in-depth study of the phytochemical composition of the extracts obtained, as well as the isolation of specific BAS fractions or individual compounds for subsequent assessment of their antimicrobial activity.

Keywords: herb, Oxytropis pilosa, thin-layer chromatography, spectrophotometry, antimicrobial activity, Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus

For citation:Karavaeva, L.V.; Shapoval, O.G.; Matvienko, U.A; at all. Phytochemical composition of extracts obtained from the herb of Oxytropis pilosa and their effect on the growth of bacterial populations. The Bulletin of Contemporary Clinical Medicine. 2026, 19 (5), 50–59. DOI: 10.20969/VSKM.2026.19(5).50-59.

REFERENCES

1. Chernyak S, Matsiyeuskaya N, Maneesha A, Ostrovskaya O. Antibiotic Resistance in Microorganisms Isolated From COVID-19 Patients During Different Periods of the Pandemic. Clinical infectology and parasitology. 2024; 13(4) : 490-502. DOI: 10.34883/PI.2024.13.4.035

2. Буданова Е.В., Горленко К.Л., Киселев Г.Ю. Вторичные метаболиты растений: механизмы антибактериального действия и перспективы применения в фармакологии // Антибиотики и химиотерапия. – 2019. – Т . 64. – №. 5-6. – С. 69-76. Budanova EV, Gorlenko KL, Kisele v GYu. Vtorichnye metabolity rasteniy: mekhanizmy antibakterial’nogo deystviya i perspektivy primeneniya v farmakologii [Secondary Plant Metabolites: Mechanisms of Antibacterial Action and Perspectives of Application in Pharmacology]. Antibiotiki i khimioterapiya [Antibiotics and Chemotherapy]. 2019; 64 (5-6): 69-76. (In Russ.). DOI: 10.24411/0235@2990@2019@10034

3. Sandanov DV, Kholina AB, Kozyrenko MM et al. Genetic Diversity of Oxytropis Species from the Center of the Genus Origin: Insight from Molecular Studies // Diversity. 2023; 15 (2): 244. DOI: 10.3390/d15020244

4. Еленевский А.Г ., Буланый Ю.И., Радыгина В.И. Конспект флоры Саратовской области // Саратов: Наука, 2008. – 232 с. Elenevskiy AG, Bulanyy YuI, R adygina VI. Konspekt flory Saratovskoy oblasti [Abstract of the flora of the Saratov region]. Saratov: Nauka [Saratov: Science]. 2008; 232 p. (In Russ.).

5. Федорова А.А. (ред.) Флора европейской части СССР . // Л: Изд-во АН СССР , 1987. – Т . 6. – 254 c. Fedorova AA (ed.). Flora evropeyskoy chasti SSSR [Flora of the European part of the USSR]. L: Izd-vo AN SSSR [L: Publishing house AN SSSR]. 1987; 6; 254 p. (In Russ.).

6. Соколов П.Д. (ред.) Растительные ресурсы СССР: Цветковые растения, их химический состав, использование; Семейства Hydrangeaceae—Haloragaceae. // Л.: Наука, 1987. — 328 с. Sokolov PD (ed.). Rastitel’nye resursy SSSR: Tsvetkovye rasteniya, ikh khimicheskiy sostav, ispol’zovanie; Semeystva Hydrangeaceae—Haloragaceae [Plant resources of the USSR: Flowering plants, their chemical composition, use; Families Hydrangeaceae—Haloragaceae]. L.: Nauka [L.: Science]; 1987; 328 p. (In Russ.).

7. Караваева Л.В., Матвиенко У.А., Дурнова Н.А. Оценка антиоксидантного потенциала травы остролодочника волосистого (Oxytropis pilosa (L.) DC.) // Достижения и перспективы создания новых лекарстве нных растительных препаратов: Сборник научных трудов Международной научно-практической конференции, М.: ФГБНУ ВИЛАР , 2023. – С. 57-61. Karavaeva LV, Matvienko UA, Durnova NA. Otsenka antioksidantnogo potentsiala travy ostrolodochnika volosistogo (Oxytropis pilosa (L.) DC.) [Evaluation of the antioxidant potential of the herb of Oxytropis pilosa (L.) DC.] Dostizheniya i perspektivy sozdaniya novykh lekarstvennykh rastitelʹnykh preparatov: Sbornik nauchnykh trudov Mezhdunarodnoj nauchno-prakticheskoj konferentsii. M.: FGBNU VILAR  [Achievements and prospects for the creation of new herbal medicines: Collection of scientific papers of the International scientific and practical conference, Moscow: Federal State Budgetary Scientific Institution VILAR]. 2023: 57-61. DOI 10.52101/9785870191102_57. (In Russ.).

8. Miladinović D, Miladinović L, Najman S. A study of the antioxidants in Oxytropis pilosa (L.) DC. Journal of the Serbian Chemical Society. 2011; 76 (4): 505-512.

9. Караваева Л.В., Шаповал О.Г., Дурнова Н.А. Скрининг антимикробной активности извлечений, полученных из травы остролодочника волосистого (Oxytropis pilosa (L.) DC.) // Достижения и перспективы создания новых лекарственных растительных препаратов: Сборник научных статей по материалам Международного научного Симпозиума, М.: ФГБНУ ВИЛАР , 2025 . – С. 626-630. Karavaeva LV, Shapoval OG, Durnova NA. Skrining antimikrobnoj aktivnosti izvlechenij, poluchennykh iz travy ostrolodochnika volosistogo (Oxytropis pilosa (L.) DC.) [Screening determination of antimicrobial activity of Oxytropis pilosa (L.) DC. extracts]. Dostizheniya i perspektivy sozdaniya novykh lekarstvennykh rastitelʹnykh preparatov: Sbornik nauchnykh statej po materialam Mezhdunarodnogo nauchnogo Simpoziuma, M.: FGBNU VILAR [Achieve ments and prospects for the creation of new herbal medicines: Collection of scientific articles based on the materials of the International Scientific Symposium, Moscow: Federal State Budgetary Scientific Institution VILAR] 2025: 626-630. (In Russ.). DOI 10.52101/9785870191164-2025-1-626.

10. Amirkhanova AS, Ustenova GO. Review of the current status of study Oxytropis. Asian Journal of Pharmaceutical and Clinical Research. 2018; 11 (4): 50-55.

11. Самылина И.А., Сорокина А.А., Пятигорская Н.В. Настои и отвары – фармакопейная лекарственная форма // Фарматека. – 2010. – №. 5. – С. 133-135. Samylina IA, Sorokina AA, Pyatigorskaya NV. Nastoi i otvary – farmakopeynaya lekarstvennaya forma [Infusions and decoctions – pharmacopoeial dosage form]. Farmateka [Pharmateka]. 2010; 5: 133-135.

12. Konovalenko I, Kriukova A. Study of the pharmacotechnological parameters of ginger rhizomes for developing the conditions extracting of extractive substances. Annals of Mechnikov’s Institute. 2023; 4: 79-83.

13. Крылов Н.Н., Компанцева Е.В. Разработка и валидационная оценка методики определения суммы флавоноидов в таблетках ноотропного действия // Разработка и регистрация лекарственных средств. – 2016. – №. 3. – С. 146-151. Krylov NN, Kompantseva EV. Razrabotka i validatsionnaya otsenka metodiki opredeleniya summy flavonoidov v tabletkakh nootropnogo deystviya [Method development and validation of total flavonoids assay in tablets with nootropic action]. Razrabotka i registratsiya lekarstvennykh sredstv [Drug development & registration]. 2016; 3: 146-151. (In Russ.).

14. Утяганова Е.В., Юртаева Е.А., Сигарева С.С. и др. Антимикробная активность спиртовых экстрактов из плодов моркови дикой и моркови посевной в отношении клинических штаммов грамположительных и грамотрицательных бактерий // Вестник Пермского университета. Серия: Биология. – 2025. – №. 1. – С. 49-58. Utyaganova EV, Yurtaeva EA, Sigareva SS et al. Antimikrobnaya aktivnost’ spirtovykh ekstraktov iz plodov morkovi dikoy i morkovi posevnoy v otnoshenii klinicheskikh shtammov grampolozhitel’nykh i gramotritsatel’nykh bakteriy [The antimicrobial activity of ethanolic extracts derived from the fruits of wild and cultivated carrots against clinical isolates of Gram-positive and Gram-negative bacteria]. Vestnik Permskogo universiteta. Seriya: Biologiya [Bulletin of Perm University. Biology]. 2025; 1: 49-58. (In Russ.). DOI: 10.17072/1994-9952-2025-1-49-58

15. Narangerel T, Bonikowski R, Jastrząbek K et al. Chemical and Biological Characteristics of Oxytropis pseudoglandulosa Plant of Mongolian Origin. Molecules. 2021; 26(24): 7573. DOI: 10.3390/molecules26247573

 

 

УДК: 614.2:615.1

DOI: 10.20969/VSKM.2026.19(5).60-65

PDF download Digital transformation of pharmaceutical supply: From challenges to regional solutions

Svetlana K. Mamsirova1, Sergey Z. Umarov2, Inal A. Abdokov3

1 Maykop State Technological University, Russia, 191 Pervomayskaya str., 385000 Maykop, Russia

2 S.M. Kirov Military Medical Academy, 6Zh Akademik Lebedev str., 194044 Saint Petersburg, Russia

3 Aptechnaya Baza, 5A Zagorodnaya str., 385000 Maykop, Russia

Abstract. Introduction. Public drug supply is one of the priority national policies. In the regions of the Russian Federation, healthcare digitalization proceeds in an uneven manner due to differences in the digital maturity levels of the constituents of Russia. In the Republic of Adygea, implementation of the Unified State Information System in Healthcare is behind the federal plan: Introduction of electronic medical records and prescriptions is just getting started, and telemedicine does not function in remote areas. Integration with the Federal State Information System for Monitoring the Movement of Medicinal Products is technically established but requires the improvement of organizational processes. Aim. To assess the impact of the digitalization process on the public drug supply in Russia, considering the specifics of technological development both nationally and internationally. Materials and Methods. We used standard regulations and statistical data for the years 2006–2026, geoinformation analysis, data from the Federal State Information System for Monitoring the Movement of Medicinal Products, and over 550 records from the logs of deferred prescriptions of Aptechnaya Baza (State Unitary Enterprise of the Republic of Adygea, operating as pharmacy storage base) for the years 2024–2025. Results and Discussion. We identified four stages of digitalization in Russia. Comparison with the models of the EU, Turkey, the UAE, and Kazakhstan showed that full traceability systems, Track and Trace, in which financing is linked to accounting data, provide better control and transparency in the pharmaceutical market. Effectivity of federal systems, i. e., the Federal State Information System for Monitoring the Movement of Medicinal Products and the Unified State Information System in Healthcare, is considered exemplified by the Republic of Adygea, where pronounced disproportions were identified: Gap in the accessibility of pharmacies between the city and the village reaches 3–5 times or more, the service area of one social pharmacy in the Maykopsky District is 3667.4 km², and a shortage of personnel was found in rural areas (13 staff units of specialists per 10 district subdivisions, with 22% of employees having a low level of digital skills). A significant shortcoming is the insufficient transformation of federal data into managerial decisions at the regional level. Conclusions. Regional level issues reflect the federally significant unresolved tasks and require the development of methods and mechanisms to overcome the barriers that have arisen. Analysis of how federal systems work at the regional level confirms the necessity of creating an organizational model that would include digital data, spatial analysis, and social management mechanisms.

Keywords: digitalization of pharmaceutical supply, EGISZ, FGIS MDLP, foreign experience, Republic of Adygea, territorial accessibility

For citation: Mamsirova, S. K.; Umarov, S.Z.; Abdokov, I. A. Digital transformation of pharmaceutical supply: From challenges to regional solutions. The Bulletin of Contemporary Clinical Medicine. 2026, 19(5), 60-65. DOI: 10.20969/VSKM.2026.19(6).60-65.

REFERENCES

1. Смышляев А.В., и др. Нормативно-правовое регулирование развития цифровых технологий в здравоохранении Российской Федерации // Медицинское право. – 2020. – № 3. – С. 22–29. Smyshlyaev AV, et al. Normativno-pravovoye regulirovaniye razvitiya tsifrovykh tekhnologiy v zdravookhranenii Rossiyskoy Federatsii [Normative and legal regulation of the development of digital technologies in healthcare of the Russian Federation]. Meditsinskoye pravo [Medical Law]. 2020; (3): 22–29. (In Russ.) DOI: 10.18572/2071-9620-2020-3-22-29

2. Затравкин С.Н., Вишленкова Е.А., Генин Ф.В. Своя игра: история фармрынка в России. – Москва: Шико, 2025. – 480 с. Zatravkin SN, Vishlenkova EA, Genin FV. Svoya igra: istoriya farmrynka v Rossii [Own game: the history of the pharmaceutical market in Russia]. Moscow: Shiko; 2025. 480 p. (In Russ.)

3. Зайцев Ю.К., Кнобель А.Ю. Торговая политика Российской Федерации в отношении продукции фармацевтической промышленности в контексте присоединения к ВТО // Вестник РУДН. Серия: Экономика. – 2013. – № 4. – С. 37–46. Zaytsev YuK, Knobel AYu. Torgovaya politika Rossiyskoy Federatsii v otnoshenii produktsii farmatsevticheskoy promyshlennosti v kontekste prisoedineniya k VTO [Trade policy of the Russian Federation regarding pharmaceutical industry products in the context of WTO accession]. Vestnik RUDN. Seriya: Ekonomika [RUDN Journal of Economics]. 2013; (4): 37–46. (In Russ.) DOI: 10.22363/2313-2329-2013-4-37-46

4. Российская Федерация. Законы. О лекарственных средствах: Федеральный закон № 86-ФЗ: [принят Государственной Думой 10 июня 1998 г .]: [одобрен Советом Федерации 17 июня 1998 г .] // Собрание законодательства РФ. – 1998. – № 26. – Ст . 3006. Rossiyskaya Federatsiya. Zakony. O lekarstvennykh sredstvakh: Federal’nyy zakon № 86-FZ [Russian Federation. Laws. On medicines: Federal Law No. 86-FZ]. Sobraniye zakonodatel’stva RF [Collection of Legislation of the Russian Federation]. 1998; (26): Art. 3006. (In Russ.)

5. Наркевич И.А., и др. История и перспективы лекарственного обеспечения в России // Фармация. – 2016. – Т . 63, № 3. – С. 26–29. Narkevich IA, et al. Istoriya i perspektivy lekarstvennogo obespecheniya v Rossii [History and prospects of pharmaceutical supply in Russia]. Farmatsiya [Pharmacy]. 2016; 63 (3): 26–29. (In Russ.) DOI: 10.29296/25419218-2016-03-06

6. Национальный атлас России. Т . 3: Население. Экономика / сост. и подгот. к изд. ПКО «Картография»; отв. ред. Г.В. Поздняк. – М.: Роскартография, 2008. – 1 электрон. опт. диск (DVD-ROM). – ISBN 5-85120-257-2. Natsional’nyy atlas Rossii. T. 3: Naseleniye. Ekonomika [National Atlas of Russia. Vol. 3: Population. Economy]. Moscow: Roskartografiya [Moscow: Roskartografiya]; 2008. 1 DVD-ROM. ISBN 5-85120-257-2. (In Russ.)

7. Лебедев Г.С., Цындымеев А.Г. Концепция унифицированного программного обеспечения для учета рецептов и отпуска лекарственных препаратов // Фармация. – 2005. – № 6. – С. 28–32. Lebedev GS, Tsyndymeev AG. Kontseptsiya unifitsirovannogo programmnogo obespecheniya dlya ucheta retseptov i otpuska lekarstvennykh preparatov [Concept of unified software for recording prescriptions and dispensing medicines]. Farmatsiya [Pharmacy]. 2005; (6): 28–32. (In Russ.) DOI: 10.29296/25419218-2005-06-07

8. О национальных целях развития Российской Федерации на период до 2030 года и на перспективу до 2036 года: Указ Президента РФ от 7 мая 2024 г. № 309 // Собрание законодательства РФ. – 2024. – № 19. – Ст . 2321. O natsional’nykh tselyakh razvitiya Rossiyskoy Federatsii na period do 2030 goda i na perspektivu do 2036 goda: Ukaz Prezidenta RF ot 7 maya 2024 g. № 309 [On the national development goals of the Russian Federation for the period up to 2030 and for the future up to 2036: Decree of the President of the Russian Federation No. 309 of May 7, 2024]. Sobraniye zakonodatel’stva RF [Collection of Legislation of the Russian Federation]. 2024; (19): Art. 2321. (In Russ.)

9. Об утверждении приоритетов цифровой трансформации здравоохранения на период до 2030 года: Распоряжение Правительства РФ от 17 апреля 2024 г. № 959-р // Собрание законодательства РФ. – 2024. – № 17. – Ст . 2432. Ob utverzhdenii prioritetov tsifrovoy transformatsii zdravookhraneniya na period do 2030 goda: Rasporyazheniye Pravitel’stva RF ot 17 aprelya 2024 g. № 959-r [On approval of priorities for digital transformation of healthcare for the period up to 2030: Order of the Government of the Russian Federation No. 959-r of April 17, 2024]. Sobraniye zakonodatel’stva RF [Collection of Legislation of the Russian Federation]. 2024; (17): Art. 2432. (In Russ.)

10. Об обращении лекарственных средств: Федеральный закон от 12 апреля 2010 г. № 61-ФЗ // Собрание законодательства РФ. – 2010. – № 16. – Ст . 1815. Ob obrashchenii lekarstvennykh sredstv: Federal’nyy zakon ot 12 aprelya 2010 g. № 61-FZ [On circulation of medicines: Federal Law No. 61-FZ of April 12, 2010]. Sobraniye zakonodatel’stva RF [Collection of Legislation of the Russian Federation]. 2010; (16): Art. 1815. (In Russ.)

11. Об утверждении Правил добровольного предоставления информации в государственную информационную систему мониторинга за оборотом товаров, подлежащих обязательной маркировке средствами идентификации, в целях подтверждения страны происхождения лекарственных препаратов для медицинского применения: Постановление Правительства РФ от 23 сентября 2025 г. № 1462 // Собрание законодательства РФ. – 2025. – № 39. – Ст . 5812. Ob utverzhdenii Pravil dobrovol’nogo predostavleniya informatsii v gosudarstvennuyu informatsionnuyu sistemu monitoringa za oborotom tovarov, podlezhashchikh obyazatel’noy markirovke sredstvami identifikatsii, v tselyakh podtverzhdeniya strany proiskhozhdeniya lekarstvennykh preparatov dlya meditsinskogo primeneniya: Postanovleniye Pravitel’stva RF ot 23 sentyabrya 2025 g. № 1462 [On approval of the Rules for voluntary provision of information to the state information system for monitoring the circulation of goods subject to mandatory identification marking in order to confirm the country of origin of medicines for medical use: Resolution of the Government of the Russian Federation No. 1462 of September 23, 2025]. Sobraniye zakonodatel’stva RF [Collection of Legislation of the Russian Federation]. 2025; (39): Art. 5812. (In Russ.)

12. EMVO [Электронный ресурс]: официальный сайт Европейской организации по верификации лекарственных средств. – URL: https://emvo-medicines.eu (дата обращения: 12.08.2026). EMVO [Internet]: official website of the European Medicines Verification Organisation. Available from: https://emvo-medicines.eu [accessed: 12.08.2026]

13. Parmaksiz K, Pisani E, Kok MO. What makes a national pharmaceutical track and trace system succeed? Lessons from Turkey. Global Health: Science and Practice. 2020; 8 (3): 431–441. DOI: 10.9745/GHSP-D-20-00084

14. MoHAP. UAE Ministry of Health and Prevention signs MoU with GS1 to enhance pharmaceutical supply chain safety [Internet]. – 2021. – URL: https://mohap.gov.ae (дата обращения: 15.08.2026). MoHAP. UAE Ministry of Health and Prevention signs MoU with GS1 to enhance pharmaceutical supply chain safety [Internet]. 2021. Available from: https://mohap.gov.ae [accessed: 15.08.2026]

15. МИНЗДРАВ РК: В систему маркировки лекарств вовлечены более 8000 аптек и свыше 1900 медорганизаций // Министерство здравоохранения Республики Казахстан: официальный сайт . – 2025. – 3 декабря. – URL: https://www.gov.kz/memleket/entities/dsm/press/news/details/1118298 (дата обращения: 10.09.2026). MINZDRAV RK: V sistemu markirovki lekarstv vovlecheny boleye 8000 aptek i svyshe 1900 medorganizatsiy [Ministry of Health of the Republic of Kazakhstan: More than 8,000 pharmacies and over 1,900 medical organizations are involved in the medicine marking system]. Ministerstvo zdravookhraneniya Respubliki Kazakhstan [Ministry of Health of the Republic of Kazakhstan]: official website. 2025 Dec 3. (In Russ.) Available from: https://www.gov.kz/memleket/entities/dsm/press/news/details/1118298 [accessed: 10.09.2026]

16. Жакипбеков К.С., и др. Актуальные вопросы развития систем лекарственного обеспечения в Республике Казахстан // Наука и здравоохранение. – 2025. – № 2. – С. 45–53. Zhakipbekov KS, et al. Aktual’nyye voprosy razvitiya sistem lekarstvennogo obespecheniya v Respublike Kazakhstan [Current issues of development of pharmaceutical supply systems in the Republic of Kazakhstan]. Nauka i zdravookhraneniye [Science and Healthcare]. 2025; (2): 45–53. (In Russ.)

17. Как работает система маркировки лекарств в Казахстане // Zakon.kz. – 2025. – 15 января. – URL: https://zakon.kz (дата обращения: 15.08.2026). Kak rabotayet sistema markirovki lekarstv v Kazakhstane [How the medicine marking system works in Kazakhstan]. Zakon.kz [Internet]. 2025 Jan 15. (In Russ.) Available from: https://zakon.kz [accessed: 15.08.2026]

18. Республика Адыгея в цифрах. 2025: Статистический сборник. – Майкоп, 2025. – 312 с. Respublika Adygeya v tsifrakh. 2025: Statisticheskiy sbornik [Republic of Adygea in figures. 2025: Statistical collection]. Maykop; 2025. 312 p. (In Russ.)

19. Беданокова М.Р ., Бат Н.М. Анализ организации льготного лекарственного обеспечения населения Республики Адыгея // Кубанский научный медицинский вестник. – 2016. – № 3 (158). – С. 23–27. Bedanokova MR, Bat NM. Analiz organizatsii l’gotnogo lekarstvennogo obespecheniya naseleniya Respubliki Adygeya [Analysis of the organization of preferential pharmaceutical supply of the population of the Republic of Adygea]. Kubanskiy nauchnyy meditsinskiy vestnik [Kuban Scientific Medical Bulletin]. 2016; (3/158): 23–27. (In Russ.)

20. Сушкова М.С. Пути оптимизации отбора и адаптации персонала аптечных организаций: автореферат диссертации ... кандидата фармацевтических наук: 3.4.3. – Пермь, 2023. – 24 с. Sushkova MS. Puti optimizatsii otbora i adaptatsii personala aptechnykh organizatsiy: avtoreferat dissertatsii ... kandidata farmatsevticheskikh nauk [Ways to optimize the selection and adaptation of personnel in pharmacy organizations: abstract of PhD dissertation in Pharmacy]. Perm; 2023. 24 p. (In Russ.)

 

 

УДК: 616.98-053.2:615.371:612.017.1

DOI: 10.20969/VSKM.2026.19(5). 66-71

PDF download Immune system status during vaccination in post-COVID-19 children

Lola Dzh. Mullaeva1, Feruza M. Gafarova1, Saodat Kh. Mukhamedova1

1 Center for the Development of Professional Qualification of Medical Professionals, 51 Parkentskaya str.,

100007 Tashkent, Uzbekistan

Abstract. Introduction. Today, the issue of routine immunization of children, especially those with health impairments, is becoming increasingly relevant. Evaluation of immune status during vaccination in children with a history of COVID-19 represents a critical and scientifically significant challenge in contemporary pediatrics. Aim. To assess the immunological profile of children during the measles vaccination following recovery from SARS-CoV-2 infection. Materials and Methods: The clinical study was conducted involving children aged 2 to 7 years who had recovered from COVID-19 (n=21 pre-vaccination and n=30 post-vaccination) and subsequently u nderwent routine measles immunization In this category of children, adaptive reactions were analyzed based on absolute immune status indicators prior to the administration of any preventive vaccinations, and the results of measles seroconversion following vaccination accord ing to the National Immunization Schedule were evaluated. Results and Discussion. In children who had recovered from COVID-19, the analysis of the results revealed an imbalance in several immune system parameters before measles vaccination, a decrease in the intensity of post-vaccination immunity, and an increased risk of infection with this vaccine-preventable disease. To increase the effectiveness of the immune response to vaccination in this category of children, it is necessary to develop preparatory measures before conducting the course of preventive measles vaccinations. Conclusions. Children who have recovered from COVID-19 exhibit low antibody titers after measl es vaccination, as well as an imbalance in immune system parameters prior to vaccination.

Keywords: children, COVID-19, vaccine prevention, measles, immune status

For citation: Mullaeva, L. Dzh.; Gafarova, F.M.; Mukhamedova, S.Kh. Immune system status during vaccination in post-COVID-19 children. The Bullet in of Contemporary Clinical Medicine. 2026, 19 (5), 66-71. DOI: 10.20969/VSKM.2026.19(5).66-71.

REFERENCES

1. Centers for Disease Control and Prevention. Global immunization: fast facts. 2025. Режим доступа [URL]: www.cdc.gov/global-immunization/fast-facts/index.html

2. Информационные бюллетени ВОЗ. Охват вакцинацией. 2025. Informacionnye byulleteni VOZ [Fact sheets WHO]. Ohvat vakcinaciej [Immunization coverage]. 2025. (In Russ.) Режим доступа [URL]: www.who.int/ru/news-room/fact-sheets/detail/immunization-coverage

3. Сахабетдинов Б.А., Сахабетдинова К.Н., Ибрагимова А.Р., [и др.]. Противопрививочное настроение: снижение коллективного иммунитета, вспышки кори и коклюша в 2023 году // Тихоокеанский медицинский журнал. – 2024. – № 4. – С. 86–90. Sahabetdinov BA, Sahabetdinova KN, Ibragimova AR, et al. Protivoprivivochnoe nastroenie: snizhenie kollektivnogo immuniteta, vspyshki kori i koklyusha v 2023 godu [Anti-vaccination attitudes: decline in herd immunity, measles and pertussis outbreaks in 2023]. Tihookeanskij medicinskij zhurnal [Pacific Medical Journal]. 2024; (4): 86–90. (In Russ.) DOI: 10.34215/1609-1175-2024-4-86-90

4. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nature Medicine. 2021; 27: 601. DOI: 10.1038/s41591-021-01283-z

5. Афонина Н.М., Михеева И.В., Мельникова А.А., Акимкин В.Г. Реализация возможности расширения Национального календаря профилактических прививок в региональных календарях // Эпидемиология и Вакцинопрофилактика. – 2025. – Т . 25, вып. 4. – С. 31–41. Afonina NM, Miheeva IV, Mel’nikova AA, Akimkin VG. Realizaciya vozmozhnosti rasshireniya Nacional’nogo kalendarya profilakticheskih privivok v regional’nyh kalendaryah [Implementation of expanding the National Immunization Schedule in regional programs]. Epidemiologiya i Vakcinoprofilaktika [Epidemiology and Vaccinoprophylaxis]. 2025; 25 (4): 31–41. (In Russ.) DOI: 10.31631/2073-3046-2025-24-4-31-41

6. Брико Н.И., Фельдблюм И.В. Национальная концепция развития вакцинопрофилактики в России // Эпидемиология и Вакцинопрофилактика. – 2024. – Т . 23, вып. 2. – С. 114–123. Briko NI, Fel’dblyum IV. Nacional’naya koncepciya razvitiya vakcinoprofilaktiki v Rossii [National concept for development of vaccination prevention in Russia]. Epidemiologiya i Vakcinoprofilaktika [Epidemiology and Vaccinoprophylaxis]. 2024; 23 (2): 114–123. (In Russ.) DOI: 10.31631/2073-3046-2024-23-2-114-123

7. Костинов М.П., Лукачев И.В. Возможности усовершенствования вакцинопрофилактики в современной России // Журнал микробиологии, эпидемиологии и иммунобиологии. – 2016. – № 4. – С. 60–65. Kostinov MP, Lukachev IV. Vozmozhnosti usovershenstvovaniya vakcinoprofilaktiki v sovremennoj Rossii [Possibilities of improving vaccine prophylaxis in modern Russia]. Zhurnal mikrobiologii, epidemiologii i immunobiologii [Journal of Microbiology, Epidemiology and Immunobiology]. 2016; (4): 60–65. (In Russ.) DOI: 10.36233/0372-9311-2016-4-60-65

8. СанПиН Республики Узбекистан №0239-07/4. Санитарно-эпидемиологические требования к иммунопрофилактике инфекционных заболеваний (2021). – С. 28–29. SanPiN Respubliki Uzbekistan №0239-07/4. Sanitarno-epidemiologicheskie trebovaniya k immunoprofilaktike infekcionnyh zabolevanij [Sanitary Rules and Norms of the Republic of Uzbekistan No. 0239-07/4. Sanitary and epidemiological requirements for immunoprophylaxis of infectious diseases]. 2021; 28–29. (In Russ.)

9. Иванова И.А., Филиппенко А.В., Труфанова А.А., [и др.]. Особенности формирования поствакцинального гуморального immune ответа у лиц, перенесших COVID-19 разной степени тяжести // Медицинская иммунология. – 2023. – Т . 25, вып. 1. – С. 181–192. Ivanova IA, Filippenko AV, Trufanova AA, et al. Osobennosti formirovaniya postvakcinal’nogo gumoral’nogo immunnogo otveta u lic, perenesshih COVID-19 raznoj stepeni tyazhesti [Features of post-vaccination humoral immune response in individuals after COVID-19 of different severity]. Medicinskaya immunologiya [Medical Immunology]. 2023; 25 (1): 181–192. (In Russ.) DOI: 10.15789/2220-7619-AOF-2107

10. Гущин В.А., Майнулов В.А., [и др.]. Иммунологическая память как основа рациональной вакцинопрофилактики населения // Вестник РГМУ . – 2017. – № 5. – С. 5–28. Gushchin VA, Mainulov VA, et al. Immunologicheskaya pamyat’ kak osnova racional’noj vakcinoprofilaktiki naseleniya [Immunological memory as a basis for rational vaccination]. Vestnik RGMU [Bulletin of RSMU]. 2017; (5): 5–28. (In Russ.)

11. Уббиниязова К.Т., Абсаттарова В.К., Оразымбетова А.Т. Динамика заболеваемости корью и состояние коллективного иммунитета среди детей Республики Каракалпакстан // Основы медицины. – 2026. – Т . 1, вып. 9. – С. 285–288. Ubbiniyazova KT, Absattarova VK, Orazymbetova AT. Dinamika zabolevaemosti kor’yu i sostoyanie kollektivnogo immuniteta sredi detej Respubliki Karakalpakstan [Dynamics of measles incidence and herd immunity among children in the Republic of Karakalpakstan]. Osnovy mediciny [Fundamentals of Medicine]. 2026; 1 (9): 285–288. (In Russ.) Режим доступа [URL]: https://journals.tnmu.uz/index.php/tas/article/view/4030

12. Жужжасарова А., Баешева Д., Турдалина Б., [и др.]. Показатель вакцинального статуса и заболеваемости корью в Республике Казахстан // Наука и здравоохранение. – 2021. – № 4. – С. 17–23. Zhuzhassarova A, Baysheva D, Turdalina B, et al. Pokazatel’ vakcinal’nogo statusa i zabolevaemosti kor’yu v Respublike Kazahstan [Vaccination status and measles incidence in the Republic of Kazakhstan]. Nauka i zdravoohranenie [Science and Healthcare]. 2021; (4): 17–23. (In Russ.) DOI: 10.34689/sh.2021.23.4.017

13. Харит С.М., Иванов Д.О., Скрипченко Н.В. Вакцинопрофилактика для практического врача: Руководство для врачей. – СПб.: Государственный педиатрический медицинский университет , 2024. – 192 с. Kharit SM, Ivanov DO, Skripchenko NV. Vakcinoprofilaktika dlya prakticheskogo vracha: Rukovodstvo dlya vrachej [Vaccination for the practicing physician: Clinical guide]. St. Petersburg: Gosudarstvennyj pediatricheskij medicinskij universitet; 2024. 192 p. (In Russ.)

14. Moore DL. Immunization of the immunocompromised child: Key principles. Paediatr Child Health. 2018; 23 (3); 203–205. DOI: 10.1093/pch/pxx180

15. Инюткина А.А., Никулина В.П., Годков М.А. Особенности иммунного ответа при COVID-19 // Russian Sklifosovsky Journal of Emergency Medical Care. – 2023. – Т . 12, вып. 1. – С. 122–129. Inyutkina AA, Nikulina VP, Godkov MA. Osobennosti immunnogo otveta pri COVID-19 [Features of the immune response in COVID-19]. Russian Sklifosovsky Journal of Emergency Medical Care [Russian Sklifosovsky Journal of Emergency Medical Care]. 2023; 12 (1): 122–129. (In Russ.) DOI: 10.23934/2223-9022-2023-12-1-122-129 

 

 

УДК. 616.12-008.1: 616.12-089: 616-08-07

DOI: 10.20969/VSKM.2026.19(5).72-80

PDF download Inflammatory markers associated with myocardial remodeling in patients with myocardial infarction

Natalia A. Mushikhina1, Ofeliia Kh. Tuzmukhametova1, Elena A. Gorbatenko1, Nikita E. Shirokov1, Oleg Kh.Tuzmukhametov1, Natalia V. Dremina1, Olivia N. Laggar1

1 Tyumen Cardiology Research Center – Branch of Tomsk National Research Medical Center of the Russian Academy of Sciences, 111 Melnikaite str., 625026 Tyumen, Russia

Abstract. Introduction. It is known that myocardial infarction can lead to the development of heart failure in many patients, but the causes of adverse myocardial remodeling are poorly understood. Ischemic myocardial injury triggers activation of the cellular and systemic inflammatory response. Studying the associations of inflammatory markers with left atrial reservoir function and global left ventricular longitudinal strain may be useful for identifying a high risk of pathological myocardial remodeling. Aim. To study the relationship between inflammatory markers and clinical, demographic, and myocardial morpho-functional parameters in patients with myocardial infarction in the acute and early post-infarction periods. Materials and Methods. The study included 99 patients with acute myocardial infarction. Inflammatory markers and echocardiographic parameters reflecting myocardial remodeling were analyzed at baseline upon hospital admission and 3 months after discharge. Results and Discussion. In the acute period of myocardial infarction, increased likelihood of elevated cellular inflammatory response indices was demonstrated in women, in patients with ST-segment elevation myocardial infarction, and, to a greater extent, in patients with chronic kidney disease. In the acute stage of myocardial infarction, negative correlations were registered: Left atrial reservoir phase deformation with the systemic inflammatory response index, N-terminal natriuretic peptide and high-sensitivity C-reactive protein; left atrial complia nce with cardiotrophin-1; left ventricular global longitudinal strain indices with matrix metalloproteinase-9 and soluble oncogenic suppressor protein 2. After 3 months, the inverse relationship persisted between the left atrial reservoir phase deformation and high-sensitivity C-reactive protein and cardiotrophin-1; and left ventricular global longitudinal strain indices with soluble oncogenic suppressor protein 2. Conclusions. Severity of cellular inflammatory response in acute myocardial infarction is associated with gender, type of myocardial infarction, and presence of chronic kidney disease. The findings of the study suggest that in the early post-infarction period, left atrial deformation indices are associated with the markers of cellular (systemic inflammatory response in dex) and systemic inflammation (high-sensitivity C-reactive protein), as well as with myocardial stress markers (N-terminal natriuretic peptide and cardiotrophin-1). Meanwhile, left ventricular deformation indices demonstrated a relationship exclusively with markers involved in myocardial remodeling processes (matrix metalloproteinase-9 and soluble tumor suppressor protein 2).

Keywords: myocardial infarction, inflammation biomarkers, myocardial remodeling, left atrial reservoir strain, global longitudinal strain.

For citation: Mushikhina, N.A.; Tuzmukhametova, O.Kh.; Gorbatenko E.A.; et al. Inflammatory markers associated with myocardial remodeling in patients with myocardial infarction. The Bulletin of Contemporary Clinical Medicine. 2026, 19(5), 72-80. DOI: 10.20969/VSKM.2026.19(5).72-80.

REFERENCES

1. Хубулава Г.Г ., Козлов К.Л., Шишкевич А.Н., [и др.]. Предикторы реперфузионного синдрома миокарда: современный взгляд на вопрос и актуальные проблемы. Часть 1: Реперфузионные аритмии, необратимое повреждение и оглушение миокарда (обзор литературы) // Регионарное кровообращение и микроциркуляция. – 2021. – Т .20, вып. 2 (78). – С.20–26. Khubulava GG, Kozlov KL, Shishkevich AN, et al. Prediktory reperfuzionnogo sindroma miokarda: sovremennyj vzglyad na vopros i aktual’nye problemy. Chast’ 1: Reperfuzionnye aritmii, neobratimoe povrezhdenie i oglushenie miokarda (obzor literatury) [Predictors of myocardial reperfusion syndrome: a modern view of the issue and current problems. Part 1: reperfusion arrhythmias, injury and stunning myocardium (review of literature)]. Regionarnoe krovoobrashchenie i mikrocirkulyaciya [Regional hemodynamics and microcirculation]. 2021; 20 (2): 20–26. (In Russ.) DOI: 10.24884/1682-6655-2021-20-2-20-26

2. Kaplangoray М, Toprak К, Deveci Е, Caglayan C, Sahin E. Could Pan-Immune-Inflammation Value be a Marker for the Diagnosis of Coronary Slow Flow Phenomenon? Cardiovascular Toxicology. 2024; 24 (5): 519–526. DOI: 10.1007/s12012-024-09855-4

3. Гельцер Б.И., Шахгельдян К.И., Пак Р.Л., [и др.]. Индикаторы системного воспалительного ответа и их взаимосвязь с фибрилляцией предсердий у больных инфарктом миокарда с подъемом сегмента ST после чрескожного коронарного вмешательства // Российский кардиологический журнал. – 2025. – Т .30, вып. 5. – С.91–98. Geltser BI, Shahgeldyan KI, Pak RL, et al. Indikatory sistemnogo vospalitel’nogo otveta i ih vzaimosvyaz’ s fibrillyaciej predserdij u bol’nyh infarktom miokarda s pod»emom segmenta ST posle chreskozhnogo koronarnogo vmeshatel’stva [Parameters of the systemic inflammatory response and their relationship with atrial fibrillation in patients with ST-elevation myocardial infarction after percutaneous coronary intervention]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology]. 2025; 30 (5):6175. (In Russ.) DOI: 10.15829/1560-4071-2025-6175

4. Поляков Д.С., Фомин И.В., Беленков Ю.Н., [и др.]. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА-ХСН // Кардиология. – 2021. – Т .61, вып. 4. – С.4–14. Polyakov DS, Fomin IV, Belenkov YuN, et al. Hronicheskaya serdechnaya nedostatochnost’ v Rossijskoj Federacii: chto izmenilos’ za 20 let nablyudeniya? Rezul’taty issledovaniya EPOHA-HSN [Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study]. Kardiologiya [Cardiology]. 2021; 61 (4): 4–14. (In Russ.) DOI: 10.18087/cardio.2021.4.n1628

5. Lange T, Gertz RJ, Schulz A, Sören J Backhaus SJ, Evertz R, Kowallick JT, Hasenfuß G, Desch S, Thiele H, Stiermaier T, Eitel I, Schuster A. Impact of myocardial deformation on risk prediction in patients following acute myocardial infarction. Frontiers in Cardiovascular Medicine. 2023; 10:1199936. DOI: 10.3389/fcvm.2023.1199936

6. Iwahashi N, Gohbara M, Kirigaya J, Abe T, Horii M, Hanajima Yo, Toya N, Takahashi H, Kimura Yu, Minamimoto Yu, Okada K, Matsuzawa Ya, Hibi K, Kosuge M, Ebina T, Tamura K, Kimura K. Prognostic Significance of the Combination of Left Atrial Reservoir Strain and Global Longitudinal Strain Immediately After Onset of ST-Elevation Acute Myocardial Infarction. Circulation Journal. 2022; 86 (10): 1499–1508. DOI: 10.1253/circj.CJ-21-0907

7. Chen C, Cong BL, Wang M, Abdullah M, Wang XL, Zhang YH, Xu SJ, Cui L. Neutrophil to lymphocyte ratio as a predictor of myocardial damage and cardiac dysfunction in acute coronary syndrome patients. Integrative Medicine Research. 2018; 7(2): 192–199. DOI: 10.1016/j.imr.2018.02.006

8. Tudurachi B-S, Anghel L, Tudurachi A, Sasc˘au RA, St˘atescu C. Assessment of Inflammatory Hematological Ratios (NLR, PLR, MLR, LMR and Monocyte/HDL–Cholesterol Ratio) in Acute Myocardial Infarction and Particularities in Young Patients. International Journal of Molecular Sciences. 2023; 24 (18): 14378. DOI: 10.3390/ijms241814378

9. Ji Z, Liu G, Guo J, Zhang R, Su Y, Carvalho A, Qu Y, Zuo W, Yao Y, Lin J, et al. The Neutrophil-to-Lymphocyte Ratio Is an Important Indicator Predicting In-Hospital Death in AMI Patients. Frontiers in Cardiovascular Medicine. 2021; 8: 706852. DOI: 10.3389/fcvm.2021.706852

10. Guo J, Huang Ya, Pang L, Zhou Yu, Yuan J, Zhou B, Fu M. Association of systemic inflammatory response index with ST segment elevation myocardial infarction and degree of coronary stenosis: a cross-sectional study. BMC Cardiovascular Disorders. 2024; 24(1): 98. DOI: 10.1186/s12872-024-03751-z

11. Jha PK, Nakano T, Itto LYU, Barbeiro MC, Lupieri A, Aikawa E, Aikawa M. Vascular inflammation in chronic kidney disease: the role of uremic toxins in macrophage activation. Frontiers in Cardiovascular Medicine. 2025; 12: 1574489. DOI: 10.3389/fcvm.2025.1574489

12. Lee H, Fessler MB, Qu P, Heymann Ju, Kopp JB. Macrophage polarization in innate immune responses contributing to pathogenesis of chronic kidney disease. BMC Nephrology. 2020; 21: 270. DOI: 10.1186/s12882-020-01921-7

13. Li H, Huang J, Sun M. The relationship among inflammatory biomarkers, hyperuricemia and chronic kidney disease: analysis of the NHANES 2015-2020. Renal Failure. 2025; 47(1): 2553808. DOI: 10.1080/0886022X.2025.2553808

14. Yang Zh, Qiao Yo, Wang D, Yan G, Tang Ch. Association Between Inflammatory Biomarkers and Contrast-induced Acute Kidney Injury in ACS Patients Undergoing Percutaneous Coronary Intervention: A Cross-sectional Study.Angiology. 2024; 75(9): 831–840. DOI: 10.1177/00033197231185445

15. Ma CS, Liao YP, Fan JL, Zhao X, Su B, Zhou BY. The novel left atrial strain parameters in diagnosing of heart failure with preserved ejection fraction. Echocardiography 2022; 39(3): 416-425. DOI: 10.1111/echo.15304

16. Миролюбова О.А., Кудрявцев А.В., Семчугова Э.О., Малютина С.К., Рябиков А.Н. C-реактивный белок и его ассоциации с кардиометаболическими факторами риска и эхокардиографическими индикаторами сердечной недостаточности: результаты исследования «Узнай свое сердце» в г. Архангельске. Кардиология. – 2020. – Т .60, вып. 9. – С.68-75. Mirolyubova OA, Kudryavtsev AV, Semchyugova EO, Malyutina SK, Ryabikov AN. C-reactive protein and its associations with сardiometabolic risk factors and echocardiographic indicators of heart failure: results of “Know your heart” study in Arkhangelsk. Kardiologiia. 2020;60(9):68-75. DOI: 10.18087/cardio.2020.9.n975

17. Пахнова Л.Р ., Башкина О.А., Воронина Л.П. Роль кардиотрофина-1 при хронической сердечной недостаточности. Медицинский вестник Юга России. – 2023. – Т .14, вып. 4. – С.108–13. Pakhnova LR, Bashkina OA, Voronina LP. Rol’ kardiotrofina-1 pri hronicheskoj serdechnoj nedostatochnosti [The role of cardiotrophin-1 in chronic heart failure]. Medicinskij vestnik Yuga Rossii [Medical Herald of the South of Russia]. 2023; 14(4): 108–113. (In Russ.) DOI: 10.21886/2219-8075-2023-14-4-108-113

18. Khosravi F, Ahmadvand N, Wartenberg M, Sauer H. Induction of Stem-Cell-Derived Cardiomyogenesis by Fibroblast Growth Factor 10 (FGF10) and Its Interplay with Cardiotrophin1 (CT-1). Biology (Basel). 2022; 11(4): 534. DOI: 10.3390/biology11040534

19. Ushakov A, Ivanchenko V, Gagarina A. Regulation of Myocardial Extracellular Matrix Dynamic Changes in Myocardial Infarction and Postinfarct Remodeling. Current Cardiology Reviews. 2020; 16(1): 11–24. DOI: 10.2174/1573403X15666190509090832

20. Movahed MR, Ramaraj R, Manrique C, Hashemzadeh M. Left ventricular hypertrophy is independently associated with all-cause mortality. American Journal of Cardiovascular Disease. 2022; 12(1): 38–41. Режим доступа [URL]: https://pmc.ncbi.nlm.nih.gov/articles/PMC8918741

21. Fabiani I, Conte L, Pugliese NR, Calogero E, Barletta V, Di Stefano R, Santoni T, Scatena C, Bortolotti U, Naccarato AG, Petronio AS, Di Bello V. The integrated value of sST2 and global longitudinal strain in the early stratification of patients with severe aortic valve stenosis: a translational imaging approach. Int J Cardiovasc Imaging. 2017;33(12):1915-1920. DOI: 10.1007/s10554-017-1203-2

22. Park S, Kim IC, Kim H, Cho YK, Lee CH, Hur SH. Ability of soluble ST2 to predict left ventricular remodeling in patients with acute coronary syndrome. Heart Vessels. 2022; 37(2): 173–183. DOI: 10.1007/s00380-021-01905-z

23. Дылева Ю.А., Груздева О.В., Акбашева О.Е., [и др.]. Возможность использования стимулирующего фактора роста 24. (st 2) для верификации постинфарктного ремоделирования миокарда. Клиническая лабораторная диагностика. – 2016. – Т .61, вып. 7. – С.412–418. Dyleva YuA, Gruzdeva OV, Akbasheva OE, et al. Vozmozhnost’ ispol’zovaniya stimuliruyushchego faktora rosta (st 2) dlya verifikacii postinfarktnogo remodelirovaniya miokarda [The possibility of application of stimulant growth factor (ST2) for verifying postinfarction remodeling of myocardium]. Klinicheskaya Laboratornaya Diagnostika [Russian Clinical Laboratory Diagnostics]. 2016; 61 (7): 412–418. (In Russ.) DOI: 10.18821/0869-2084-2016-61-7-412-418

24. Фетисова В.И., Намитоков А.М., Гилевич И.В., Космачева Е.Д. Растворимый белок подавления онкогенности (sST2) в качестве возможного биомаркера у пациентов с острым коронарным синдромом. Южно-Российский журнал терапевтической практики. – 2023. – Т .4, вып. 2. – С.7–17. Fetisova VI, Namitokov AM, Gilevich IV, Kosmacheva ED. Rastvorimyj belok podavleniya onkogennosti (sST2) v kachestve vozmozhnogo biomarkera u pacientov s ostrym koronarnym sindromom [Soluble tumorigenicity suppression protein (sST2) as a possible biomarker in patients with acute coronary syndrome]. Yuzhno-Rossijskij zhurnal terapevticheskoj praktiki [South Russian Journal of Therapeutic Practice]. 2023; 4(2): 7–17. (In Russ.) DOI: 10.21886/2712-8156-2023-4-2-7-17

 

 

УДК: 615.322:615.468:615.03

DOI: 10.20969/VSKM.2026.19(5).81-88

PDF download Development of a gel formulation containing a liquid extract of jujube leaves and evaluation of its wound-healing activity

Elena B. Nikiforova1, Anastasia I. Shevchenko2,Naira A. Davitavyan2, Irina N. Krylova1, Liana K. Martirosyan2, Olga V. Krivenkova1, Galina A. Barannikova1

1 University “Synergy,” 27 Partizanskaya str., 121351 Moscow, Russia

2 Kuban State Medical University, 4 M. Sedin str., 350063 Krasnodar, Russia

Abstract. Introduction. Development of effective and safe wound treatments is still an important task, the successful solution of which is reasonably associated with the development and use of herbal preparations. A scientifically substantiated source for creating wound-healing herbal remedies is plant materials containing biologically active substances of a phenolic nature, primarily from the group of flavonoids, which exhibit antioxidant, anti-inflammatory, and membrane-stabilizing activity and are thus capable of providing positive response to treatment at various stages of the wound process. One of the promising types of plant materials, rich in phenolic compounds with a predominance of flavonoids, are jujube (Ziziphus jujuba Mill.) leaves available within the supply of raw materials in Russia. A gel that optimally combines processing, consumer, and biopharmaceutical properties is presented as the optimal dosage form for the wound-healing agent being developed. Aim. To develop a composition and study the wound-healing effect of a gel containing a liquid extract of jujube leaves. Materials and Methods. The study involved experimental gel formulations containing the liquid extract of jujube leaves prepared using various gelling agents, such as sodium carboxymethylcellulose, carbopol-940, polyethylene oxide-400, and polyethylene oxide-1500. Adhesive properties of gel formulations were studied by measuring the peel force using a modified balance. Biopharmaceutical properties of the gels were assessed using the agar diffusion method. Wound-healing activity of the gel was studied in male white laboratory rats using a planar skin wound model. Statistical analysis was performed using the StatTech v. 4.9.5 software developed by StatTech LLC, Russia. Results and Discussion. A comparative assessment of the adhesive and biopharmaceutical properties of experimental gel samples showed that the most optimal properties are demonstrated by a formulation containing 10.0 g of liquid jujube leaf extract, 2.0 g of carbopol-940, 2.0 g of triethanolamine, 2.0 g of glycerin, and up to 100.0 g of purified water. Results of the study of the wound-healing activity of this formulation generally indicate that its use in the experiment markedly activated the processes of repair of damaged tissues and contributed to a reduction in wound-healing time by an average of 6 days compared with that in the groups of untreated animals. Conclusions. A gel formulation containing liquid jujube leaf extract was developed, and its wound-healing activity was studied. The experimental results provide grounds for considering this gel as a potentially therapeutically significant herbal wound-healing agent.

Keywords: jujube, leaves, liquid extract, flavonoids, gel, wound-healing activity

For citation: Nikiforova, E.B.; Shevchenko, A.I.; Davitavyan, N.A. [et al.]. Development of a gel formulation containing a liquid extract of jujube leaves and evaluation of its wound-healing activity. The Bulletin of Contemporary Clinical Medicine. 2026, 19(5), 81-88. DOI: 10.20969/VSKM.2026.19(5).81-88.

REFERENCES

1. Criollo-Mendoza MS, Contreras-Angulo LA, Leyva-López N, [et al.]. Wound Healing Properties of Natural Products: Mechanisms of Action. Molecules. 2023; 28(2): 598. DOI: 10.3390/molecules28020598

2. Shedoeva A, Leavesley D, Upton Z, [et al.]. Wound Healing and the Use of Medicinal Plants. Evid Based Complement Alternat Med. 2019; 2019: 2684108. DOI: 10.1155/2019/2684108

3. Vitale S, Colanero S, Placidi M, [et al.]. Phytochemistry and Biological Activity of Medicinal Plants in Wound Healing: An Overview of Current Research. Molecules. 2022; 27(11): 3566. DOI: 10.3390/molecules27113566

4. Кирилюк А.А., Петрище Т.Л. Особенности влияния биологически активных веществ лекарственных растений на фармакологическую активность лекарственных средств //  Современные проблемы здравоохранения и медицинской статистики. – 2017. – №2. – C. 1-12. Kirilyuk AA, Petrishche TL. Osobennosti vliyaniya biologicheski aktivnyh veshchestv lekarstvennyh rastenij na farmakologicheskuyu aktivnost’ lekarstvennyh sredstv [Features of the influence of biologically active substances of medicinal plants on the pharmacological activity of drugs]. Sovremennye problemy zdravoohraneniya i medicinskoj statistiki [Modern problems of health care and medical statistics]. 2017; 2: 1-12. (In Russ.). Режим доступа [URL]: https://cyberleninka.ru/article/n/osobennosti-vliyaniya-biologicheski-aktivnyh-veschestv-lekarstvennyh-rasteniy-na-farmakologicheskuyu-aktivnost-lekarstvennyh/viewer

5. Никифорова Е.Б., Шевченко А.И ., Нечаева А.Г . [и др.]. Актуальные вопросы химического состава, биологического действия и перспективы медицинского применения листьев зизифуса настоящего // Медико-фармацевтический журнал Пульс. – 2023. – Т . 25, № 6. – С.119-124. Nikiforova EB, Shevchenko AI, Nechaeva AG, [et al.]. Aktual’nye voprosy himicheskogo sostava, biologicheskogo dejstviya i perspektivy medicinskogo primeneniya list’ev zizifusa nastoyashchego [Current issues of the chemical composition, biological effect, and prospects for medical use of the leaves of Ziziphus jujube]. Mediko-farmacevticheskij zhurnal Pul’s [Medical and Pharmaceutical Journal Pulse]. 2023; 25(6): 119-124. (In Russ.) DOI:10.29296/25877313-2023-08-01

6. Rodríguez Villanueva J, Rodríguez Villanueva L. Experimental and Clinical Pharmacology of Ziziphus jujuba Mills. Phytother Research. 2017; 31(3): 347-365. DOI: 10.1002/ptr.5759

7. Zhang L, Liu P Li L, [et al.]. Identification and Antioxidant Activity of Flavonoids Extracted from Xinjiang Jujube (Ziziphus jujube Mill.) Leaves with Ultra-High Pressure Extraction Technology. Molecules. 2018; 24(1): 122. DOI:10.3390/molecules24010122

8. Damiano S, Forino M, De A, [et al.]. Antioxidant and antibiofilm activities of secondary metabolites from Ziziphus jujuba leaves used for infusion preparation. Food Chemistry. 2017; 230: 24-29. DOI: 10.1016/j.foodchem.2017.02.141

9. Hovanet MV, Ozon EA, Moros AN, [et al.]. Wound Healing and AntiInflammatory Effects of a Newly Developed Ointment Containing Jujube Leaves Extract. Life (Basel). 2022; 12(12):1947. DOI: 10.3390/life12121947

10. Ковальская Г.Н., Е. Н. Михалевич Е.Н., Колмакова Е.С. Гели как лекарственная форма в государственной фармакопее XIV издания, нормативно-правовых актах Минздрава России и Государственном реестре лекарственных средств // Вопросы обеспечения качества лекарственных средств. – 2020. – № 1(27). – С. 76-85. Koval‘skaya GN, Mihalevich EN, Kolmakova ES. Geli kak lekarstvennaya forma v gosudarstvennoj farmakopee XIV izdaniya, normativno-pravovyh aktah Minzdrava Rossii i Gosudarstvennom reestre lekarstvennyh sredstv [Gels as a dosage form in the State Pharmacopoeia of the XIV edition, regulatory legal acts of the Ministry of Health of Russia and the State Register of Medicines]. Voprosy obespecheniya kachestva lekarstvennyh sredstv [Issues of quality assurance of medicines]. 2020; 1(27): 76-85. (In Russ.). DOI:10.34907/JPQAI.2020.76.13.010

11. Rachmawati P. Basics: A Review: In Situ Gel Dosage Forms for Herbal Medicine Delivery. Int J Pharm Compd. 2023; 27(1): 24-29.  Режим доступа [URL]: https://pubmed.ncbi.nlm.nih.gov/36720060/

12. Сампиев А.М., Никифорова Е.Б., Шевченко А.И. Флавоноиды листьев зизифуса настоящего // Химико-фармацевтический журнал. – 2020. – Т .54, № 8. – С. 13-17. Sampiev AM, Nikiforova EB, Shevchenko AI. Flavonoidy list’ev zizifusa nastoyashchego [Flavonoids of the leaves of zizyphus jujube]. Himiko-farmacevticheskij zhurnal [Chemical and pharmaceutical journal]. 2020; 54 (8): 13-17. (In Russ.). DOI: 10.30906/0023-1134-2020-54-8-13-17

13. Пальвинский А.Г ., Бахрушина Е.О., Козлова Ж.М. [и др.]. Разработка термореверсивного стоматологического геля с берберином // Разработка и регистрация лекарственных средств. – 2020. – Т . 9, №4. – С. 88-92. Pal’vinskij AG, Bahrushina EO, Kozlova ZhM. [et al.]. Razrabotka termoreversivnogo stomatologicheskogo gelya s berberinom [Development of a thermoreversible dental gel with berberine]. Razrabotka i registraciya lekarstvennyh sredstv [Drug Development and Registration]. 2020; 9(4): 88-92. (In Russ.). DOI: 10.33380/2305-2066-2020-9-4-88-92

14. Пальвинский А.Г ., Бахрушина Е.О., Холина П.А. [и др.]. Биофармацевтическое изучение стоматологического геля берберина бисульфата // Вопросы биологической, медицинской и фармацевтической химии. – 2022. – Т . 25, №3. – С. 10-14. Pal’vinskij AG, Bahrushina EO, Holina PA, [et al.]. Biofarmacevticheskoe izuchenie stomatologicheskogo gelya berberina bisul’fata [Biopharmaceutical study of berberine bisulfate dental gel]. Voprosy biologicheskoj, medicinskoj i farmacevticheskoj himii [Issues of Biological, Medical and Pharmaceutical Chemistry]. 2022; 25 (3): 10-14. (In Russ.). DOI: 10.29296/25877313-2022-03-02

15. Поздняков Д.И., Сергеева Е.О., Юртаева Е.А. [и др.]. Изучение антибактериального и ранозаживляющего действия нового порошка наружного применения // Вестник Смоленской государственной медицинской академии. – 2024. – № 23(3). – С. 193-200. Pozdnyakov DI, Sergeeva EO, YUrtaeva EA, [et al.]. Izuchenie antibakterial’nogo i ranozazhivlyayushchego dejstviya  novogo poroshka naruzhnogo primeneniya [Study of the antibacterial and wound-healing effects of a new topical powder]. Vestnik Smolenskoj gosudarstvennoj medicinskoj akademii [Bulletin of the Smolensk State Medical Academy]. 2024; 23(3): 193-200. (In Russ.). DOI: 10.37903/vsgma.2024.3.24

16. Довнар Р.И. Моделирование кожных ран в эксперименте // Новости хирургии. – 2021. – № 29(4). – С. 480-489. Dovnar RI. Modelirovanie kozhnyh ran v eksperimente [Modeling of skin wounds in the experiment]. Novosti hirurgii [Surgery News]. 2021; 29(4): 480-489. (In Russ.). DOI: 10.18484/2305-0047.2021.4.480

17. A program for data collection and analysis. Available from: https://stattech.ru / [Accessed 15th October 2025].

 

 

УДК 616.12-008-002.1-089-08:615.273:577.175.14

DOI: 10.20969/VSKM.2026.19(5).89-94

PDF download Changes in interleukin-6 levels during atorvastatin and pitavastatin therapy in patients with ST-segment elevation acute coronary syndrome after percutaneous coronary intervention

Luiza M. Nurieva1, Zulfiya F. Kim1,2, Ilgizya I. Zakirova1, Rufina R. Abdullina1, Gulnisa Sh. Sharifullina1

1 City Clinical Hospital No. 7 named after M. N. Sadykov, 54 Chuykov str., 420103 Kazan, Russia

2 Kazan State Medical University, 49 Butlerov str., 420012 Kazan, Russia

Abstract. Introduction. It is currently known that inflammatory processes play an important role in both forming atherosclerotic plaque and injuring a stable atheroma. Activation of interleukin-6 plays an important role in leading to enhanced coagulation. Aim. To study changes in the interleukin-6 levels in patients with ST-segment elevation acute coronary syndrome after percutaneous coronary intervention, while being treated with atorvastatin and pitavastatin. Materials and Methods. The study included 40 patients aged 33–88 years, hospitalized in the cardiology department of City Clinical Hospital No. 7 named after M. N. Sadykov (Kazan) with ST-segment elevation acute coronary syndrome. All patients met the inclusion, non-inclusion, and exclusion criteria. Blood samples were collected from all patients to determine their interleukin-6 levels as a marker of systemic inflammation before percutaneous coronary intervention and on days 7–8 of hospitalization. Descriptive statistics methods were used for statistical data processing. Results and Discussion. The total study group consisted of 40 patients aged 33 to 88 years, with the mean age of 60.65±13.35 years. To rule out contrast-induced nephropathy, we analyzed the dynamics of serum creatinine upon admission, 24–48 hours later, and before their discharge. No patients were diagnosed with contrast-induced nephropathy. To monitor the changes in pro-inflammatory cytokines, we assessed interleukin-6 levels before coronary angiography (within the first 24 hours of acute coronary syndrome) and on day 7 after the onset of the disease. According to our findings, the level of interleukin-6 decreased by an average of 5.12 pg/mL during treatment with atorvastatin and by 1.06 pg/mL during treatment with pitavastatin, with no statistically significant differences. Conclusions. Thus, the study demonstrated comparable positive changes in interleukin-6 levels in patients with ST-segment elevation acute coronary syndrome after percutaneous coronary intervention, during therapy with both atorvastatin and pitavastatin. This indicates a pronounced and equally effective pleiotropic anti-inflammatory effect of both drugs in the acute phase of the disease.

Keywords: acute coronary syndrome, atherosclerosis, interleikin-6, atorvastatin, pitavastatin.

For citation: Nurieva, L.M.; Kim, Z.F.; Zakirova, I.I.; Abdullina, R.R.; Sharifullina, G.Sh. Dynamics of interleukin-6 levels during therapy with atorvastatin and pitav astatin in patients with acute coronary syndrome with ST-segment elevation after percutaneous coronary intervention. The Bulletin of Contemporary Clinical Medicine. 2026, 19(5), 89-94. DOI: 10.20969/VSKM.2026.19(5).89-94.

REFERENCES

1. Федеральная служба государственной статистики. Federal’naya sluzhba gosudarstvennoj statistiki [Federal State Statistics Service]. (In Russ.) Режим доступа [URL]: https://rosstat.gov.ru/

2. Аймагамбетова А.О. Атерогенез и воспаление. Обзор литературы // Наука и Здравоохранение. – 2016. – №1. – С.24-39. Aimagambetova AO. Aterogenez i vospalenie Obzor literatury [Аtherogenesis and inflammation. Reviews]. Nauka i Zdravookhranenie [Science & Healthcare]. 2016; 1: 24-39. (In Russ.)

3. Рагино Ю.И. Факторы и механизмы коронарного атеросклероза и его осложнений // Атеросклероз. – 2012. – T.8 (1). – C.61-64. Ragino YuI. Faktory i mekhanizmy koronarnogo ateroskleroza i ego oslozhnenij [Factors and mechanisms of coronary atherosclerosis and its complications]. Ateroskleroz [Ateroscleroz]. 2012; 8 (1): 61-64. (In Russ.)

4. Van Eeden S, Leipsic J, Paul Man SF, Sin DD. The relation ship between lung inflammation and cardiovascular disease. Am J Respir Crit Care Med. 2012; 186 (1): 11–16. DOI: 10.1164/rccm.201203-0455PP

5. Наумов А.В., Прокофьева Т.В., Полунина О.С., и др. Провоспалительные цитокины у больных с острым инфарктом миокарда на фоне хронической обструктивной болезни легких // Медицинский вестник Юга России. – 2020. – Т . 11 (3). – С. 40-47. Naumov AV, Prokofieva TV, Polunina OS, et al. Provospalitel’nye citokiny u bol’nyh s ostrym infarktom miokarda na fone hronicheskoj obstruktivnoj bolezni legkih [Proinflammatory cytokines in patients with acute myocardial infarction against the background of chronic obstructive pulmonary disease]. Medicinskij vestnik Yuga Rossii [Medical Herald of the South of Russia]. 2020; 11(3): 40-47. (In Russ.) DOI: 10.21886/2219-8075-2020-11-3-40-47

6. Danesh J, Kaptoge S, Mann AG, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLOS Medicine. 2008; 5(4): e78. DOI: 10.1371/journal.pmed.0050078

7. Кобалова Ж.Д., Ефремовцева М.А., Виллевальде С.В. Кардиоренальные синдромы // Клиническая нефрология. – 2011. – №6. – С.9-15. Kobalova ZhD, Efremovtseva MA, Villevalde SV. Kardiorenal’nye sindromy [Cardio-renal syndromes]. Klinicheskaya nefrologiya [Clinical Nephrology]. 2011; 6:9-15. (In Russ.)

8. Петров В.И., Кудашева А.А., Фролов Д.В. Контраст-индуцированная нефропатия: распространенность, диагностика, меры профилактики и лечение // Вестник Волгоградского государственного медицинского университета. – 2022. – №2. – С. 7-18. Petrov V.I., Kudasheva A.A., Frolov D.V. Kontrast-inducirovannaya nefropatiya: rasprostranennost’, diagnostika, mery profilaktiki i lechenie [Contrast-induced nephropathy: prevalence, diagnosis, prevention and treatment] Vestnik Volgogradskogo gosudarstvennogo medicinskogo universiteta [Journal of Volgograd state Medical University] 2022;2: 7-18. (In Russ.) DOI: 10.19163/1994-9480-2022-19-2-7-18

9. Волгина Г.В., Козловская Н.Н., Щекочихин Д.Ю. Клинические рекомендации и по профилактике, диагностике и лечению контраст-индуцированной нефропатии // Научное общество нефрологов России, Ассоциация нефрологов России. – 2016. Volgina GV, Kozlovskaya NN, Shchekochikhin DU. Klinicheskie rekomendacii i po profilaktike, diagnostike i lecheniyu kontrast-inducirovannoj nefropatii [Clinical guidelines for the prevention, diagnosis and treatment of contrast-induced nephropathy]. Nauchnoe obshchestvo nefrologov Rossii, Associaciya nefrologov Rossii [Scientific Society of Nephrologists of Russia Association of Nephrologists of Russia]. 2016. (In Russ.)

10. Российское кардиологическое общество. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2020 // Российский кардиологический журнал. – 2020. – 25(11). – 4103. Rossijskoe kardiologicheskoe obshchestvo [Russian Society of Cardiology]. Ostryj infarkt miokarda s pod”emom segmenta ST elektrokardiogrammy. Klinicheskie rekomendacii 2020 [2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology]. 2020. –№ 25, вып.11. – 4103. (In Russ.) DOI: 10.15829/1560-4071-2020-4103

11. Zhou Q, Liao JK. Pleiotropic effects of statins. Basic research andclinical perspectives. Circulation Journal. 2010; May; 74(5): 818-826. DOI: 10.1253/circj.cj-10-0110

12. Долженкова Т.В. Противовоспалительное, кардио- и эндотелиопротективное действие ингибиторов ГМК-Ко-А-редуктазы симвастатина, аторвастатина, розувастатина и L-аргинина, и резвератрола в эксперименте: автореферат диссертации на соискание ученой степени кандидата медицинских наук // Курск, 2007. Dolzhenkova T.V. Protivovospalitel’noe, kardio- i endote lioprotektivnoe deistvie inhibitorov GMK-KoA-reduktazy simvastatina, atorvastatina, rosuvastatina i L-arginina, i rezveratrola v eksperimente: avtoreferat dissertatsii na soiskanie uchenoi stepeni kandidata meditsinskikh nauk [Anti-inflammatory, cardio- and endothelio-protective action of HMG-CoA reductase inhibitors simvastatin, atorvastatin, rosuvastatin, L-arginine, and resveratrol in experiments: abstract of PhD thesis]. Kursk, 2007. (In Russ.) Режим доступа [URL]: https://medical-diss.com/medicina/protivovospalitelnoe-kardio-i-endotelioprotektivnoe-deystvie-ingibitorov-gmg-ko-a-reduktazy-simvastatina-atorvastatina-ro

13. Khurana S, Gupta S, Bhalla H, et al. Comparison of antiinflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome. J Pharmacol Pharmacother. 2015; 6 (3): 130-5. DOI: 10.4103/0976-500X.162011

14. Cheng BF, Gao YX, Lian JJ, et al. Anti-inflammatory effects of pitavastatin in interleukin-1β-induced SW982 human synovial cells. Int Immunopharmacol. 2017 Sep; 50: 224-229. DOI: 10.1016/j. intimp.2017.06.032

15. Saito Y. Pitavastatin: an overview. Atheroscler Suppl. 2011 Nov; 12(3): 271-6. DOI: 10.1016/S1567-5688(11)70886-8. PMID: 22152281

16. Ахмедов В.А., Тращенко А.С. Участие иммунологических нарушений в клинико-патогенетических механизмах формирования осложнений инфаркта миокарда с зубцом Q // Актуальные проблемы медицины. – 2011. – №10 (105). – С. 118-123. Ahmedov VA, Trashchenko AS. Uchastie immunologicheskih narushenij v kliniko-patogeneticheskih mekhanizmah formirovaniya oslozhnenij infarkta miokarda s zubcom Q [Participation Of Immunological Disturbances In Clinical And Pathogenetic Mechanisms Of Complications Formation In Patients With Myocardial Infarction With Q]. Aktual’nye problemy mediciny [Challenges in modern medicine]. 2011; 10(105): 118-123. (In Russ.)

17. Kimura G, Kasahara M, Ueshima K, et al. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial. Clin Exp Nephrol. 2017 Jun; 21(3): 417-424. DOI: 10.1007/s10157-016-1304-6

18. Kimura K, Shimano H, Yokote K, et al. Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study. J Atheroscler Thromb. 2010 Jun 30; 17(6): 601-9. DOI: 10.5551/jat.3764

 

 

УДК 616-008.8/616-092.6

DOI:10.20969/VSKM.2026.19(5).95-100

PDF download Relationship between oral health indicators, inflammatory markers in saliva, and cardiac pathology

Kazim A. Ozden1, Saida Sh. Galimova2, Artyom Yu. Vedenkin1, Kamil Sh. Galimov2, Nikita A. Zhadan1, Liana Z. Kyarova1, Elmira F. Galimova2

1First Moscow State Medical University, 8-2 Trubetskaya str., 119991 Moscow, Russia

2Bashkir State Medical University, 3 Lenin str., 450008 Ufa, Russia

Abstract. Introduction. Cardiovascular diseases are the leading cause of mortality worldwide. Saliva represents a promising non-invasive diagnostic medium; however, studies investigating the relationship between oral health and cardiovascular pathology remain limited. Aim. To conduct a correlation analysis of the relationships between systemic inflammation markers, oral health status, and cardiovascular pathology. Materials and Methods. The study included 277 patients. The study group consisted of 220 patients with cardiovascular diseases, such as coronary artery disease, atrial fibrillation, or myocardial infarction; while the control group comprised 57 individuals. Dental examination was performed with calculation of the OHI-S hygiene index, determination of oral fluid pH, and levels of C-reactive protein (CRP) and troponin I in saliva using enzyme immunoassay. Results and Discussion. Patients with cardiovascular pathology demonstrated a high prevalence of dental diseases, namely: Edentulism (75.1%), dental plaque (75.6%), and gingivitis (43%). Strong correlations were found between salivary troponin levels and history of myocardial infarction (r=0.72; p<0.001), as well as between CRP concentration and atrial fibrillation (r=0.63; p<0.001). A correlation was observed between gingivitis severity and CRP levels (r=0.42; p<0.001), and a negative correlation was found between salivary volume and atrial fibrillation (r= -0.47; p<0.001). Conclusions. The findings confirm the role of systemic inflammation in the pathogenesis of cardiovascular diseases and demonstrate the relationship between dental and cardiovascular statuses. Patients with rhythm disorders constitute a risk group for hyposalivation development, justifying the need for an interdisciplinary approach and dental screening.

Keywords: saliva, oral fluid, cardiovascular diseases, C-reactive protein, troponin, gingivitis, systemic inflammation, atrial fibrillation, myocardial infarction, non-invasive diagnostics.

For reference: Ozden, K.A.; Galimova, S.Sh.; Vadenkin, A.Yu.; et al. Relationship between oral health indicators, inflammatory markers in saliva, and cardiac pathologyю The Bulletin of Contemporary Clinical Medicine. 2026; 19(5): 95-100. DOI: 10.20969/VSKM.2026.19(5).95-100.

REFERENCES

1. Bahbah EI, Noehammer C, Pulverer W, Jung M, Weinhaeusel A. Salivary biomarkers in cardiovascular disease: An insight into the current evidence. FEBS J. 2021;288(22):6392-6405. PMID: 33370493. DOI: 10.1111/febs.15689

2. Al-Sufyanee AA. Correlation of serum biochemical parameters and saliva pH in healthy individuals. Saudi J Biol Sci. 2023;30(11):103793. PMID: 37744004; PMCID: PMC10514437. DOI: 10.1016/j.sjbs.2023.103793

3. Gohel V, Jones JA, Weler SJ. Biomarkers in Saliva and Cardiovascular Diseases: A Systematic Review. Clin Chem Lab Med. 2018;56(9):1432-1442. PMID: 29630504. DOI: 10.1515/cclm-2017-1018

4. Khuri ZKh, Sultan AS. Effect of saliva and salivary gland dysfunction on prosthetic restorations. J Prosthodont. 2023;32(9):766-775. PMID: 37302138. DOI: 10.1111/jopr.13725

5. Abdul Rehman S, Khurshid Z, Hussain Niazi F, et al. Role of Salivary Biomarkers in Detection of Cardiovascular Diseases (CVD). Proteomes. 2017;5(3):21. PMID: 28783097; PMCID: PMC5620538. DOI: 10.3390/proteomes5030021

6. Miller CS, Foley JD 3rd, Floriano PN, et al. Utility of salivary biomarkers for demonstrating acute myocardial infarction. J Dent Res. 2014;93(7 Suppl):72S-79S. PMID: 24879575; PMCID: PMC4107546. DOI: 10.1177/0022034514537522

7. Krikheli NI, Pustovoit EV, Zhuravleva EG. Effektivnost’ primeneniya zubnoi pasty parodontax v kompleksnom lechenii khronicheskogo gingivita [The effectiveness of parodontax toothpaste in the complex treatment of chronic gingivitis]. Stomatologiia (Mosk). 2021;100(2):50-54. (In Russ.) PMID: 33874661. DOI: 10.17116/stomat202110002150

8. Галимова С.Ш., Абдрахманова Н.И., Себякина И.Д., и др. Тромбоцитопения и С-реактивный белок как маркеры геморрагической лихорадки с почечным синдромом, осложненной острой почечной недостаточностью. Вестник современной клинической медицины. 2024;17(6):13-18. Galimova SSh, Abdrakhmanova NI, Sebyakina ID, et al. Trombotsitopeniya i S-reaktivnyy belok kak markery gemorragicheskoy likhoradki s pochechnym sindromom, oslozhnennoy ostroy pochechnoy nedostatochnost’yu [Thrombocytopenia and C-reactive protein as markers of hemorrhagic fever with renal syndrome complicated by acute renal failure]. Vestnik sovremennoy klinicheskoy meditsiny [Bulletin of Contemporary Clinical Medicine]. 2024;17(6):13-18. (In Russ.) DOI: 10.20969/VSKM.2024.17(6).13-18

9. Еловикова Т.М., Григорьев С.С. Слюна как биологическая жидкость и ее роль в здоровье полости рта. Екатеринбург: Издательский Дом «Тираж»; 2018. 136 с. Elovikova TM, Grigoriev SS. Slyuna kak biologicheskaya zhidkost’ i ee rol’ v zdorov’e polosti rta [Saliva as a biological fluid and its role in oral health]. Ekaterinburg: Publishing House «Tirazh»; 2018. 136 p. (In Russ.)

10. Glick A, Sista V, Johnson C. Oral Manifestations of Commonly Prescribed Drugs. Am Fam Physician. 2020;102(10):613-621. PMID: 33179891.

11. Thayer JF, Yamamoto SS, Brosschot JF. Relationships between autonomic imbalance, heart rate variability, and cardiovascular risk factors. Int J Cardiol. 2010;141(2):122-131. PMID: 19910061. DOI: 10.1016/j.ijcard.2009.09.543

12. Jamali HK, Waqar F, Gerson MC. Cardiac autonomic innervation. J Nucl Cardiol. 2017;24(5):1558-1570. PMID: 27844333. DOI: 10.1007/s12350-016-0725-7

13. Lafues WP, Wozniak DJ, Rajaram MVS. The role of cardiac macrophages in cardiac inflammation, fibrosis, and repair. Cells. 2020;10(1):51. PMID: 33396359; PMCID: PMC7824389. DOI: 10.3390/cells10010051

14. Struppek J, Schnabel RB, Walter K, et al. Periodontitis, dental plaque, and atrial fibrillation in the Hamburg Community Health Study. PLoS One. 2021;16(11):e0259652. PMID: 34807935; PMCID: PMC8608306. DOI: 10.1371/journal.pone.0259652

15. Kwon CH, Kang JG, Lee HJ, et al. C-reactive protein and the risk of atrial fibrillation in East Asians. Europace. 2017;19(10):1643-1649. PMID: 27915263. DOI: 10.1093/europace/euw298

16. Fernando H, Adams N, Mitra B. Benefit of troponin testing and other investigations in patients admitted to the emergency department with supraventricular tachycardia. Emerg Med Australas. 2019;31(1):35-42. PMID: 29752780. DOI: 10.1111/1742-6723.12971

17. Chang KW, Hsu JC, Toomu A, Fox S, Maisel AS. Clinical Applications of Biomarkers in Atrial Fibrillation. Am J Med. 2017;130(12):1351-1357. PMID: 28822701. DOI: 10.1016/j.amjmed.2017.08.003

18. Isaeva A, Averyanov SV, Iskhakov IR, Galimov ShN, Galimova EF, Kinyabaev T. Characteristics of cytokine profile of oral fluid in patients with chronic simple marginal gingivitis. Archiv EuroMedica. 2021;11(3):75-79. DOI: 10.35630/2199-885X/2021/11/3.18

19. Proctor GB, Carpenter GH. Salivary secretion: mechanism and neural regulation. Monogr Oral Sci. 2014;24:14-29. PMID: 24862591. DOI: 10.1159/000358781

20. Аверьянов С.В., Исаева А.И., Галимов Ш.Н., Галимова Э.Ф., Исхаков И.Р. Цитокиновый статус, баланс про- и антиоксидантных процессов, состояние системы комплемента и уровня иммунных пептидов в ротовой жидкости у пациентов с гингивитом. Dental Forum. 2021;2(81):2-12. Averyanov SV, Isaeva AI, Galimov ShN, Galimova EF, Iskhakov IR. Tsitokinovyy status, balans pro- i antioksidantnykh protsessov, sostoyanie sistemy komplementa i urovnya immunnykh peptidov v rotovoy zhidkosti u patsientov s gingivitom [Cytokine status, balance of pro- and antioxidant processes, state of the complement system and level of immune peptides in oral fluid in patients with gingivitis]. Dental Forum. 2021;2(81):2-12. (In Russ.)

 

 

УДК:616.61:616.127-005.8+616.24-007.272-036.12

DOI: 10.20969/VSKM.2026.19(5).101-108

PDF download Renal dysfunction in patients with myocardial infarction and various phenotypes of concomitant chronic obstructive pulmonary disease

Tatyana V. Prokofieva1, Andrey A. Polunin2, Irina S. Belyakova1, Nadezhda Y. Perova1

1 Astrakhan State Medical University, 121 Bakinskaya str., , 414000 Astrakhan, Russia

2 Regional Clinical Oncological Dispensary, 57 B. Alekseev str., 414041 Astrakhan, Russia

Abstract. Introduction. Patients with chronic obstructive pulmonary disease exhibit numerous extrapulmonary manifestations of the disease, which are caused by the systemic effect of chronic inflammation. The presence of this disease adversely affects the course of myocardial infarction. In patients with chronic obstructive pulmonary disease who develop myocardial infarction, there are higher levels of markers of systemic inflammation and endothelial dysfunction, as well as more pronounced indices of hypoxemia. Different phenotypes of chronic obstructive pulmonary disease independently and differentially affect renal dysfunction through the systemic effects of the disease. Aim. To analyze kidney function in patients in the acute phase of myocardial infarction with various phenotypes of underlying chronic obstructive pulmonary disease. Materials and Methods. A total of 539 people were examined. Three observation groups were identified: Study group (Group 1) included patients with myocardial infarction associated with chronic obstructive pulmonary disease; comparison group (Group 2) included patients with chronic obstructive pulmonary disease, and control group (Group 3) included individuals without any somatic pathology. Patients with chronic obstructive pulmonary disease were divided into subgroups depending on the phenotype of the disease. The study group included patients with acute coronary syndrome who, upon admission to the cardiology department, were diagnosed with myocardial infarction and had chronic obstructive pulmonary disease of various phenotypes as a concomitant condition. Results and Discussion. The highest urea levels were observed in the group of patients with myocardial infarction associated with the chronic obstructive pulmonary disease of bronchitic and mixed phenotypes. The highest creatinine levels, low glomerular filtration rate, and a high proportion of individuals with a glomerular filtration rate of under 90 ml/min/1,73 m2 and proteinuria were found in patients with the mixed phenotype of chronic obstructive pulmonary disease. No differences were noted when comparing indicators of impaired kidney function in patients with different phenotypes of chronic obstructive pulmonary disease. Conclusions. Based on the findings, we can conclude that the mixed phenotype of chronic obstructive pulmonary disease is the most unfavorable in terms of the development of renal dysfunction in the event of a myocardial infarction.

Keywords: myocardial infarction, chronic obstructive pulmonary disease, phenotypes of chronic obstructive pulmonary disease, renal dysfunction.

For citation: Prokofieva, T.V., Polunin, А.A., Belyakova, I.S., Perova, N.Y. Renal dysfunction in patients with myocardial infarction and various phenotypes of concomitant chronic obstructive pulmonary disease. The Bulletin of Contemporary Clinical Medicine. 2026, 19(5),101-108. DOI: 10.20969/VSKM.2026.19(5).101-108.

REFERENCES

1. Алейникова К.С., Оболонкова Н.И., Киселевич М.М., [и др]. Особенности клинического течения хронической обструктивной болезни легких у больных с сопутствующей ишемической болезнью сердца // Актуальные проблемы медицины. – 2020. – Т . 43, № 3. – С. 337-350. Alejnikova KS, Obolonkova NI, Kiselevich M.M., et al. Osobennosti klinicheskogo techeniya hronicheskoj obstruktivnoj bolezni legkih u bol’nyh s soputstvuyushchej ishemicheskoj bolezn’yu serdca [Features of the clinical course of chronic obstructive pulmonary disease in patients with concomitant ischemic heart disease]. Aktual’nye problemy mediciny [Actual problems of medicine]. 2020; 43 (3): 337-350. (In Russ.) DOI: 10.18413/2687-0940-2020-43-3-337-350.

2. Беккер К.Н., Мишланов ВЮ, Каткова А.В., [и др]. Распространенность сердечно-сосудистой патологии у больных с различными фенотипами хронической обструктивной болезни легких // Вестник современной клинической медицины. – 2019. – Т . 12, вып. 1. – С. 24-30. Bekker KN, Mishlanov VYu, Katkova AV, et al. Rasprostranennost’ serdechno-sosudistoj patologii u bol’nyh s razlichnymi fenotipami hronicheskoj obstruktivnoj bolezni legkih [Prevalence of cardiovascular pathology in patients with different phenotypes of chronic obstructive pulmonary disease]. Vestnik sovremennoj klinicheskoj mediciny [Bulletin of modern clinical medicine]. 2019; 12 (1): 24-30. (In Russ.) DOI: 10.20969/VSKM.2019.12(1).24-30

3. Зафираки В.К., Космачева Е.Д., Мирзаев С.Г ., [и др.] Хроническая обструктивная болезнь легких у больных ишемической болезнью сердца ухудшает отдаленный прогноз после чрескожных коронарных вмешательств // Кардиология. – 2021. – Т . 61, № 11. – С. 24–32. Zafiraki VK, Kosmacheva ED, Mirzaev SG, et al. Hronicheskaya obstruktivnaya bolezn’ legkih u bol’nyh ishemicheskoj bolezn’yu serdca uhudshaet otdalennyj prognoz posle chreskozhnyh koronarnyh vmeshate l’stv [Chronic obstructive pulmonary disease in patients with coronary heart disease worsens the long-term prognosis after percutaneous coronary interventions]. Kardiologiya [Cardiology]. 2021; 61 (11): 24–32. (In Russ.) DOI: 10.18087/cardio.2021.11.n1820

4. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD [Electronics Resourse], 2022. URL: https://goldcopd.org/2022-gold-reports-2/. Accessed November 9, 2022. (дата обращения: 11.12.2025).

5. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised, 2018. – 142 с. URL: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf

6. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2020 [Electronics Resourse], 2020. www.goldcopd.com (дата обращения: 11.12.2025).

7. Хроническая обструктивная болезнь легких. Клинические рекомендации. [Электронный ресурс] Hronicheskaya obstruktivnaya bolezn’ legkih. Klinicheskie rekomendacii [Chronic obstructive pulmonary disease. Clinical guidelines]. Elektronnyj resurs [Electronic resource]. (In Russ.) URL: https://spulmo.ru/upload/kr/HOBL_2021.pdf

8. Хроническая обструктивная болезнь легких. Федеральные клинические рекомендации. Год утверждения: 2018. – 76 с. Hronicheskaya obstruktivnaya bolezn’ legkih. Federal’nye klinicheskie rekomendacii. God utverzhdeniya: 2018. [Chronic obstructive pulmonary disease. Federal clinical guidelines. Year of approval: 2018], 76 s. (In Russ.) https://spulmo.ru/upload/federal_klinicheskie_rekomendaciy_hobl.pdf

9. Хроническая обструктивная болезнь легких. Федеральные клинические рекомендации. Год утверждения: 2021. – 91 с. Hronicheskaya obstruktivnaya bolezn’ legkih. Federal’nye klinicheskie rekomendacii. God utverzhdeniya: 2021 [Chronic obstructive pulmonary disease. Federal clinical guidelines. Year of approval: 2021], 91 s. (In Russ.) https://spulmo.ru/upload/kr/HOBL_2021.pdf

10. Аверков О.B., Арутюнян Г.К., Дупляков Д.В., [и др]. Острый коронарный синдром без подъема сегмента ST электрокардиограммы. Клинические рекомендации 2024 // Российский кардиологический журнал. – 2025. – Т . 30 (5). – С. 6319. Averkov OV, Arutyunyan GK, Duplyakov DV, et al. Ostryj koronarnyj sindrom bez pod”ema segmenta ST elektrokardiogrammy. Klinicheskie rekomendacii 2024 [Acute coronary syndrome without ST segment elevation of the electrocardiogram. Clinical guidelines 2024]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology]. 2025; 30 (5): 6319. (In Russ.) DOI: 10.15829/1560-4071-2025-6319

11. Аверков О.В., Арутюнян Г.К., Дупляков Д.В., [и др]. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации // Российский кардиологический журнал. – 2025. – Т . 30, вып. 3. – С. 6306. Averkov OV, Arutyunyan GK, Duplyakov DV, et al. Ostryj infarkt miokarda s pod”emom segmenta ST elektrokardiogrammy. Klinicheskie rekomendacii [Acute myocardial infarction with ST segment elevation of the electrocardiogram. Clinical guidelines]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology]. 2025; 30 (3): 6306. (In Russ.) DOI: 10.15829/1560-4071-2025-6306

12. Шишкина Е.А., Хлынова О.В., Лебедева Ю.И., [и др]. Фибрилляция предсердий и инфаркт миокарда: клинико-патогенетические взаимосвязи и влияние на прогноз // Доктор. Ру . – 2023. – Т . 22, вып. 8. – С. 23-28. Shishkina EA, Hlynova OV, Lebedeva YuI, et al. Fibrillyaciya predserdij i infarkt miokarda: kliniko-patogeneticheskie vzaimosvyazi i vliyanie na prognoz [Atrial fibrillation and myocardial infarction: clinical and pathogenetic relationships and impact on prognosis]. Doktor.Ru. [Doctor.Ru.]. 2023; 22 (8): 23–28. (In Russ.) DOI: 10.31550/1727-2378-2023-22-8-23-28

13. Каретникова В.Н., Калаева В.В., Евсеева М.В., [и др]. Роль хронической болезни почек в оценке риска неблагоприятного течения госпитального периода инфаркта миокарда с подъемом сегмента ST // Терапевтический архив. – 2016. – Т . 88, вып. 6. – C. 26-32. Karetnikova VN, Kalaeva VV, Evseeva MV, et al. Rol’ hronicheskoj bolezni pochek v ocenke riska  neblagopriyatnogo techeniya gospital’nogo perioda infarkta miokarda s pod»emom segmenta ST [The role of chronic kidney disease in assessing the risk of the poor course of hospital ST-segment elevation myocardial infarction]. Therapeutic Archive [Terapevticheskij arhiv]. 2016; 88(6): 26-32. (In Russ.) DOI: 10.17116/terarkh201688626-32

14. Демчук О.В., Сукманова И.А. Прогнозирование частоты развития хронической болезни почек у пациентов с инфарктом миокарда и острым повреждением почек. Российский кардиологический журнал. – 2023. – Т . 28, вып. 6. – С. 5247. Demchuk OV, Sukmanova IA. Prognozirovanie chastoty razvitiya hronicheskoj bolezni pochek u pacientov s infarktom miokarda i ostrym povrezhdeniem pochek [Predicting the incidence of chronic kidney disease in patients with myocardial infarction and acute kidney injury]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology]. –2023; 28 (6): 5247. (In Russ.)

15. Муркамилов И.Т ., Сабиров И.С., Фомин В.В., [и др]. Клинико-патогенетические аспекты формирования хронической болезни почек при хронической обструктивной болезни легких. // The Scientific Heritage. – 2022. –№ 55. – С. 18–24. Murkamilov IT, Sabirov IS, Fomin VV, et al. Kliniko-patogeneticheskie aspekty formirovaniya hronicheskoj bolezni pochek pri hronicheskoj obstruktivnoj bolezni legkih [Clinical and pathogenetic aspects of the formation of chronic kidney disease in chronic obstructive pulmonary disease]. The Scientific Heritage [The Scientific Heritage]. 2022; 55: 18–24. (In Russ.)

 

 

REVIEWS

УДК 615.322: 615.017

DOI: 10.20969/VSKM.2026.19(5).109-120

PDF download Inula helenium L. as a source of active pharmaceutical substances: A review of recent advances in pharmacology

Uliana A. Matvienko1, Ludmila V. Karavaeva1, Tatiana Yu. Kalyuta 1, Alexandr S. Phedonnikov1

1 Saratov State Medical University named after V.I. Razumovsky, 112B Kazachya str., 410012 Saratov, Russia

Abstract Introduction. Inula helenium L. is a pharmacopeial plant rich in sesquiterpene lactones, phenolic compounds, and polysaccharides. This systematic review summarizes current data on the pharmacological activity of its extracts and individual compounds. Aim. To summarize and critically analyze the results of modern experimental in vitro and in vivo studies on the pharmacological properties of extracts and secondary metabolites of Inula helenium L., with detailed consideration of action mechanisms. Materials and Methods. Peer-reviewed publications were searched for in PubMed/MEDLINE, Google Scholar, and eLibrary.ru, covering the period from 2020 to 2026, with the inclusion of earlier fundamental studies. The study design was a systematic literature review performed in accordance with the PRISMA recommendations. Results and Discussion. Alantolactone and isoalantolactone suppress pro-inflammatory cytokines, such as IL-6, IL-8, TNF-α, IL-1β, and IL-17a; inhibit NLRP3 inflammasome assembly by disrupting NLRP3–NEK7 interaction, and block STAT3/RORγt signaling, thereby preventing Th17 cell differentiation. Igalan inhibits JAK/STAT and activates NRF2, exerting anti-inflammatory and barrier-protective effects. Sesquiterpene lactones, such as alantolactone, isoalantolactone, 5α-epoxylantolactone, and alloalantolactone, induce  apoptosis and cell cycle arrest in various cancer cell lines by inhibiting signaling pathways, i. e., PI3K/AKT/mTOR, Wnt/β-catenin, NF-κB, and STAT3, and activating kinases, such as p38 MAPK and JNK. Isoalantolactone overcomes chemoresistance by promoting BCR-ABL degradation in imatinib-resistant cells and enhances the cytotoxicity of doxorubicin and oxaliplatin. 5α-Epoxyalantolactone is described as the first small-molecule ANXA2 inhibitor. Sesquiterpenoid fraction modulates the tumor microenvironment by increasing CD8+ T-cells and reducing myeloid-derived suppressor cells (MDSC), thereby potentiating the response to anti-PD-1 therapy. Alantolactone exhibits hepatoprotective effects in non-alcoholic fatty liver disease via NRF2 induction and NF-κB inhibition and cardioprotective properties, such as reduction of oxidative stress and modulation of calcium channels. Isoalantolactone protects dopaminergic neurons in the Parkinson’s disease model through the AKT/NRF2/HO-1 cascade. Ethanolic extracts show high antiglycation activity. Antimicrobial and antifungal activities have been confirmed against Bacillus, Staphylococcus, Enterococcus, Candida, Aspergillus, and other genera. The extracts demonstrate antioxidant activity in FRAP, CUPRAC, DPPH, and ABTS assays. Conclusions. Thus, I. helenium represents a promising source of bioactive substances for the development of anticancer and anti-inflammatory agents. Further preclinical studies are necessary, regarding their pharmacokinetics, safety, and comparative efficacy.

Keywords: Inula helenium, elecampane, sesquiterpene lactones, alantolactone, isoalantolactone, anticancer activity, anti-inflammatory activity, antimicrobial activity

For citation: Matvienko, U. A.; Karavaeva, L. V.; Kalyuta, T. Yu.; Fedonnikov, A. S. Inula helenium L. as a source of active pharmaceutical substances: A review of recent advances in pharmacology. The Bulletin of Contemporary Clinical Medicine. 2026, 19(5), 109-120. DOI: 10.20969/VSKM.2026.19(5).109-120.

REFERENCES

1. Bolatkyzy N, Shepilov D, Turmanov R, et al. Medicinal plants for skin disorders: Phytochemistry and pharmacological insights. Molecules. 2025; 30(15): 3281. DOI:10.3390/molecules30153281

2. Ma L, Li Q, Ma X, et al. Effect of remained stem height on yield, quality of Inula helenium L. and on soil water content. Saudi J Biol Sci. 2018; 25 (6): 1208-1211. DOI: 10.1016/j.sjbs.2017.10.016

3. Shikov AN, Pozharitskaya ON, Makarov VG, et al. Medicinal plants from the 14th edition of the Russian Pharmacopoeia, recent updates. J Ethnopharmacol. 2021; 268: 113685. DOI: 10.1016/j.jep.2020.113685

4. Meral HD, Özcan FŞ, Özcan N, Bozkurt F, Sağdiç O. Determination of prebiotic activity and probiotic encapsulation ability of inulin type fructans obtained from Inula helenium roots. J Food Sci. 2024; 89: 5335-5349. DOI: 10.1111/1750-3841.17261

5. Lkhagvaa A, Dambiinyam J, Bat-Erdene A, et al. The Technological Study to Develop Granules from Plants Used in Traditional Mongolian Medicine. Cent Asian J Med Sci. 2025; 11 (1): 34-45. DOI: 10.24079/CAJMS.2025.01.005

6. Buza V, Nădășan A, Ghibu S, et al. Biological activities and chemical profile of Gentiana asclepiadea and Inula helenium ethanolic extracts. Molecules. 2022; 27 (11): 3560. DOI: 10.3390/molecules27113560

7. Han JS, Lee JH, Kim YH, et al. Targeted isolation of dimeric sesquiterpene lactones and sesquiterpene derivatives from the roots of Inula helenium. Phytochemistry. 2025; 229: 114258. DOI:10.1016/j.phytochem.2024.114258

8. Moradi N, Ghanbari A, Khorrami M, et al. Diversity in photosynthetic pigments and phytochemical compounds among Iranian populations of Inula helenium L. Genet Resour Crop Evol. 2025; 72 (1): 751-765. DOI: 10.1007/s10722-024-01955-y

9. Gierlikowska B, Gierlikowski W, Bekier K, et al. Inula helenium and Grindelia squarrosa as a source of compounds with anti-inflammatory activity in human neutrophils and cultured human respiratory epithelium. J Ethnopharmacol. 2020; 249: 112311. DOI: 10.1016/j.jep.2019.112311

10. Said O, Khamaysi I, Kmail A, et al. In Vitro and Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy and Safety of Nine Antiacne Medicinal Plants. Evid Based Complement Alternat Med. 2020; 2020: 3231413. DOI: 10.1155/2020/3231413

11. Chen HL, Tang CH, Liu YL, et al. Alantolactone alleviates collagen-induced arthritis and inhibits Th17 cell differentiation through modulation of STAT3 signalling. Pharm Biol. 2021; 59 (1): 132-143. DOI: 10.1080/13880209.2021.1876102

12. Fang ZE, Li Y, Zhang H, et al. Helenine blocks NLRP3 activation by disrupting the NEK7-NLRP3 interaction and ameliorates inflammatory diseases. Phytomedicine. 2024; 122: 155159. DOI:10.1016/j.phymed.2023.155159

13. Zheng X, Wang J, Zhang L, et al. Bioactive sesquiterpenes from Inula helenium. Bioorg Chem. 2021; 114: 105066. DOI: 10.1016/j.bioor g.2021.105066

14. Dao TTP, Nguyen TH, Lee S, et al. Igalan from Inula helenium (L.) suppresses the atopic dermatitis-like response in stimulated HaCaT keratinocytes via JAK/STAT3 signaling. Inflamm Res. 2020; 69 (3): 309-319. DOI: 10.1007/s00011-020-01322-4

15. Cai YS, Wu Z, Zheng XQ, et al. Spiroalanpyrroids A and B, sesquiterpene alkaloids with a unique spiroeudesmanolide-pyrrolizidine skeleton from Inula helenium. Org Chem Front. 2020; 7: 303-309. DOI: 10.1039/C9QO01248F

16. Zhou C, Chen J, Liu K, et al. Isoalantolactone protects against ethanol-induced gastric ulcer via alleviating inflammation through regulation of PI3K-Akt signaling pathway and Th17 cell differentiation. Biomed Pharmacother. 2023; 160: 114315. DOI: 10.1016/j.biopha.2023.114315

17. Wang H, Li H, Zhao P, et al. Inula helenium extract and lidocaine-loaded electrospun wound dressings for managing skin wounds pain and their healing: An in vitro and in vivo study. J Biomater Appl. 2024; 39 (4): 367-376. DOI: 10.1177/08853282241265920

18. Kenny CR, O’Connor PM, O’Brien NM, et al. From monographs to chromatograms: the antimicrobial potential of Inula helenium L. (Elecampane) naturalised in Ireland. Molecules. 2022; 27 (4): 1406. DOI: 10.3390/molecules27041406

19. Alan Y, Yılmaz N, Cabuk M. Inula helenium subsp. pseudohelenium: Phenolic Content, In Vitro Antimicrobial, Antioxidant, Antiproliferative, and DNA Protective Activities. 2023; 8. DOI: 10.20944/preprints202311.0484.v1.

20. Özcan FŞ, Meral HD, Özcan N, et al. Extraction of sesquiterpene lactones from Inula helenium roots by high-pressure homogenization and effects on antimicrobial, antioxidant, and antiglycation activities. Food Bioprocess Technol. 2024; 17 (11): 4071-4082. DOI: 10.1007/s11947-024-03361-9

21. Özcan FŞ, Meral HD, Özcan N, et al. Microwave-assisted extraction optimization of sesquiterpene lactones from Inula helenium roots: A sustainable approach to reduce energy consumption and carbon footprint. Food Sci Nutr. 2024; 12 (1): 255-267. DOI: 10.1002/fsn3.3775

22. Budán F, Kunsági-Máté S, Szabó I, et al. Antimicrobial activity and potential secondary signal transduction mechanisms of elecampane (Inula helenium L.) root extract. PCBMB. 2021; 22: 86-92. DOI: 10.5625/lar.2015.31.2.78

23. Stojanović-Radić Z, Čomić L, Radulović N, et al. Anticandidal activity of Inula helenium root essential oil: Synergistic potential, anti-virulence efficacy and mechanism of action. Ind Crops Prod. 2020; 149: 112373. DOI: 10.1002/cbdv.202500270

24. Dusmatova DE, Mukhamatkhanova RF, Sasmakov SA, et al. Volatile components of Inula helenium and I. grandis, growing in Uzbekistan. Khimiya Rastitelnogo Syrya. 2024; (3): 144-149. DOI: 10.14258/jcprm.20240313541

25. Stancheva R, Damyanova T, Paunova-Krasteva T, et al. Cationic Polymer Micelles as Carriers of Bioactive Sesquiterpene Lactones from Inula helenium L. for Effective Treatment of Bacterial Biofilms. Pharmaceutics. 2025; 17: 800. DOI: 10.3390/pharmaceutics17060800

26. Yang L, Zhong L, Ma Z, et al. Antifungal effects of alantolactone on Candida albicans: an in vitro study. Biomed Pharmacother. 2022; 149: 112814. DOI: 10.1016/j.biopha.2022.112814

27. Wu X, Liu J, Li H, et al. Inhibitory effect of Alantolactone against varicella-zoster virus in vitro. Virol J. 2025; 22 (1): 138. DOI: 10.1186/s12985-025-02759-x

28. Staicu V, Tomescu JA, Neagu M, et al. Ultrasonic-Assisted Extraction of Bioactive Compounds from Elecampagne (Inula helenium, Radix Inulae). J ISSN. 2023; 2766: 2276. DOI: 10.37871/jbres1785

29. Aybastier Ö. Efficacy of methanol-water extract of Inula helenium root against oxidative DNA damage. J Tradit Chin Med. 2021; 41 (2). DOI: 10.19852/j.cnki.jtcm.20210209.008

30. Chun J, Kim YS, Lee J, et al. The sesquiterpene lactone-rich fraction of Inula helenium L. enhances the antitumor effect of anti-PD-1 antibody in colorectal cancer: integrative phytochemical, transcriptomic, and experimental analyses. Cancers. 2023; 15 (3): 653. DOI: 10.3390/cancers15030653

31. Sulutas RB, Gökçe EH, Oğuztüzün S, et al. Electrospun amygdalin and Inula helenium extract-loaded polylactic acid (PLA)/Polyvinylpyrrolidone (PVP) nanofibrous patches for colon cancer  treatment: Fabrication, characterization and antitumour effect results. J Drug Deliv Sci Technol. 2024; 99: 105940. DOI: 10.1016/j.jddst.2024.105940

32. Zhang Y, Wang X, Li Y, et al. Alantolactone induced apoptosis and DNA damage of cervical cancer through ATM/CHK2 signaling pathway. Biol Pharm Bull. 2024; 47 (7): 1255-1264. DOI: 10.1248/bpb.b23-00804

33. Sun X, Wang Y, Zhang L, et al. Alantolactone inhibits cervical cancer progression by downregulating BMI1. Sci Rep. 2021; 11 (1): 9251. DOI: 10.1038/s41598-021-87781-z

34. Yang C, Chen L, Wang Y, et al. Alantolactone inhibits proliferation, metastasis and promotes apoptosis of human osteosarcoma cells by suppressing Wnt/β-catenin and MAPKs signaling pathways. Genes Dis. 2022; 9 (2): 466-478. DOI:10.1016/j.gendis.2020.07.014

35. Zhang Y, Wang X, Liu S, et al. Alantolactone suppresses human osteosarcoma through the PI3K/AKT signaling pathway. Mol Med Rep. 2020; 21 (2): 675-684. DOI: 10.3892/mmr.2019.10882

36. Dang X, He B, Ning Q, et al. Alantolactone suppresses inflammation, apoptosis and oxidative stress in cigarette smoke-induced human bronchial epithelial cells through activation of NRF2/HO-1 and inhibition of the NF-κB pathways. Respir Res. 2020; 21 (1): 95. DOI: 10.1186/s12931-020-01358-4

37. Wang Z, Zhang H, Liu J, et al. Inhibition of growth of esophageal cancer by alantolactone via Wnt/β-catenin signaling. Anticancer Agents Med Chem. 2021; 21 (18): 2525-2535. DOI:10.2174/1871520621666210112124546

38. Chen J, Li X, Wang Y, et al. Alantolactone inhibits oesophageal adenocarcinoma cells through nuclear factor erythroid 2-related factor 2-mediated reactive oxygen species increment. Basic Clin Pharmacol Toxicol. 2023; 132 (3): 253-262. DOI: 10.1111/bcpt.13824

39. Wang X, Liu Z, Zhang H, et al. Alantolactone suppresses the metastatic phenotype and induces the apoptosis of glioblastoma cells by targeting LIMK kinase activity and activating the cofilin/G-actin signaling cascade. Int J Mol Med. 2021; 47 (5): 68. DOI:10.3892/ijmm.2021.4901

40. Shi C, Zhang Y, Li M, et al. Alantolactone inhibits cell autophagy and promotes apoptosis via AP2M1 in acute lymphoblastic leukemia. Cancer Cell Int. 2020; 20 (1): 442. DOI: 10.1186/s12935-020-01537-9

41. Ren Y, Liu X, Li Y, et al. Alantolactone exhibits antiproliferative and apoptosis-promoting properties in colon cancer model via activation of the MAPK-JNK/c-Jun signaling pathway. Mol Cell Biochem. 2021; 476 (12): 4387-4403. DOI: 10.1007/s11010-021-04247-6

42. Hu Y, Wen Q, Cai Y, et al. Alantolactone induces concurrent apoptosis and GSDME-dependent pyroptosis of anaplastic thyroid cancer through ROS mitochondria-dependent caspase pathway. Phytomedicine. 2023; 108: 154528. DOI: 10.1016/j.phymed.2022.154528

43. Zhi L, Yuan L. Alantolactone curbs the malignant progression of bladder cancer partly via the HSP90AB1/LRP5/β-catenin axis. Mamm Genome. 2026; 37 (1): 20. DOI: 10.1007/s00335-025-10182-4

44. Kim MY, Kim YC, Cho YH, et al. Induction of apoptosis by isoalantolactone in human hepatocellular carcinoma Hep3B cells through activation of the ROS-dependent JNK signaling pathway. Pharmaceutics. 2021; 13 (10): 1627. DOI:10.3390/pharmaceutics13101627

45. Li J, Zhang X, Chen Y, et al. Isoalantolactone induces cell cycle arrest, apoptosis and autophagy in colorectal cancer cells. Front Pharmacol. 2022; 13: 903599. DOI: 10.3389/fphar.2022.903599

46. Wu ZC, Huang L, Wang Q, et al. Antiproliferative effects of isoalantolactone in human liver cancer cells are mediated through caspase-dependent apoptosis, ROS generation, suppression of cell migration and invasion and targeting Ras/Raf/MEK signalling pathway. Acta Biochim Pol. 2022; 69 (2): 299-304. DOI: 10.18388/abp.2020_5704

47. Peng W, Liu F, Yang L, et al. Isoalantolactone inhibits the proliferation of human liver cancer cells by inducing intrinsic apoptosis. Trop J Pharm Res. 2024; 23 (2): 273-278. DOI: 10.4314/tjpr.v23i2.6

48. Zhang C, Liu H, Pan Y, et al. Isoalantolactone inhibits pancreatic cancer proliferation by regulation of PI3K and Wnt signal pathway. PLoS One. 2021; 16 (3): e0247752. DOI: 10.1371/journal.pone.0247752

49. Chun J. Isoalantolactone suppresses glycolysis and resensitizes cisplatin-based chemotherapy in cisplatin-resistant ovarian cancer cells. Int J Mol Sci. 2023; 24 (15): 12397. DOI: 10.3390/ijms241512397

50. Huang H, Chen J, Peng Y, et al. Isoalantolactone increases the sensitivity of prostate cancer cells to cisplatin treatment by inducing oxidative stress. Front Cell Dev Biol. 2021; 9: 632779. DOI: 10.3389/fcell.2021.632779

51. Hu F, Yang P. Isoalantolactone exerts anticancer effects on human HEC-1-B endometrial cancer cells via induction of ROS mediated apoptosis and inhibition of MEK/ERK signalling pathway. Acta Biochim Pol. 2022; 69 (2): 453-458. DOI: 10.18388/abp.2020_5965

52. Lv X, Wang Y, Zhang L, et al. Isoalantolactone suppresses gallbladder cancer progression via inhibiting the ERK signalling pathway. Pharm Biol. 2023; 61 (1): 556-567. DOI: 10.1080/13880209.2023.2191645

53. Sung MT, Wang Y, Chen H, et al. Anticancer potential of isoalantolactone in testicular cancer: an analysis of cytotoxicity, apoptosis, and signaling pathways. Aging (Albany NY). 2024; 16 (19): 12820. DOI: 10.18632/aging.206076

54. Xie Z, Li X, Zhang Y, et al. Dual regulation of Akt and glutathione caused by isoalantolactone effectively triggers human ovarian cancer cell apoptosis. Acta Biochim Biophys Sin. 2023; 55 (1): 62. DOI: 10.3724/abbs.2023003

55. Li JK, Jiang XL, Zhang Z, et al. Isoalantolactone exerts anti-melanoma effects via inhibiting PI3K/AKT/mTOR and STAT3 signaling in cell and mouse models. Phytother Res. 2024; 38 (6): 2800-2817. DOI: 10.1002/ptr.8132

56. Lee SO, Joo SH, Lee NY, et al. Isoalantolactone induces the apoptosis of oxaliplatin-resistant human colorectal cancer cells mediated by ROS generation and activation of JNK and p38 MAPK. Sci Rep. 2025; 15 (1): 14912. DOI: 10.1038/s41598-025-98499-7

57. Yin SS, Chen C, Liu Z, et al. Isoalantolactone mediates the degradation of BCR-ABL protein in imatinib-resistant CML cells by down-regulating survivin. Cell Cycle. 2023; 22 (12): 1407-1420. DOI: 10.1080/15384101.2023.2209963

58. Lee NY, Nam AY, Yoon G, et al. Isoalantolactone induces apoptosis of non-small cell lung cancer cells by targeting EGFR and MET kinases and ROS generation. Heliyon. 2026; 12 (3): e44551. DOI: 10.1016/j.heliyon.2026.e44551

59. Yan YY, Zhang L, Chen H, et al. Active ingredients of Inula helenium L. exhibits similar anti-cancer effects as isoalantolactone in pancreatic cancer cells. Nat Prod Res. 2020; 34 (17): 2539-2544. DOI: 10.1080/14786419.2018.1543676

60. Wei M, Zhou Y, Li C, et al. 5α-Epoxyalantolactone Inhibits Metastasis of Triple-Negative Breast Cancer Cells by Covalently Binding a Conserved Cysteine of Annexin A2. J Med Chem. 2021; 64 (17): 12537-12547. DOI: 10.1021/acs.jmedchem.1c00267

61. Inomjonov D, Abdullaev I, Omonturdiev S, et al. In vitro and in vivo Studies of Crategus and Inula helenium extracts: Their Effects on Rat Blood Pressure. Trends Sci. 2025; 22 (3): 9158. DOI: 10.48048/tis.2025.9158

62. Fatima M, Andleeb H, Rehman T, et al. Effect of alantolactones on cardiac parameters of animals under artificially induced oxidative stress. Biomedicine (Taipei). 2024; 14 (3): 12-22. DOI: 10.37796/2211-8039.1457

63. Yuan R, Li Z, Zhang Y, et al. Alantolactone mitigates the elevation of blood pressure in mice induced by angiotensin II by inhibiting calcium channel activation. BMC Cardiovasc Disord. 2025; 25 (1): 7. DOI: 10.1186/s12872-024-04461-2

64. Chuo WH, Tung YT, Wu CL, et al. Alantolactone Suppresses Proliferation and the Inflammatory Response in Human HaCaT Keratinocytes and Ameliorates Imiquimod-Induced Skin Lesions in a Psoriasis-Like Mouse Model. Life. 2021; 11: 616. DOI: 10.3390/life11070616

65. Гаккоева К.О., Каркусова М.Д., Дзитоева С.Г. Предотвращение пол-специфичной оланзапин-индуцируемой гиперфагии и набора веса у Drosophila melanogaster посредством применения девясила высокого (Inula helenium L.) // Acta Biomedica Scientifica. – 2026. – Т . 11, вып. 1. – С. 231-237. Gakkoeva KO, Karkusova MD, Dzitoeva SG. Predotvrashchenie pol-spetsifichnoy olanzapin-indutsiruemoy giperfagii i nabora vesa u Drosophila melanogaster posredstvom primeneniya devyasila vysokogo (Inula helenium L.) [Prevention of sex-specific olanzapine-induced hyperphagia and weight gain in Drosophila melanogaster by treatment with Elecampane (Inula helenium L.)]. Acta Biomedica Scientifica [Acta Biomedica Scientifica]. 2026; 11 (1): 231-237. (In Russ.) DOI: 10.29413/ABS.2026-11.1.22

66. Jung YS, Jeong YJ, Kim JH, Jeon CH, Lee SO. Elecampane (Inula helenium) root extract and its major sesquiterpene lactone, alantolactone, inhibit adipogenesis of 3T3-L1 preadipocytes. Molecules. 2022; 27 (15): 4765. DOI: 10.3390/molecules27154765

67. Wang J, Li Z, Zhang H, et al. Alantolactone attenuates high-fat diet-induced inflammati on and oxidative stress in non-alcoholic fatty liver disease. Nutr Diabetes. 2024; 14 (1): 41. DOI:10.1038/s41387-024-00300-7

68. He D, Liu Y, Li J, et al. Isoalantolactone (IAL) regulates neuroinflammation and neuronal apoptosis to curb pathology of Parkinson’s disease. Cells. 2022; 11 (18): 2927. DOI: 10.3390/cells11182927

69. Wang S, Cai Q, Xu L, et al. Isoalantolactone relieves depression-like behaviors in mice after chronic social defeat stress via the gut-brain axis. Psychopharmacology. 2023; 240 (8): 1775-1787. DOI:10.1007/s00213-023-06413-8

 

 

УДК: 616.153.915

DOI:10.20969/VSKM.2026.19(5).121-130

PDF download Dyslipidemia in pregnant women as a risk factor for gestational complications

Alsu F. Molostvova1, Zulfiya F. Kim1,2, Rushanya I. Gabidullina1,2

1 Kazan State Medical University, 49 Butlerov str., 420012 Kazan, Russia

2 City Clinical Hospital No.7 named after M. N. Sadykov, 54 Marshal Chuykov str., 420103 Kazan, Russia

Abstract. Introduction. It is known that during gestation, woman’s body suffers significant changes aimed at maintaining pregnancy. In lipid metabolism, as pregnancy progresses, a physiological increase is observed in cholesterol and its fractions, as well as in triglycerides; their levels return to normal values within 3–6 months after delivery. However, physicians often encounter supraphysiological changes in lipid metabolism. A logical question arises: Is dyslipidemia in women a factor that increases the risk of pregnancy complications and adverse perinatal outcomes? Aim. To study the association between dyslipidemia and pregnancy and delivery complications based on a systematic analysis of data available in the scientific literature. Material and Methods. Data were analyzed from clinical, randomized and cohort studies, systematic reviews and meta-analyses available in full-text publications from scientific databases, such as PubMed, eLibrary.ru, and Google Scholar, for the period of 2007–2025, using the following keywords: pregnant women, dyslipidemia, preeclampsia, arterial hypertension, gestational diabetes mellitus, fetal macrosomia, and preterm birth. Results and Discussion. Dyslipidemia before pregnancy and supraphysiological elevation of atherogenic lipids during pregnancy increase the risk of adverse perinatal outcomes. Maternal obesity, diabetes mellitus, and hypertensive disorders may exacerbate adverse changes in lipid metabolism and clinical outcomes. Conclusions. Lipid profiling in early pregnancy may become a useful tool for predicting and subsequently preventing pregnancy complications. The main technique for correcting lipid changes during pregnancy is behavioral interventions. Women at high / very high risk of cardiovascular events and those with familial hypercholesterolemia require special attention.

Keywords: pregnant women, dyslipidemia, preeclampsia, arterial hypertension, gestational diabetes mellitus, fetal macrosomia, preterm birth.

For citation: Molostvova A.F.; Kim Z.F.; Gabidullina R.I. Dyslipidemia in pregnant women as a risk factor for gestational complications. The Bulletin of Contemporary Clinical Medicine. 2026, 19(5), 121-130. DOI: 10.20969/VSKM.2026.19(5).121-130.

REFERENCES

1. Григорьева Н.А., Косова И.В., Григорьева В.Н., [и др.]. Особенности изменений липидного спектра крови у первородящих различных возрастных групп, их значение в диагностике физиологического течения гестации // Современные проблемы науки и образования. – 2015. – № 1-1. – С. 1369. Grigorieva NA, Kosova IV, Grigorieva VN, et al. Osobennosti izmeneniy lipidnogo spektra krovi u pervorodyashchik h razlichnykh vozrastnykh grupp, ikh znachenie v diagnostike fiziologicheskogo techeniya gestatsii [Peculiarities of changes in blood lipid spectrum in primiparas of different age groups, their significance in the diagnosis of the physiological course of gestation]. Sovremennye problemy nauki i obrazovaniya [Modern Problems of Science and Education]. 2015; 1(1):1396. (In Russ.)

2. Vrijkotte TG, Krukziener N, Hutten BA, Vollebregt KC, van Eijsden M, Twickler MB. ABCD study. J Clin Endocrinol Metab. 2012;97(11):3917–25. DOI: 10.1210/jc.2012-1295

3. Волынец Л.И., Конышко Н.А., Конышко Г.С., Капустина Е.Е. Дислипидемия беременных женщин в норме и при патологии. Возможности лекарственной терапии // Вопросы гинекологии, акушерства и перинатологии. – 2023. – Т . 22, вып.5. – С.87–94. Volynec LI, Konyshko NA, Konyshko GS, Kapustina EE. Dislipidemiya beremennyh zhenshchin v norme i pri patologii. Vozmozhnosti lekarstvennoj terapii [Dyslipidemia in Pregnant Women in Health and Disease: Possibilities of Drug Therapy]. Voprosy ginekologii, akusherstva i perinatologii [Gynecology, Obstetrics and Perinatology]. 2023; 22(5):87-94. (In Russ.) DOI: 10.20953/1726-1678-2023-5-87-94

4. Stadler JT, Wadsack C, Marsche G. Fetal high-density lipoproteins: current knowledge on particle metabolism, composition and function in health and disease. Biomedicines. 2021;9(4):349. DOI: 10.3390/biomedicines9040349

5. Mulder JWCM, Groen B, van den Berg SA, et al. Lipid metabolism during pregnancy: consequences for mother and child. Curr Opin Lipidol. 2024;35(3):133–40. DOI: 10.1097/MOL.0000000000000922.

6. Jiang L, Tang K, Magee LA, von Dadelszen P, Payne B, et al. A global view of hypertensive disorders and diabetes mellitus during pregnancy. Nat Rev Endocrinol. 2022;18(12):760–75. DOI: 10.1038/s41574-022-00734-y

7. Ткачева О.Н., Балушкина А.А., Карева Е.Н. [и др.]. Российское многоцентровое эпидемиологическое исследование «Лечебно-диагностическая тактика ведения беременных с артериальной гипертонией в России «ДИАЛОГ II»: анализ результатов и пути решения проблемы // Фарматека. – 2010. – №9. – С. 203. Tkacheva ON, Balushkina AA, Kareva EN, et al. Rossijskoe mnogocentrovoe epidemiologicheskoe issledovanie «Lechebno-diagnosticheskaya taktika vedeniya beremennyh s arterial’noj gipertoniej v Rossii «DIALOG II»: analiz rezul’tatov i puti resheniya problemy [Russian Multicenter Epidemiological Study «Diagnostic and Therapeutic Management of Pregnant Women with Arterial Hypertension in Russia – DIALOG II»: Analysis of Results and Solutions to the Problem]. Farmateka [Farmateka]. 2010; 9: 203. (In Russ.)

8. Magee LA, Brown MA, Hall DR, Gupte S, Hennessy A, Karumanchi SA, et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2022; 27: 148–69. DOI: 10.1016/j. preghy.2021.09.008

9. Belo L, Caslake M, Gaffney D, Santos-Silva A, Pereira-Leite L, Quintanilha A, et al. hanges in LDL size and HDL concentration in normal and preeclamptic pregnancies. Atherosclerosis. 2002;162(2):425–32. DOI: 10.1016/S0021-9150(01)00734-1

10. Qin X, Ai F, Zhou Q, Zhang Y, Yan X. Pre-eclampsia, gestational hypertension, and lipid levels during pregnancy: a systematic review and meta-analysis. Arch Gynecol Obstet. 2025;312(2):385–402. DOI: 10.1007/s00404-025-08052-0

11. Poornima IG, Mackey RH, Allison MA, Manson JE, Carr JJ, LaMonte MJ, et al. Hyperlipidemia and risk for preeclampsia. J Clin Lipidol. 2022;16(3):253–60. DOI: 10.1016/j.jacl.2022.02.007

12. Bernier E, Gagné A, Ouellet A, Girard S, Soucy-Giguère H, Rassart É, et al. Circulating immune cells from early- and late-onset pre-eclampsia displays distinct profiles with differential impact on endothelial activation. J Immunol. 2024;213(9):1292–304. DOI: 10.4049/jimmunol.2400114

13. Song S, Kim YH, Park MH, Lee J, Kwon HS, Lee J. An elevated triglyceride-glucose index in the first-trimester predicts adverse pregnancy outcomes: a retrospective cohort study. Arch Gynecol Obstet. 2025; [Epub ahead of print]. DOI: 10.1007/s00404-025-08100-9

14. Melchiorre K, Giorgione V, Thilaganathan B. The placenta and preeclampsia: villain or victim? Am J Obstet Gynecol. 2022;226(2S): S954–62. DOI: 10.1016/j.ajog.2020.10.024

15. Purisch SE, Gyamfi-Bannerman C. Epidemiology of preterm birth. Semin Perinatol. 2017; 41(7):387–91. DOI: 10.1053/j.semperi.2017.07.009

16. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013;13(10):709–21. DOI: 10.1038/nri3520

17. Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015;15(2):104–16. DOI: 10.1038/nri3793

18. Mezouar S, Benammar I, Boumaza A, Diallo AB, Chartier C, Buffat C, et al. Full-term human placental macrophages eliminate Coxiella burnetii through an IFN-gamma autocrine loop. Front Microbiol. 2019; 10: 2434. DOI: 10.3389/fmicb.2019.02434

19. Chen J, Hua L, Luo F, Chen J. Maternal hypercholesterolemia may involve in preterm birth. Front Cardiovasc Med. 2022; 9: 818202. DOI: 10.3389/fcvm.2022.818202

20. Smith CJ, Baer RJ, Oltman SP, Breheny PJ, Bao W, Robinson JG, et al. Maternal dyslipidemia and risk for preterm birth. PLoS One. 2018;13(12):e0209579. DOI: 10.1371/journal.pone.0209579

21. Zhou LY, Xu Z, Wen L, Li Y, Yang H, Wang Y. The association of early pregnancy dyslipidemia with preterm birth in twin pregnancies: a retrospective cohort study. BMC Pregnancy Childbirth. 2024;24(1):616. DOI: 10.1186/s12884-024-06789-1

22. Jiang S, Jiang J, Xu H, Wang S, Zhang Z, Li D, et al. Maternal dyslipidemia during pregnancy may increase the risk of preterm birth: a meta-analysis. Taiwan J Obstet Gynecol. 2017;56(1):9–15. DOI: 10.1016/j.tjog.2016.07.012

23. Cunningham FG, Leveno KJ, Bloom SL, Spong CY, Dashe JS, Hoffman BL, et al. Williams obstetrics. 24th ed. New York: McGraw-Hill Education; 2014. 

24. Liu J, Zhai Q, Wang J, Ma L, Zhang Y, Liu Y, et al. Maternal dyslipidemia in the first trimester and adverse pregnancy and offspring outcomes: based on the Tianjin birth cohort. Lipids Health Dis. 2025;24(1):335. DOI: 10.1186/s12944-025-02751-y

25. Sánchez-Vera I, Bonet B, Viana M, Quintanar A, Martín MD, Blanco P, et al. Changes in plasma lipids and increased low-density lipoprotein susceptibility to oxidation in pregnancies complicated by gestational diabetes: consequences of obesity. Metabolism. 2007;56(11):1527–33. DOI: 10.1016/j.metabol.2007.06.020

26. Macrosomia: ACOG Practice Bulletin Summary, Number 216. Obstet Gynecol. 2020;135(1):246–8. DOI: 10.1097/AOG.0000000000003607

27. Cho KH, Yoon SJ, Lim J. Epidemiology of macrosomia in Korea: growth and development. J Korean Med Sci. 2021;36(47):e320. DOI: 10.3346/jkms.2021.36.e320

28. Martin JA, Hamilton BE, Osterman MJK. Births: final data for 2019. Natl Vital Stat Rep. 2019;68(13):1–47.

29. Котова Е.Г ., Кобякова О.С., Стародубов В.И., [и др]. Основные показатели здоровья матери и ребенка, деятельность службы охраны детства и родовспоможения в Российской  Федерации: статистические материалы // М.: ФГБУ «ЦНИИОИЗ» Минздрава России. – 2021. – 171 с. Kotova EG, Kobyakova OS, Starodubov VI, et al. Osnovnye pokazateli zdorov’ya materi i rebenka, deyatel’nost’ sluzhby ohrany detstva i rodovspomozheniya v Rossijskoj Federacii: statisticheskie materialy [Main Indicators of Maternal and Child Health, Activities of the Child Protection and Obstetric Care Service in the Russian Federation: Statistical Materials]. M.: FGBU «CNIIOIZ» Minzdrava Rossii [Moscow: FSBI “CRIHOI” of the Ministry of Health of Russia]. 2021; 171 p. (In Russ.)

30. Johnsson IW, Haglund B, Ahlsson F, Gustafsson J. A high birth weight is associated with increased risk of type 2 diabetes and obesity. Pediatr Obes. 2015;10(2):77–83. DOI: 10.1111/ijpo.230

31. Walsh JM, McAuliffe FM. Prediction and prevention of the macrosomic fetus. Eur J Obstet Gynecol Reprod Biol. 2012;162(2):125–30. DOI: 10.1016/j.ejogrb.2012.03.005

32. Xi F, Chen H, Chen Q, Chen D, Chen Y, Sagnelli M, et al. Second-trimester and third trimester maternal lipid profiles significantly correlated to LGA and macrosomia. Arch Gynecol Obstet. 2021;304(4):885–94. DOI: 10.1007/s00404-021-06010-0

33. Wang X, Guan Q, Zhao J, Yang J, Shen Z, Zhou J, et al. Association of maternal serum lipids at late gestation with the risk of neonatal macrosomia in women without diabetes mellitus. Lipids Health Dis. 2018;17(1):78. DOI: 10.1186/s12944-018-0707-7

34. Wang Y, Liu H, Wang J, Hu X, Wang A, Nie Z, et al. Development and validation of a new predictive model for macrosomia at late-term pregnancy: a prospective study. Front Endocrinol (Lausanne). 2022; 13:1019234. DOI: 10.3389/fendo.2022.1019234

35. Капустин Р.В., Цыбук Е.М., Алексеенкова Е.Н., [и др]. Роль дислипидемии в патогенезе перинатальных осложнений при сахарном диабете у матери // Журнал акушерства и женских болезней. – 2021. – Т .70, № 1. – С. 89–100. Kapustin RV, Cybuk EM, Alekseenkova EN, et al. Rol’ dislipidemii v patogeneze perinatal’nyh oslozhnenij pri saharnom diabete u materi [The role of dyslipidemia in the pathogenesis of perinatal complications in maternal diabetes mellitus]. Zhurnal akusherstva i zhenskih boleznej [Journal of Obstetrics and Women’s Diseases]. 2021:70(1): 89-100. (In Russ.) DOI: 10.17816/JOWD48566

36. La Gil-Acevedo A, Ceballos G, Torres-Ramos Y. Foetal lipoprotein oxidation and preeclampsia. Lipids Health Dis. 2022;21(1):86. DOI: 10.1186/s12944-022-01689-9

37. Калашникова М.Ф., Шиллаева Д.М., Кузнецова И.В., [и др]. Репродуктивное здоровье пациенток с сахарным диабетом 1-го типа // Вопросы гинекологии, акушерства и перинатологии. – 2023.– Т . 22, №1. – С. 59–68. Kalashnikova MF, Shillaeva DM, Kuznecova IV, et ai. Reproduktivnoe zdorov’e pacientok s saharnym diabetom 1-go tipa [Reproductive health of female patients with type 1 diabetes mellitus]. Voprosy ginekologii, akusherstva i perinatologii [Current gynecology, obstetrics and perinatology]. 2023; 22(1): 59-68. (In Russ.) DOI: 10.20953/1726-1678-2023-1-59-68

38. Ryckman KK, Spracklen CN, Smith CJ, Robinson JG, Saftlas AF. Maternal lipid levels during pregnancy and gestational diabetes: a systematic review and meta-analysis. BJOG. 2015;122(5):643–51. DOI: 10.1111/1471-0528.13261

39. Rahnemaei FA, Pakzad R, Amirian A, Pakzad I, Abdi F. Effect of gestational diabetes mellitus on lipid profile: a systematic review and meta-analysis. Open Med (Wars). 2021;17(1):70–86. DOI: 10.1515/med-2021-0402

40. O’Malley EG, Reynolds CM, O’Kelly R, Killalea A, Sheehan SR, Turner MJ. Maternal obesity and dyslipidemia associated with gestational diabetes mellitus (GDM). Eur J Obstet Gynecol Reprod Biol. 2020; 246:67–71. DOI: 10.1016/j.ejogrb.2020.01.007

41. Liu Y, Liu Y, Zhang J, Huang X, Li S, Chen Y, et al. Pre-pregnancy LDL/HDL and total cholesterol/HDL ratios are strong predictors of gestational diabetes mellitus in women undergoing assisted reproductive technologies. Reprod Biol Endocrinol. 2024;22(1):155. DOI: 10.1186/s12958-024-01312-3

42. Ye R, Onodera T, Scherer PE. Lipotoxicity and β cell maintenance in obesity and type 2 diabetes. J Endocr Soc. 2019;3(3):617–31. DOI: 10.1210/js.2018-00372

43. Wu YT, Zhang CJ, Mol BW, Kawai A, Li C, Chen L, et al. Early prediction of gestational diabetes mellitus in the Chinese population via advanced machine learning. J Clin Endocrinol Metab. 2021;106(3):e1191–205. DOI: 10.1210/clinem/dgaa898

44. Sun L, Zhao Y, Sun Y, Li M, Wang S, Wang X, et al. The establishment of lipid profiles reference ranges during pregnancy: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2025;23(1):110. DOI: 10.1186/s12958-025-01363-0

45. Marra MV, Bailey RL. Position of the Academy of Nutrition and Dietetics: micronutrient supplementation. J Acad Nutr Diet. 2018;118(11):2162–73. DOI: 10.1016/j.jand.2018.07.022

46. France M, Rees A, Datta D, Dawson L, Durrington P, Humphries SE, et al. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. Atherosclerosis. 2016;255:128–39. DOI: 10.1016/j.atherosclerosis.2016.10.017

47. Grześk G, Dorota B, Wołowiec Ł, Wołowiec A, Osiak J, Kozakiewicz M, et al. Safety of PCSK9 inhibitors. Biomed Pharmacother. 2022;156:113957. DOI: 10.1016/j.biopha.2022.113957

48. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1046–81. DOI: 10.1161/CIR.0000000000000624

49. Perak AM, Lancki N, Kuang A, Labarthe DR, Allen NB, Shah SH, et al. Cardiovascular health among pregnant women, aged 20 to 44 years, in the United States. J Am Heart Assoc. 2020;9(4):e015123. DOI: 10.1161/JAHA.119.015123

50. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. DOI: 10.1093/eurheartj/ehz455

51. International Weight Management in Pregnancy (i-WIP) Collaborative Group. Effect of diet and physical activity based interventions in pregnancy on gestational weight gain and pregnancy outcomes: meta-analysis of individual participant data from randomised trials. BMJ. 2017;358:j3119. DOI: 10.1136/bmj.j3119

 

 

УДК: 616.65-002

DOI: 10.20969/VSK M.2026.19(5).131-138

PDF download A review of the microbiota of the male urogenital tract in health and disease

Alexander A. Fuzeynikov1, Evgeny I. Kanaev1, Evgeny A. Boriaev1, Dmitriy V. Alekseev1

1 Samara State Medical University, 89 Chapaevskaya str., 443099, Samara, Russia

Abstract. Introduction. Modern methods of microbiological analysis have made it possible to synthesize current knowledge on the microbiota of the male urogenital tract. This became possible owing to the wider adoption of sequencing methods used by microbiology laboratories and their close collaboration with physicians in clinical departments. A growing number of studies are being published in the scientific literature that, to varying degrees, address colonizing the male urogenital tract by various microorganisms and the effects of these microorganisms on human health. The mechanism by which the prostate microbiota is formed remains an open question, given the wide variety of colonization sources and the specific anatomical and physiological features of this organ. Aim. To  summarize current knowledge on the role of the normal, opportunistic, and obligate pathogenic microbiota in the development of prostate pathology. Materials and Methods. Scientific articles describing microbiological studies of prostate tissue in patients with various diseases of this organ were analyzed using the PubMed and Google Scholar bibliographic databases. Results and Discussion. Prostate tissues are colonized by microbial taxa, such as Staphylococcus spp., Propionibacterium spp., Flavobacterium spp., Corynebacterium spp., Clostridium spp., Bacteroidetes spp., Paracoccus spp., Actinobacter spp., Moraxella spp., Proteobacteria spp., Streptococcus spp., Pseudomonas spp., Escherichia spp. Previously, it was believed that these microorganisms can colonize the urogenital tract only in various infections, but currently there is evidence that they might also be present in healthy condition in these loci. Understanding of microbiota involved in acute and chronic prostatitis has expanded. In acute prostatitis, Esherichia coli, Klebsiella pneumoniae, Proteus spp., Serratia spp., Enterobacter spp., Enterococcus spp.. play the leading role, while E. coli, Klebsiella spp., Proteus spp., Pseudomonas spp., Enterococcus spp., Staphylococcus spp., Streptococcus milleri group, Streptococcus mitis group, Streptococcus agalactiae и Streptococcus parasanguinis. are mostly considered in case chronic prostatitis. Involvement of sexually transmitted infections (such as those caused by Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis, and Neisseria gonorrhoeae) is proven regarding these diseases. Data regarding the importance of chronic inflammation in emergence of benign prostatic hyperplasia is of great interest. Most frequently, this effect is caused by infectious agents detected in bacterial prostatitis. This is due to stimulation of cell proliferation and fibrosis, leading to an increase in prostate volume. Conclusions. Therefore, modern methods of microbiological research allow for a deeper study of the etiology and pathogenesis of various diseases of the male genitourinary system and a more targeted management of them.

Keywords: urogenital tract microbiota, prostate microbiota, prostate microbiota in benign hyperplasia of prostate, acute bacterial prostatitis, chronic bacterial prostatitis.

For citation: Fuzeynikov A.A.; Kanaev E.I.; Boriaev E.A.; Alekseev D.V. A review of the microbiota of the male urogenital tract in health and disease. The Bulletin of Contemporary Clinical Medicine. 2026, 19(5), 131-138. DOI: 10.20969/VSKM.2026.19(5).131-138.

REFERENCES

1. Lu H, Giordano F, Ning Z. Oxford Nanopore MinION Sequencing and Genome Assembly. Genomics Proteomics Bioinformatics. 2016;14(5):265-279. DOI: 10.1016/j.gpb.2016.05.004

2. Magistro G, Stief CG. The Urinary Tract Microbiome: The Answer to All Our Open Questions? Eur Urol Focus. 2019;5(1):36-38. DOI: 10.1016/j.euf.2018.06.011

3. Farahani L, Tharakan T, Yap T, Ramsay JW, Jayasena CN, Minhas S. The semen microbiome and its impact on sperm function and male fertility: A systematic review and meta-analysis. Andrology. 2021;9(1):115-144. DOI: 10.1111/andr.12886

4. Toh E, Xing Y, Gao X, et al. Sexual behavior shapes male genitourinary microbiome composition. Cell Rep Med. 2023;4(3):100981. DOI: 10.1016/j.xcrm.2023.100981

5. Betschart C, Dedes I, Scheiner D. Rezidivierende urogy-näkologische Infektionen [Recurrent Urogynecological Infections]. Praxis (Bern 1994). 2020;109(2):79-85. DOI: 10.1024/1661-8157/a003368

6. Brandão P, Gonçalves-Henriques M, Ceschin N. Seminal and testicular microbiome and male fertility: A systematic review. Porto Biomed J. 2021;6(6):e151. DOI: 10.1097/j.pbj.0000000000000151

7. Baud D, Pattaroni C, Vulliemoz N, et al. Sperm Microbiota and Its Impact on Semen Parameters. Front Microbiol. 2019;10:234. DOI:10.3389/fmicb.2019.00234

8. Deng ZC, Yang JC, Huang YX, et al. Translocation of gut microbes to epididymal white adipose tissue drives lipid metabolism disorder under heat stress. Sci China Life Sci. 2023;66(12):2877-2895. DOI: 10.1007/s11427-022-2320-y

9. Malewski W, Milecki T, Tayara O, et al. Role of Systematic Biopsy in the Era of Targeted Biopsy: A Review. Curr Oncol. 2024;31(9):5171-5194. DOI: 10.3390/curroncol31090383

10. Pradere B, Veeratterapillay R, Dimitropoulos K, et al. Nonantibiotic Strategies for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis. J Urol. 2021;205(3):653-663. DOI: 10.1097/JU.0000000000001399

11. Wu EH, De Cicco FL. Anatomy, Abdomen and Pelvis, Male Genitourinary Tract. In: StatPearls. Treasure Island (FL): StatPearls Pu

12. Zuber A, Peric A, Pluchino N, et al. Human Male Genital Tract Microbiota. Int J Mol Sci. 2023;24(8):6939. DOI: 10.3390/ijms24086939

13. Lei H, Han H, Feng Y, et al. Altered microbiota profile in seminal vesicles of men presenting with refractory hematospermia. Mol Biol Rep. 2023;50(3):2381-2389. DOI:10.1007/s11033-022-08139-w

14. Hsieh MH. Infections in Urology. Urol Clin North Am. 2024;51(4):xv. DOI: 10.1016/j.ucl.2024.08.001

15. Kranz J, Bartoletti R, Bruyère F, et al. European Association of Urology Guidelines on Urological Infections: Summary of the 2024 Guidelines. Eur Urol. 2024;86(1):27-41. DOI: 10.1016/j.eururo.2024.03.035

16. Stamatiou K. The undefined role of Gram positive bacteria in chronic prostatitis development. Infez Med. 2013;21(1):85-87.

17. Krieger JN, Thumbikat P. Bacterial Prostatitis: Bacterial Virulence, Clinical Outcomes, and New Directions. Microbiol Spectr. 2016;4(1):UTI-0004-2012. DOI: 10.1128/microbiolspec.UTI-0004-2012

18. Lundy SD, Sangwan N, Parekh NV, et al. Functional and Taxonomic Dysbiosis of the Gut, Urine, and Semen Microbiomes in Male Infertility. Eur Urol. 2021;79(6):826-836. DOI: 10.1016/j.eururo.2021.01.014

19. Lin X, Yu Z, Liu Y, et al. Gut-X axis. Imeta. 2025;4(1):e270. DOI: i:10.1002/imt2.270

20. Feliciano J, Teper E, Ferrandino M, et al. The incidence of fluoroquinolone resistant infections after prostate biopsy are fluoroquinolones still effective prophylaxis? J Urol. 2008;179(3):952-955. DOI: 10.1016/j.juro.2007.10.071

21. Carignan A, Roussy JF, Lapointe V, et al. Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis? Eur Urol. 2012;62(3):453-459. DOI:10.1016/j.eururo.2012.04.044

22. Gill BC, Shoskes DA. Bacterial prostatitis. Curr Opin Infect Dis. 2016;29(1):86-91. DOI: 10.1097/QCO.0000000000000222

23. Yoon BI, Kim S, Han DS, et al. Acute bacterial prostatitis: how to prevent and manage chronic infection? J Infect Chemother. 2012;18(4):444-450. DOI: 10.1007/s10156-011-0350-y

24. Kim SH, Ha US, Yoon BI, et al. Microbiological and clinical characteristics in acute bacterial prostatitis according to lower urinary tract manipulation procedure. J Infect Chemother. 2014;20(1):38-42.DOI: 10.1016/j.jiac.2013.11.004

25. Karaiskos I, Galani L, Sakka V, et al. Oral fosfomycin for the treatment of chronic bacterial prostatitis. J Antimicrob Chemother. 2019;74(5):1430-1437. DOI: 10.1093/jac/dkz015

26. Oliveira P, Andrade JA, Porto HC, Filho JE, Vinhaes AF. Diagnosis and treatment of prostatic abscess. Int Braz J Urol. 2003;29(1):30-34. DOI: 10.1590/s1677-55382003000100006

27. Brehm TJ, Trautner BW, Kulkarni PA. Acute and Chronic Infectious Prostatitis in Older Adults. Infect Dis Clin North Am. 2023;37(1):175-194. DOI: 10.1016/j.idc.2022.09.004

28. Coker TJ, Dierfeldt DM. Acute Bacterial Prostatitis: Diagnosis and Management. Am Fam Physician. 2016;93(2):114-120.

29. Nagy V, Kubej D. Acute bacterial prostatitis in humans: current microbiological spectrum, sensitivity to antibiotics and clinical findings. Urol Int. 2012;89(4):445-450. DOI: 10.1159/000342653

30. Khan FU, Ihsan AU, Khan HU, et al. Comprehensive overview of prostatitis. Biomed Pharmacother. 2017;94:1064-1076. DOI: 10.1016/j.biopha.2017.08.016

31. Khudhur H, Brunckhorst O, Muir G, et al. Prostatic abscess: A systematic review of current diagnostic methods, treatment modalities and outcomes. Turk J Urol. DOI: 10.5152/tud.2020.19273

32. Wu Y, Jiang H, Tan M, Lu X. Screening for chronic prostatitis pathogens using high-throughput next-generation sequencing. Prostate. 2020;80(7):577-587. DOI: 10.1002/pros.23971

33. Lam JC, Stokes W. Acute and Chronic Prostatitis. Am Fam Physician. 2024;110(1):45-51.

34. Stamatiou K, Pierris N. Mounting resistance of uropathogens to antimicrobial agents: A retrospective study in patients with chronic bacterial prostatitis relapse. Investig Clin Urol. 2017;58(4):271-280. DOI: 10.4111/icu.2017.58.4.271

35. Kogan MI, Ibishev KS, Naboka YL, et al. Antibiotic therapy of chronic bacterial prostatitis is more effective considering antibiotic susceptibility of all pathogens isolated. Investig Clin Urol. 2022;63(3):325-333. DOI: 10.4111/icu.20210451

36. Stamatiou K, Magri V, Perletti G, et al. Chronic prostatic infection: Microbiological findings in two Mediterranean populations. Arch Ital Urol Androl. 2019;91(3):10.4081/aiua.2019.3.177. DOI: 10.4081/aiua.2019.3.177

37. Wu Y, Jiang H, Tan M, Lu X. Screening for chronic prostatitis pathogens using high-throughput next-generation sequencing. Prostate. 2020;80(7):577-587. DOI: 10.1002/pros.23971

38. Xiong S, Liu X, Deng W, et al. Pharmacological Interventions for Bacterial Prostatitis. Front Pharmacol. 2020;11:504. DOI: 10.3389/fphar.2020.00504

39. Magri V, Boltri M, Cai T, et al. Multidisciplinary approach to prostatitis. Arch Ital Urol Androl. 2019;90(4):227-248. DOI: 10.4081/aiua.2018.4.227

40. Papeš D, Pasini M, Jerončić A, et al. Detection of sexually transmitted pathogens in patients with chronic prostatitis/chronic pelvic pain: a prospective clinical study. Int J STD AIDS. 2017;28(6):613-615. DOI: 10.1177/0956462417691440

41. Krieger JN, Lee SW, Jeon J, et al. Epidemiology of prostatitis. Int J Antimicrob Agents. 2008;31 Suppl 1(Suppl 1):S85-S90. DOI: 10.1016/j.ijantimicag.2007.08.028

42. Fibbi B, Penna G, Morelli A, et al. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl. 2010;33(3):475-488. DOI: 10.1111/j.1365-2605.2009.00972.x

43. Nickel JC, Roehrborn CG, O’Leary MP, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54(6):1379-1384. DOI: 10.1016/j.eururo.2007.11.026

44. Pei X, Liu L, Han Y. Advances in human microbiome and prostate cancer research. Front Immunol. 2025;16:1576679. DOI: 10.3389/fimmu.2025.1576679

45. Zhong W, Wu K, Long Z, et al. Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axis. Microbiome. 2022;10(1):94. DOI: 10.1186/s40168-022-01289-w

46. Ward Grados DF, Ergun O, Miller CD, et al. Prostate Tissue Microbiome in Patients with Prostate Cancer: A Systematic Review. Cancers (Basel). 2024;16(8):1549. DOI: 10.3390/cancers16081549

47. Wang SY, Cai Y, Hu X, et al. P. gingivalis in oral-prostate axis exacerbates benign prostatic hyperplasia via IL-6/IL-6R pathway. Mil Med Res. 2024;11(1):30. DOI: 10.1186/s40779-024-00533-8

48. De Nunzio C, Presicce F, Tubaro A. Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat Rev Urol. 2016;13(10):613-626. DOI: 10.1038/nrurol.2016.168

49. Miyake M, Tatsumi Y, Ohnishi K, et al. Prostate diseases and microbiome in the prostate, gut, and urine. Prostate Int. 2022;10(2):96-107. DOI: 10.1016/j.prnil.2022.03.004

50. Vignozzi L, Cellai I, Santi R, et al. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. J Endocrinol. 2012;214(1):31-43. DOI: 10.1530/JOE-12-0142

51. Che B, Zhang W, Xu S, et al. Prostate Microbiota and Prostate Cancer: A New Trend in Treatment. Front Oncol. 2021;11:805459. Published 2021 Dec 10. DOI: 10.3389/fonc.2021.805459

52. Qin J, Shi X, Xu J, et al. Characterization of the Genitourinary Microbiome of 1,165 Middle-Aged and Elderly Healthy Individuals. Front Microbiol. 2021;12:673969. DOI: 10.3389/fmicb.2021.673969

53. Shrestha E, White JR, Yu SH, et al. Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer. J Urol. 2018;199(1):161-171. DOI: 10.1016/j.juro.2017.08.001

54. Kriger O, Belausov N, Gefen-Halevi S, et al. Optimizing the Yield of In-and-Out Urinary Catheter Cultures by Applying a “Midstream-Like” Approach in Pediatric Patients. Pediatr Infect Dis J. 2024;43(3):e108-e110. DOI: 10.1097/INF.0000000000004219

55. Набока Ю. Л., Чибичян М. Б., Ильяш А. В. Микробная контаминация ткани предстательной железы при доброкачественной гиперплазии и раке предстательной железы // Вестник урологии. – 2013. – № 1. – С. 28-38. Naboka YL, Chibichyan MB, Ilyash AV. Mikrobnaya kontaminaciya tkani predstatel’noj zhelezy pri dobrokachestvennoj giperplazii i rake predstatel’noj zhelezy [A microbial contamination of prostatic tissue in benign prostatic hyperplasia and prostate cancer]. Vestnik urologii [Urology Herald]. 2013;(1):28-38. (In Russ.) DOI: 10.21886/2308-6424-2013-0-1-28-38

 

 

УДК: 616.12-008.318.4

DOI: 10.20969/VSKM.2026.19(5).139-145

PDF download Burden and phenotype of extrasystoles as determinants of prognosis

Svetlana A. Chepurnenko1,2, Nina V. Burtseva3, Galina V. Shavkuta2, Margarita S. Chepurnenko2

1 Rostov Regional Clinical Hospital, 170 Blagodatnaya str., 344015 Rostov-on-Don, Russia

2 Rostov State Medical University, 29 Nakhichevansky Lane, 344022 Rostov-on-Don, Russia

3 N.V. Sklifosovsky Institute for Emergency Medicine, 3 Bolshaya Sukharevskaya Sq., 129090 Moscow, Russia

Abstract. Introduction. Supraventricular and ventricular premature beats have traditionally been regarded as “benign” rhythm disturbances; however, accumulating evidence indicates their association with some adverse cardiovascular outcomes and the need for clinical risk stratification. Aim. To summarize the current evidence on the prognostic significance of supraventricular and ventricular premature beats, including dose-response relationships, phenotypic characteristics, and practical approaches to risk assessment. Materials and Methods. Publications addressing the prognostic significance of supraventricular and ventricular extrasystoles were reviewed on a systemic basis, including the impact of their burden and phenotypic characteristics on the risk of atrial fibrillation, ischemic stroke, left ventricular remodeling, chronic heart failure, and mortality. The literature search was performed in PubMed, eLibrary.ru, and Google Scholar, while studies were selected stepwise in accordance with the PRISMA recommendations. Results and Discussion. Frequent ventricular premature beats are associated with the risk of reduced left ventricular ejection fraction and incident chronic heart failure; prognostic significance is determined by both the ventricular premature beat burden (percentage) and the phenotype. Supraventricular premature beats serve as a marker of  subsequent atrial fibrillation detection and an embolic stroke phenotype. Conclusions. Supraventricular and ventricular premature beats should be considered markers of electrophysiological and structural remodeling that require quantitative and qualitative assessment, risk stratification, and personalized follow-up.

Keywords: premature beat, supraventricular extrasystoles, ventricular extrasystoles, atrial fibrillation, prognosis, cardiovascular mortality

For citation: Chepurnenko, S.A.; Burtseva, N.V.; Shavkuta, G.V.; Chepurnenko M.S. Burden and phenotype of extrasystoles as determinants of prognosis. The Bulletin of Contemporary Clinical Medicine. 2026, 19(5), 139-145. DOI: 10.20969/VSKM.2026.19(5).139-145.

REFERENCES

1. Hingorani P, Karnad DR, Rohekar P, et al. Arrhythmias seen in baseline 24-hour Holter ECG recordings in healthy normal volunteers during phase 1 clinical trials. The Journal of Clinical Pharmacology. 2016; 56 (7): 885–893. DOI: 10.1002/jcph.679

2. Voskoboinik A, Hadjis A, Alhede C, et al. Predictors of adverse outcome in patients with frequent premature ventricular complexes: The ABC-VT risk score. Heart Rhythm. 2020; 17 (7): 1066–1074. DOI: 10.1016/j.hrthm.2020.02.020

3. Тихоненко В.М., Тулинцева Т.Э., Лышова О.В., [и др.]. Нарушения ритма и проводимости сердца у здоровых лиц // Вестник аритмологии. – 2018. – № 91. – С. 11–20. Tikhonenko VM, Tulintseva TE, Lyshova OV, et al. Narusheniya ritma i provodimosti serdtsa u zdorovykh lits [Disorders of cardiac rhythm and conduction in healthy individuals]. Vestnik aritmologii [Journal of Arrhythmology]. 2018; (91): 11–20. (In Russ.) URL: https://cyberleninka.ru/article/n/narusheniya-ritma-i-provodimosti-serdtsa-u-zdorovyh-lits

4. Варлашина К.А., Балыкова Л.А., Ивянский С.А., [и др.]. Распространенность нарушений ритма и проводимости сердца у юных спортсменов // Огарёв-Online. – 2019. – № 2. – С. 123. Varlashina KA, Balykova LA, Ivyansky SA, et al. Rasprostranennost’ narusheniy ritma i provodimosti serdtsa u yunykh sportsmenov [The prevalence of cardiac rhythm and conduction disorders in young athletes]. Ogarev-Online [Ogarev-Online]. 2019; (2): 123. (In Russ.) URL: https://cyberleninka.ru/article/n/rasprostranennost-narushe-niy-ritma-i-provodimosti-serdtsa-u-yunyh-sportsmenov

5. Гетман С.И. Распространенность нарушений ритма сердца и проводимости среди обратившихся за медицинской помощью к кардиологу на амбулаторном этапе // Кардиология. – 2018. – Т . 58, № 6. – С. 20–28. Getman SI. Rasprostranennost’ narusheniy ritma serdtsa i provodimosti sredi obrativshikhsya za meditsinskoy pomoshch’yu k kardiologu na ambulatornom etape [The  prevalence of cardiac rhythm and conduction disorders among patients who sought cardiology care at the outpatient stage]. Kardiologiya [Cardiology]. 2018; 58 (6): 20–28. (In Russ.) DOI: 10.18087/cardio.2018.6.10130

6. Dong Y, Li X, Zheng W, et al. Prevalence and heart rate variability characteristics of premature ventricular contractions detected by 24-hour Holter among outpatients with palpitations in China: a cross-sectional study. BMJ Open. 2022; 12 (8): e059337. DOI: 10.1136/bmjopen-2021-059337

7. Sirichand S, Killu AM, Padmanabhan D, et al. Incidence of idiopathic ventricular arrhythmias: a population-based study. Circulation: Arrhythmia and Electrophysiology. 2017; 10 (2): e004662. DOI: 10.1161/CIRCEP.116.004662

8. Lin CY, Lin YJ, Chen YY, et al. Prognostic significance of premature atrial complexes burden in prediction of long-term outcome. Journal of the American Heart Association. 2015; 4: e002192. DOI: 10.1161/JAHA.115.002192

9. Harms PP, Himmelreich JCL, Blom MT, et al. Longitudinal association of premature atrial contractions with atrial fibrillation and brain ischemia in people with type 2 diabetes: The Hoorn Diabetes Care System cohort. American Heart Journal Plus: Cardiology Research and Practice. 2023; 34: 100321. DOI: 10.1016/j.ahjo.2023.100321

10. Durmaz E, Ikitimur B, Kilickiran Avci B, et al. The clinical significance of premature atrial contractions: How frequent should they become predictive of new-onset atrial fibrillation. Annals of Noninvasive Electrocardiology. 2020; 25: e12718. DOI: 10.1111/anec.12718

11. Sasaki K, Nakajima I, Higuma T, et al. Revisit to the prognostic value of premature atrial contraction burden in 24-h Holter electrocardiography for predicting undiagnosed atrial fibrillation: A propensity score-matched study. Circulation Journal. 2021; 85 (8): 1265–1272. DOI: 10.1253/circj.CJ-20-1277

12. Larsen BS, Aplin M, Nielsen OW, et al. Excessive supraventricular ectopic activity and risk of incident atrial fibrillation in a consecutive population referred to ambulatory cardiac monitoring. Heart Rhythm O2. 2021; 2 (3): 231–238. DOI: 10.1016/j.hroo.2021.04.002

13. Raman D, Kaffashi F, Lui L-Y, et al. Polysomnographic heart rate variability indices and atrial ectopy associated with incident atrial fibrillation risk in older community-dwelling men. JACC Clinical Electrophysiology. 2017; 3 (5): 451–460. DOI: 10.1016/j.jacep.2016.09.001

14. Shimada Y, Todo K, Doijiri R, et al. Higher frequency of premature atrial contractions correlates with atrial fibrillation detection after cryptogenic stroke. Stroke. 2024; 55 (4): 946–953. DOI: 10.1161/STROKEAHA.123.044813

15. Cha JJ, Lee KY, Chung H, et al. Frequent premature atrial contractions as a poor prognostic factor in cryptogenic stroke patients with concomitant non-sustained atrial tachycardia. Yonsei Medical Journal. 2020; 61 (11): 965–969. DOI: 10.3349/ymj.2020.61.11.965

16. Gunda S, Akyeampong D, Gomez-Arroyo J, et al. Consequences of chronic frequent premature atrial contractions: Association with cardiac arrhythmias and cardiac structural changes. Journal of Cardiovascular Electrophysiol. 2019; 30 (10): 1952–1959. DOI: 10.1111/jce.14067

17. O’Neal WT, Kamel H, Kleindorfer D, et al. Premature atrial contractions on the screening electrocardiogram and risk of ischemic stroke: The Reasons for Geographic and Racial Differences in Stroke study. Neuroepidemiology. 2016; 47 (1): 53–58. DOI: 10.1159/000448619

18. Marinheiro R, Parreira L, Amador P, et al. Excessive atrial ectopic activity as an independent risk factor for ischemic stroke. International Journal of Cardiology. 2017; 249: 226–230. DOI: 10.1016/j.ijcard.2017.08.054

19. Larsen BS, Kumarathurai P, Falkenberg J, et al. Excessive atrial ectopy and short atrial runs increase the risk of stroke beyond incident atrial fibrillation. Journal of the American College of Cardiology. 2015; 66 (3): 232–241. DOI: 10.1016/j.jacc.2015.05.018

20. Kim JU, Snell A, Kabunga P, et al. Atrial premature complex burden as a risk stratification predictor of paroxysmal atrial fibrillation and embolic stroke. Journal of Stroke and Cerebrovascular  Diseases. 2025; 34: 108369. DOI: 10.1016/j.jstrokecerebrovasdis.2025.108369

21. Haeusler KG, Tütüncü S, Fiessler C, et al. Excessive supra ventricular ectopic activity in patients with acute ischemic stroke is associated with atrial fibrillation detection within 24 months after stroke: a predefined analysis of the MonDAFIS study. Journal of the American Heart Association. 2025; 14: e034512. DOI: 10.1161/JAHA.123.034512

22. Mattsson N, Kumarathurai P, Larsen BS, et al. Mild hypokalemia and supraventricular ectopy increases the risk of stroke in community-dwelling subjects. Stroke. 2017; 48 (3): 537–543. DOI: 10.1161/STROKEAHA.116.015439

23. Py A, Schaaf M, Duhamel S, et al. Atrial premature activity detected after an ischaemic stroke unveils atrial myopathy. Archives of Cardiovascular Disease. 2020; 113: 227–236. DOI: 10.1016/j.acvd.2019.12.002

24. Heckbert SR, Jensen PN, Austin TR, et al. Associations of left atrial function and structure with supraventricular ectopy: The Multi-Ethnic Study of Atherosclerosis. Journal of the American Heart Association. 2021; 10: e018093. DOI: 10.1161/JAHA.120.018093

25. Higuchi S, Voskoboinik A, Im SI, et al. Frequent premature atrial contractions lead to adverse atrial remodelling and atrial fibrillation in a swine model. Circulation. 2024; 149 (6): 463–474. DOI: 10.1161/CIRCULATIONAHA.123.065874

26. Huang TC, Lee PT, Huang MS, et al. Higher premature atrial complex burden from the Holter examination predicts poor cardiovascular outcome. Scientific Reports. 2021; 11: 12198. DOI: 10.1038/s41598-021-91800-4

27. Rooney MR, Norby FL, Maheshwari A, et al. Frequent premature atrial contractions are associated with poorer cognitive function in the Atherosclerosis Risk in Communities (ARIC) Study. Mayo Clinic Proceedings. 2021; 96 (5): 1147–1156. DOI: 10.1016/j.mayocp.2021.01.025

28. Agarwal SK, Chao J, Peace F, et al. Premature ventricular complexes on screening electrocardiogram and risk of ischemic stroke. Stroke. 2015; 46 (5): 1365–1367. DOI: 10.1161/STROKEAHA.114.008447

29. Johnson JA, Haq KT, Lutz KJ, et al. Electrophysiological ventricular substrate of stroke: a prospective cohort study in the Atherosclerosis Risk in Communities (ARIC) study. BMJ Open. 2021; 11: e048542. DOI: 10.1136/bmjopen-2020-048542

30. Ahmad MI, Soliman MZ, Soliman EZ. Relationship between premature ventricular complexes and stroke mortality in the general population. Journal of Electrocardiology. 2023; 77: 41–45. DOI: 10.1016/j.jelectrocard.2022.12.004

31. Dukes JW, Dewland TA, Vittinghoff E, et al. Ventricular ectopy as a predictor of heart failure and death. Journal of the American College of Cardiology. 2015; 66 (2): 101–109. DOI: 10.1016/j.jacc.2015.04.062

32. Kim YG, Choi YY, Han KD, et al. Premature ventricular contraction increases the risk of heart failure and ventricular tachyarrhythmia. Scientific Reports. 2021; 11: 12698. DOI: 10.1038/s41598-021-92088-0

33. Torrado J, Sima A, Comstuck C, et al. Prevalence of frequent premature ventricular contractions and left-ventricular systolic dysfunction in patients receiving Holter monitoring. Journal of Cardiovascular Electrophysiology. 2025; 36: 54–61. DOI: 10.1111/jce.16478

34. Limpitikul WB, Dewland TA, Vittinghoff E, et al. Premature ventricular complexes and development of heart failure in a community-based population. Heart. 2022; 108 (2): 105–110. DOI: 10.1136/heartjnl-2021-319473

35. Ogiso S, Arita T, Suzuki S, et al. Association between ventricular arrhythmia (premature ventricular contractions burden and nonsustained ventricular tachycardia) and cardiovascular events in patients without structural heart disease. Journal of Arrhythmia. 2025; 41: e13203. DOI: 10.1002/joa3.13203

36. Bas HD, Shah AJ, Arkles JS, et al. Effect of circadian variability in frequency of premature ventricular complexes on left ventricular function. Heart Rhythm. 2016; 13 (1): 98–102. DOI: 10.1016/j.hrthm.2015.07.038

37. Huizar JF, Fisher SG, Ramsey FV, et al. Outcomes of premature ventricular contraction-cardiomyopathy in the veteran population: A secondary analysis of the CHF-STAT Study. JACC Clinical Electrophysiology. 2021; 7 (3): 380–390. DOI: 10.1016/j.jacep.2020.08.028

38. Haruta D, Akahoshi M, Hida A, et al. Prognostic significance of premature ventricular contractions without obvious heart diseases determined by standard 12-lead electrocardiography considering their morphology. Annals of Noninvasive Electrocardiology. 2016; 21 (2): 142–151. DOI: 10.1111/anec.12275

39. Scorza R, Jonsson M, Friberg L, et al. Prognostic implication of premature ventricular contractions in patients without structural heart disease. Europace. 2023; 25 (3): 517–525. DOI: 10.1093/europace/euac184

40. Lin CY, Chang SL, Lin YJ, et al. An observational study on the effect of premature ventricular complex burden on long-term outcome. Medicine (Baltimore). 2017; 96 (1): e5476. DOI: 10.1097/MD.0000000000005476

41. Lee PT, Huang TC, Huang MH, et al. The burden of ventricular premature complex is associated with cardiovascular mortality. Frontiers in Cardiovascular Medicine. 2022; 8: 797976. DOI: 10.3389/fcvm.2021.797976

42. Parreira L, Marinheiro R, Amador P, et al. Frequent premature ventricular contractions: Association of burden and complexity with prognosis according to the presence of structural heart disease. Annals of Noninvasive Electrocardiology. 2021; 26: e12800. DOI: 10.1111/anec.12800

43. Yen K-C, Chan Y-H, Wang C-L, et al. Number of premature ventricular complexes predicts long-term outcomes in patients with persistent atrial fibrillation. Biomedicines. 2024; 12 (6): 1149. DOI: 10.3390/biomedicines12061149

44. Maneheim A, Engström G, Juhlin T, et al. Elevated premature ventricular complex counts on 24-hour electrocardiogram predict incident atrial fibrillation and heart failure: A prospective population-based cohort study. Heart Rhythm O2. 2022; 3 (4): 344–350. DOI: 10.1016/j.hroo.2022.05.008

45. Nguyen KT, Vittinghoff E, Dewland TA, et al. Ectopy on a single 12-lead ECG, incident cardiac myopathy, and death in the community. Journal of the American Heart Association. 2017; 6: e006028. DOI: 10.1161/JAHA.117.006028

46. Lee P-T, Huang M-H, Huang T-C, et al. High burden of premature ventricular complex increases the risk of new-onset atrial fibrillation. Journal of the American Heart Association. 2023; 13: e027674. DOI: 10.1161/JAHA.122.027674

47. Orini M, van Duijvenboden S, Young WJ, et al. Premature atrial and ventricular contractions detected on wearable-format electrocardiograms and prediction of cardiovascular events. European Heart Journal – Digital Health. 2023; 4: 112–118. DOI: 10.1093/ehjdh/ztad007

48. Gao Y, Jiang R, Liu Y, et al. Assessment of palpitations in patients with frequent premature ventricular contractions. Journal of Cardiovascular Electrophysiology. 2025; 36 (1): 32–41. DOI: 10.1111/jce.16476

49. Hwang JK, Park SJ, On YK, et al. Clinical characteristics and features of frequent idiopathic ventricular premature complexes in the Korean population. Korean Circulation Journal. 2015; 45 (5): 391–397. DOI: 10.4070/kcj.2015.45.5.391

50. Meyer M, Arnold A, Stein T, et al. Arrhythmias among older adults receiving comprehensive geriatric care: Prevalence and associated factors. Clinical Practice. 2024; 14: 132–147. DOI: 10.3390/clinpract14010011

 

 

УДК: [616.94-02:616.24-008.4]-085.38-073.43

DOI: 10.20969/VSKM.2026.19(5).146-156

PDF download Infusion therapy in adult patients with sepsis and sepsis-associated acute respiratory distress syndrome: A systematic review of current strategies and an ultrasound-guided approach

Visolat Kh. Sharipova1,2, Alla L. Rosstalnaya2, Shoirа A. Yuldosheva1, Malika I. Narimova1

1 Republic Research Center of Emergency Medicine, 2 Kichik Halka Yuli str., 100115 Tashkent, Uzbekistan

2 Center for the Development of Professional Qualifications of Medical Workers, 51 Parkentskaya str., 100007 Tashkent, Uzbekistan

Abstract. Introduction. Fluid therapy remains a cornerstone of intensive care in sepsis; however, current views on the optimal strategy have changed substantially. Accumulating evidence indicates that a universal approach offers no clear advantage and may be harmful when fluid administration is either excessive or insufficient, especially in patients with sepsis complicated by acute respiratory distress syndrome. The limited value of traditional methods for assessing volume status justifies the use of personalized approaches supported by ultrasound guidance. Aim: To perform a systematic analysis of current evidence on the effectiveness of different fluid therapy strategies in adult patients with sepsis, septic shock, and sepsis-associated acute respiratory distress syndrome, with a focus on the role of ultrasound assessment of volume status and tolerance to fluid loading. Materials and Methods. A systematic literature review was conducted using the PubMed/MEDLINE, Scopus, Web of Science, Google Scholar, and eLibrary databases for the period 2015–2025, with inclusion of landmark earlier studies. Results and Discussion. Of 3,147 initially identified publications, 176 were included in the final analysis, including randomized clinical trials, reviews, meta-analyses, and clinical guidelines. A liberal fluid strategy was associated with increased extravascular lung water,  prolonged duration of mechanical ventilation by 1.5–3.2 days, and a 2–7% increase in mortality. A restrictive strategy did not demonstrate convincing survival benefits, although it contributed to a lower cumulative fluid balance. Static indicators of volume status showed low predictive value for assessing responsiveness to fluid loading. Ultrasound assessment of inferior vena cava diameter demonstrated moderate diagnostic accuracy, whereas lung ultrasound showed high sensitivity for detecting interstitial edema and correlated well with the severity of lung tissue injury. The Fluid Administration Limited by Lung Sonography protocol makes it possible to improve the accuracy of hypovolemia assessment, reduce the risk of fluid overload, and detect interstitial edema at an early stage. Conclusions. Current evidence does not support the effectiveness of a universal fluid therapy strategy in sepsis and sepsis-associated acute respiratory distress syndrome. A personalized approach based on ultrasound assessment of volume status and tolerance to fluid loading appears to be the most promising strategy for optimizing fluid therapy. The Fluid Administration Limited by Lung Sonography protocol may be used as a practical tool for individualizing treatment with regard to hemodynamic response and the risk of pulmonary complications.

Keywords: sepsis, sepsis-associated acute respiratory distress syndrome, fluid therapy, ultrasound monitoring, hemodynamics

For citation: SharipovaV.Kh.; Rosstalnaya A.L.; Yuldosheva, Sh.А.; Narimova, M.I. Infusion therapy in adult patients with sepsis and sepsis-associated acute respiratory distress syndrome: systematic review of modern strategies and ultrasound-guided approach The Bulletin of Contemporary Clinical Medicine. 2026, 19(5), 146-156. DOI: 10.20969/VSKM.2026.19(5).146-156.

REFERENCES

1. Bos LD, Ware LB. Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes. Lancet. 2022;400(10358):1145-1156. DOI:10.1016/S0140-6736(22)01485-4

2. Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315(8):788-800. DOI:10.1001/jama.2016.0291

3. Liu L, Wu L, Chen Y, et al. Clinical management of sepsis-associated acute respiratory distress syndrome: current evidence and future directions. Front Med. 2025; 12:1531275. DOI:10.3389/fmed.2025.1531275

4. Гайгольник Д.В., Беляев К.Ю., Грицан Е.А., [и др.]. Биомеханика и газообмен в процессе респираторной поддержки у пациентов с некротическим панкреатитом в зависимости от исходов лечения // Вестник интенсивной терапии им. А.И. Салтанова. – 2019. - №1. – С.65-77. Gaigolnik DV, Belyaev KYu, Gritsan EA, et al. Biomechanics and gas exchange during respiratory support in patients with necrotic pancreatitis depending on treatment outcomes. Annals of Critical Care. 2019;(1):65-77. DOI:10.21320/1818-474X-2019-1-65-77

5. Grasselli G, Calfee CS, Camporota L, et al. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies. Intensive Care Med. 2023;49(7):727-759. DOI:10.1007/s00134-023-07050-7

6. Sun B, Lei M, Zhang J, et al. Acute lung injury caused by sepsis: How does it happen? Front Med (Lausanne). 2023; 10:1289194. DOI:10.3389/fmed.2023.1289194

7. Corl KA, Levy MM, Holder AL, et al. Moderate IV fluid resuscitation is associated with decreased sepsis mortality. Crit Care Med. 2024;52(4):e557-e567. DOI:10.1097/CCM.0000000000006394

8. Meyhoff TS, Hjortrup PB, Wetterslev J, et al. Restriction of Intravenous Fluid in ICU Patients with Septic Shock. N Engl J Med. 2022;386(26):2459-2470. DOI:10.1056/NEJMoa2202707

9. Shapiro NI, Douglas IS, Brower RG, et al. Early Restrictive or Liberal Fluid Management for Sepsis-Induced Hypotension. N Engl J Med. 2023;388(6):499-510. DOI:10.1056/NEJMoa2212663

10. Teboul JL, Liu J, Hamzaoui O. Initial fluid resuscitation in septic shock: Reassessing the 30 mL/kg paradigm. J Intensive Med. 2025;5(4):298-300. DOI: 10.1016/j.jointm.2025.08.001

11. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181-1247. DOI:10.1007/s00134-021-06506-y

12. Mekontso Dessap A, AlShamsi F, Belletti A, et al. European Society of Intensive Care Medicine (ESICM) 2025 clinical practice guideline on fluid therapy in adult critically ill patients: part 2–the  volume of resuscitation fluids. Intensive Care Med. 2025;51(3):461-477. DOI:10.1007/s00134-025-07840-1

13. Van Mourik N, Metske HA, Hofstra JJ, et al. Cumulative fluid balance predicts mortality and increases time on mechanical ventilation in ARDS patients: An observational cohort study. PLoS One. 2019;14(10):e0224563. DOI: 10.1371/journal.pone.0224563

14. Messmer AS, Zingg C, Müller M, et al. Fluid overload and mortality in adult critical care patients–a systematic review and meta-analysis of observational studies. Crit Care Med. 2020;48(12):1862-1870. DOI:10.1097/CCM.0000000000004617

15. Ostermann M, Al Shamsi F, Artigas Raventos A, et al. European Society of Intensive Care Medicine clinical practice guideline on fluid therapy in adult critically ill patients: Part 3–fluid removal at de-escalation phase. Intensive Care Med. 2025; 51:1749-1763. DOI:10.1007/s00134-025-08058-x

16. Ярошецкий А.И., Грицан А.И., Авдеев С.Н., [и др.] Острый респираторный дистресс-синдром (у взрослых пациентов). Клинические рекомендации (пересмотр 2025 г .) // Вестник интенсивной терапии им. А.И. Салтанова. – 2025. - №4. – С.7-68. Yaroshetskiy AI, Gritsan AI, Avdeev SN, et al. Acute respiratory distress syndrome (in adult patients). Clinical guidelines (2025 revision). Annals of Critical Care. 2025; 4:7-68. DOI:10.21320/1818-474X-2025-4-7-68)

17. Ingelse SA, IJland MM, van Loon LM, et al. Early restrictive fluid resuscitation has no clinical advantage in experimental severe pediatric acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol. 2021;320(6): L1126-L1136. DOI:10.1152/ajplung.00613.2020

18. Famous KR, Delucchi K, Ware LB, et al. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med. 2017;195(3):331-338. DOI:10.1164/rccm.201603-0645OC

19. Malbrain MLNG, Van Regenmortel N, Saugel B, et al. Principles of fluid management and stewardship in septic shock: it is time to consider the four D’s and the four phases of fluid therapy. Ann Intensive Care. 2018;8(1):66. DOI:10.1186/s13613-018-0402-x

20. Dessap AM, AlShamsi F, Belletti A, et al. European Society of Intensive Care Medicine (ESICM) 2025 clinical practice guideline on fluid therapy in adult critically ill patients: part 2–the volume of resuscitation fluids. Intensive Care Med. 2025; 51:461-477. DOI:10.1007/s00134-025-07840-1

21. Vignon P, Evrard B, Asfar P, et al. Fluid administration and monitoring in ARDS: which management? Intensive Care Med. 2020;46(12):2252-2264. DOI:10.1007/s00134-020-06209-w

22. Rola Ph, Haycock K, Spiegel R. What every intensivist should know about the IVC. J Crit Care. 2024; 80:154455. DOI: 10.1016/j.jcrc.2023.154455

23. Polyzogopoulou E, Velliou M, Verras C, et al. Point-of-care ultrasound: a multimodal tool for the management of sepsis in the emergency department. Medicina (Kaunas). 2023;59(6):1180. DOI:10.3390/medicina59061180

24. Zhang H, Jiang J, Dai M, et al. Predictive accuracy of changes in the inferior vena cava diameter for predicting fluid responsiveness in patients with sepsis: a systematic review and meta-analysis. PLoS One. 2025;20(5):e0310462. DOI: 10.1371/journal.pone.0310462

25. Soldati G, Smargiassi A, Inchingolo R, et al. Is there a role for lung ultrasound during the COVID-19 pandemic? J Ultrasound Med. 2020;39(7):1459-1462. DOI:10.1002/jum.15284

26. Jackson K, Butler R, Aujayeb A. Lung ultrasound in the COVID19 pandemic. Postgrad Med J. 2021;97(1143):34-39. DOI:10.1136/postgradmedj-2020-138137

27. Khan U, Mento F, Nicolussi LG, et al. Deep learning-based classification of reduced lung ultrasound data from COVID-19 patients. IEEE Trans Ultrason Ferroelectr Freq Control. 2022;69(5):1661

-1669. DOI:10.1109/TUFFC.2022.3160822

28. Матюшков Н.С., Тюрин И.Н., Авдейкин С.Н. Респираторная поддержка у пациентов с COVID-19. Опыт инфекционного госпиталя в Коммунарке: одноцентровое ретроспективное исследование // Вестник интенсивной терапии имени А.И. Салтанова. – 2021. - №3. – С.47-60. Matyushkov NS, Tyurin IN, Avdeykin SN. Respiratory support in patients with COVID-19. Experience of the infectious diseases hospital in Kommunarka: a single-center retrospective study. Annals of Critical Care. 2021;(3):47-60. DOI:10.21320/1818-474X-2021-3-47-60

29. Щепарев И.С., Теплых Б.А., Киреева Г.С. [и др.]. Эволюция методики и новые протоколы ультразвукового исследования легких при COVID-19 пневмониях. //Общая реаниматология. – 2023. – №19, вып.6. – С.39-47. Shcheparev IS, Teplykh BA, Kireeva GS, et al. Evolution of methods and new protocols for lung ultrasound in COVID-19 pneumonia. General Reanimatology.  2023;19(6):39-47. DOI:10.15360/1813-9779-2023-6-39-47

30. Лахин Р.Е., Жирнова Е.А., Щеголев А.В. Сопоставление ультразвуковых признаков, данных компьютерной томографии и морфологического исследования легких у пациентов с коронавирусной инфекцией: post hoc анализ. // Вестник интенсивной терапии имени А.И. Салтанова. – 2023. – №3. – С.82-96. Lakhin RE, Zhirnova EA, Shchegolev AV. Comparison of ultrasound signs, CT scan data and lung morphology in COVID-19 patients: a post hoc analysis. Annals of Critical Care. 2023;(3):82-96. DOI:10.21320/1818-474X-2023-3-82-96

31. Лахин Р.Е., Жирнова Е.А., Щеголев А.В. Ультразвуковой индекс поражения легких как предиктор исходов лечения: когортное исследование 388 пациентов с коронавирусной  инфекцией. //Вестник интенсивной терапии имени А.И. Салтанова. – 2022. – №3. – С. 45-56. Lakhin RE, Zhirnova EA, Shchegolev AV. Lung ultrasound score as a predictor of treatment outcome: a cohort study of 388 patients with coronavirus infection. Annals of Critical Care. 2022;(3):45-56. DOI:10.21320/1818-474X-2022-3-45-56

32. Петриков С.С., Попова И.Е., Абучина В.М. Диагностические возможности ультразвуковой диагностики изменений легких по сравнению с компьютерной томографией при COVID-19. // Сеченовский вестник. – 2020. – №11. вып.2. – С. 5-18. Petrikov SS, Popova IE, Abuchina VM. Diagnostic possibilities of lung ultrasound compared to computed tomography in COVID-19. Sechenov Medical Journal. 2020;11(2):5-18. DOI:10.47093/2218-7332.2020.11.2.5-18

33. Заболотских И.Б., Киров М.Ю., Лебединский К.М., [и др.]. Анестезиолого-реанимационное обеспечение пациентов с новой коронавирусной инфекцией COVID-19. Методические рекомендации. // Вестник интенсивной терапии им. А.И. Салтанова. – 2020. - S1. вып.9 – С.120. Zabolotskikh IB, Kirov MYu, Lebedinskiy KM, et al. Anesthesiology and intensive care for patients with the new coronavirus infection COVID-19. Guidelines. Annals of Critical Care. 2020; S1:9-120. DOI:10.21320/1818-474X-2020-S1-9-120

34. Gorman EA, O’Kane CM, McAuley DF. Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequelae, and management. Lancet. 2022;400(10358):1157-1170. DOI:10.1016/S0140-6736(22)01439-8

35. Корсунский Д.В., Утина Т.Г ., Джиоева О.Н., [и др.]. Опыт применения фокусного ультразвукового исследования легких в практике врача анестезиолога-реаниматолога. // Кардиоваскулярная терапия и профилактика. – 2022. – №21. вып.12. – С.50-54. Korsunsky DV, Utina TG, Dzhioeva ON, et al. Experience of using focused lung ultrasound in the practice of an anesthesiologist-intensivist. Cardiovascular Therapy and Prevention. 2022;21(12):50-54. DOI:10.15829/1728-8800-2022-3406

36. Назаров А.А., Парфеня А.В., Петраков Д.О. Ультразвуковая диагностика на этапе скорой медицинской помощи по протоколу BLUE. // Парадигма. – 2025. – №2. – С.42-47. Nazarov AA, Parfenya AV, Petrakov DO. Ultrasound diagnostics at the ambulance stage using the BLUE protocol. Paradigm. 2025;(2):42-47.

37. Rathore A, Bhatt DD, Yadav DK, et al. Lung ultrasound score and its correlation with modified Ross score in infants with left to right shunt. Cardiol Young. 2025;35(7):1329-1334. DOI:10.1017/S1047951125001738

38. Smit MR, Hagens LA, Heijnen NFL, et al. Lung ultrasound prediction model for acute respiratory distress syndrome: a multicenter prospective observational study. Am J Respir Crit Care Med. 2023;207(12):1591-1601. DOI:10.1164/rccm.202210-1882OC

39. Mongodi S, De Luca D, Colombo A, et al. Quantitative lung ultrasound: technical aspects and clinical applications. Anesthesiology. 2021; 134:949-965. DOI:10.1097/ALN.0000000000003757

40. Rocca E, Zanza C, Longhitano Y, et al. Lung ultrasound in critical care and emergency medicine: clinical review. Adv Respir Med. 2023; 91:203-223. DOI:10.3390/arm91030017

41. Liang Z, Meng Q, You C, et al. Roles of lung ultrasound score in the extubation failure from mechanical ventilation among premature infants with neonatal respiratory distress syndrome. Front Pediatr. 2021; 9:709160. DOI:10.3389/fped.2021.709160

42. Stivi T, Padawer D, Dirini N, et al. Using artificial intelligence to predict mechanical ventilation weaning success in patients with respiratory failure, including those with acute respiratory distress syndrome. J Clin Med. 2024; 13:1505. DOI:10.3390/jcm13051505

43. Lindow T, Quadrelli S, Ugander M. Noninvasive imaging methods for quantification of pulmonary edema and congestion: a systematic review. JACC Cardiovasc Imaging. 2023; 16:1469-1484. DOI: 10.1016/j.jcmg.2023.06.023

44. Mayr U, Lukas M, Habenicht L, et al. B-lines scores derived from lung ultrasound provide accurate prediction of extravascular lung water index: an observational study in critically ill patients. J Intensive Care Med. 2022; 37:21-31. DOI:10.1177/0885066620967655

45. Lichtenstein DA. BLUE-protocol and FALLS-protocol: two applications of lung ultrasound in the critically ill. Chest. 2015;147(6):1659-1670. DOI:10.1378/chest.14-1319

46. Li Q, Xu J, Zhao J, et al. Ultrasound-guided fluid volume management in patients with septic shock: a randomized controlled trial. J Trauma Nurs. 2025;32(2):90-99. DOI:10.1097/JTN.0000000000000839

47. Acilu MG, Santafé M, Roca O. Use of thoracic ultrasound in acute respiratory distress syndrome. Ann Transl Med. 2023;11(9):320. DOI:10.21037/atm-22-4576

48. Araiza-Garaygordobil D, Gopar-Nieto R, Martinez-Amezcua P, et al. A randomized controlled trial of lung ultrasound-guided therapy in heart failure (CLUSTER-HF study). Am Heart J. 2020; 227:31-39. DOI: 10.1016/j.ahj.2020.06.003

49. Da Hora Passos R, Caldas J, Ramos JGR, et al. Ultrasound-based clinical profiles for predicting the risk of intradialytic hypotension in critically ill patients on intermittent dialysis: a prospective observational study. Crit Care. 2019;23(1):389. DOI:10.1186/s13054-019-2668-2

50. Bar S, Yee C, Lichtenstein D, et al. Assessment of fluid unresponsiveness guided by lung ultrasound in abdominal surgery: a prospective cohort study. Sci Rep. 2022;12(1):1350. DOI:10.1038/s41598-022-05251-6

51. Anile A, Russo J, Castiglione G, et al. A simplified lung ultrasound approach to detect increased extravascular lung water in critically ill patients. Crit Ultrasound J. 2017;9(1):13. DOI:10.1186/s13089-017-0068-x

52. Maw AM, Hassanin A, Ho PM, et al. Diagnostic accuracy of point-of-care lung ultrasonography and chest radiography in adults with symptoms suggestive of acute decompensated heart failure: a systematic review and meta-analysis. JAMA Network Open. 2019;2(3):e190703. DOI:10.1001/jamanetworkopen.2019.0703

53. Rivas-Lasarte M, Álvarez-García J, Fernández-Martínez J, et al. Lung ultrasound-guided treatment in ambulatory patients with heart failure: a randomized controlled clinical trial (LUS-HF study). Eur J Heart Fail. 2019;21(12):1605-1613. DOI:10.1002/ejhf.1645

54. Zoccali C, Torino C, Mallamaci F, et al. A randomized multicenter trial on a lung ultrasound-guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk. Kidney Int. 2021;100(6):1325-1333. DOI: 10.1016/j.kint.2021.07.024

55. Rodríguez-Contreras FJ, Calvo-Cebrián A, Díaz-Lázaro J, et al. Lung ultrasound performed by primary care physicians for clinically suspected community-acquired pneumonia: a multicenter prospective study. Ann Fam Med. 2022;20(3):227-236. DOI:10.1370/afm.2796

56. Reisinger N, Lohani S, Hagemeier J, et al. Lung ultrasound to diagnose pulmonary congestion among patients on hemodialysis: comparison of full versus abbreviated scanning protocols. Am J Kidney Dis. 2022;79(2):193-201.e1. DOI: 10.1053/j.ajkd.2021.04.007

57. Mojoli F, Bouhemad B, Mongodi S, et al. Lung ultrasound for critically ill patients. Am J Respir Crit Care Med. 2019; 199:701-714. DOI:10.1164/rccm.201802-0236CI

 

 

УДК: 616.831-005.1/.4-036.82:615.814.1

DOI: 10.20969/VSKM.2026.19(5).157-162

PDF download Pharmacopuncture in stroke patients: An integrative approach to recovery and rehabilitation

Nargiza O. Ergasheva1, Kumushjon I. Reyimberdiyeva1, Muxabbat A. Maxamadxodjaeva2, Saodat K. Sobirova2, Sardor A. Alixonov2, Xilola J. Mardonova2, Eldor I. Abduqodirov2

1Center for the Development of Professional Qualifications of Medical Workers, 51 Parkentskaya str., 100000 Tashkent, Uzbekistan

2 Tashkent State Medical University, 2 Farobiy str., Admazar District, 100109 Tashkent, Uzbekistan

Abstract. Introduction. Stroke remains one of the leading causes of mortality and long-term disability worldwide. Despite significant advances in modern medicine, a substantial proportion of stroke survivors continue to experience persistent neurological deficits that adversely affect their quality of life and social functioning. In this regard, integrative medical approaches aimed at enhancing the effectiveness of rehabilitation interventions have attracted increasing attention. A promising therapeutic modality is pharmacopuncture that combines the principles of acupuncture and  pharmacotherapy through the administration of medicinal substances into specific acupuncture points. Therefore, evaluating the potential of pharmacopuncture in comprehensive post-stroke rehabilitation is of considerable scientific and clinical importance. Aim. To analyze current literature on the use of pharmacopuncture in the rehabilitation of stroke patients and to assess its effects on neurological status, functional recovery, and quality of life. Materials and Methods. A systematic review of domestic and international scientific publications investigating the application of  pharmacopuncture in post-stroke rehabilitation was conducted. Literature searches were performed in the major bibliographic databases, including PubMed, Scopus, Web of Science, Google Scholar, eLIBRARY.RU, and CyberLeninka. Original research articles, literature reviews, meta-analyses, and clinical practice guidelines published in recent years and addressing the efficacy and safety of pharmacopuncture in stroke rehabilitation were included in the analysis. Results and Discussion. The reviewed literature indicates that pharmacopuncture, when incorporated into comprehensive  rehabilitation programs, may contribute to improved neurological outcomes, enhanced motor recovery, reduced pain intensity and muscle spasticity, and improved quality of life. Evidence suggests that this therapeutic approach may positively influence neuroplasticity and facilitate functional restoration of the central nervous system. In most studies, pharmacopuncture was reported to be a safe adjunctive treatment associated with a low incidence of adverse effects. Nevertheless, the available evidence highlights the need for standardized treatment protocols and well-designed multicenter randomized controlled trials to further validate its clinical effectiveness. Conclusions. Pharmacopuncture represents a promising component of multidisciplinary post-stroke rehabilitation, with a potential to enhance functional recovery and improve rehabilitation outcomes. However, further high-quality studies based on evidence-based medicine principles and standardized outcome assessment methods are required to establish its efficacy and optimize its integration into routine clinical practice.

Keywords: stroke, pharmacopuncture, rehabilitation, restorative treatment, acupuncture, integrative medicine, post-stroke disorders, neurological deficit, neuroplasticity, quality of life.

For citation: Ergasheva, N.O.; Reyimberdiyeva, K.I.; Maxamadxodjaeva, M.A.; et al. Pharmacopuncture in stroke patients: An integrative approach to recovery and rehabilitation. The Bulletin of  Contemporary Clinical Medicine. 2026, 19(5), 157-162. DOI: 10.20969/VSKM.2026.19(5).157-162.

REFERENCES

1. Winstein CJ, Stein J, Arena R, et al. Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016; 47: e98-e169.

2. Langhorne P, Stott DJ, Robertson L, et al. Medical complications after stroke: a multicenter study. Stroke. 2000; 31 (6): 1223-1229. DOI: 10.1161/01.STR.31.6.1223

3. Mead GE, Sposato LA, Sampaio Silva G, et al. A systematic review and synthesis of global stroke guidelines on behalf of the World Stroke Organization. Int J Stroke. 2023; 18 (5): 499-531. DOI: 10.1177/17474930231156753

4. Yang A, Wu HM, Tang JL, et al. Acupuncture for stroke rehabilitation. Cochrane Database Syst Rev. 2016; 2016 (8): CD004131. DOI: 10.1002/14651858.CD004131.pub3

5. Dai CY, Lu F. Efficacy observation on the treatment of sequelae of cerebral infarction in 46 patients by integrating Chinese with modern medicine. Practical Journal of Integrating Chinese with Modern Medicine. 1997; 10 (1): 438.

6. Chau AC, Cheung RT, Jiang X. Acupuncture of motor-implicated acupoints on subacute stroke patients: an fMRI evaluation study. Med Acupunct. 2009; 21 (4): 233-241.

7. Chow ESL, Lau PMY, Chau RMW. Effectiveness of acupuncture treatment in stroke rehabilitation. Neurorehabil Neural Repair. 2006; 20: 209.

8. Wang H, Xiang Y, Wang C, et al. Effects of trans cutaneous electrical acupoint stimulation on upper-limb impairment after stroke: a randomized, controlled, sin gle-blind trial. Clin Rehabil. 2023; 37 (5): 667-678. DOI: 10.1177/02692155221138916

9. Lee KB, Lim SH, Kim KH, et al. Six-month functional recovery of stroke patients: a multi-time-point study. Int J Rehabil Res. 2015; 38: 173-180.

10. Pollock A, Farmer SE, Brady MC, et al. Interventions for improving upper limb function after stroke. Cochrane Database Syst Rev. 2014; 2014: CD010820. DOI: 10.1002/14651858.CD010820.pub2

11. Coscia M, Wessel MJ, Chaudary U, et al. Neurotechnology-aided interventions for upper limb motor rehabilitation in severe chronic stroke. Brain. 2019; 142: 2182-2197.

12. Hubbard IJ, Parsons MW, Neilson C, Carey LM. Task-specific training: evidence for and translation to clinical practice. Occup Ther Int. 2009; 16: 175-189.

13. Wang H, Arceo R, Chen S, et al. Effectiveness of interventions to improve hand motor function in individuals with moderate to severe stroke: a systematic review protocol. BMJ Open. 2019; 9: e032413.

14. Ng SS, Hui-Chan CW. Transcutaneous electrical stimulation on acupoints combined with task-related training to improve motor function and walking performance in an individual 7 years poststroke: a case study. J Neurol Phys Ther. 2010; 34: 208-213.

15. Alwhaibi RM, Mahmoud NF, Zakaria HM, et al. Therapeutic efficacy of transcutaneous electrical nerve stimulation acupoints on motor and neural recovery of the affected upper extremity in chronic stroke: a sham-controlled randomized clinical trial. Healthcare (Basel). 2021; 9 (5): 614.

16. Francis RP, Johnson MI. The characteristics of acupuncture-like transcutaneous electrical nerve stimulation (acupuncture-like TENS): a literature review. Acupunct Electrother Res. 2011; 36: 231-258.

17. Zhu SP, Luo L, Zhang L, et al. Acupuncture De-qi: from characterization to underlying mechanism. Evid Based Complement Alternat Med. 2013; 2013: 518784.

18. Tang Y, Wang L, He J, et al. Optimal method of electrical stimulation for the treatment of upper limb dysfunction after stroke: a systematic review and Bayesian network meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat. 2021; 17: 2937-2954.

19. Zhang B, Zhu Y, Jiang C, et al. Effects of transcutaneous electrical acupoint stimulation on motor functions and self-care ability in children with cerebral palsy. J Altern Complement Med. 2018; 24: 55-61.

20. Kim YS, Hong JW, Na BJ, et al. The effect of low versus high frequency electrical acupoint stimulation on motor recovery after ischemic stroke by motor evoked potentials study. Am J Chin Med. 2008; 36: 45-54.

21. Zhang WT, Jin Z, Cui GH, et al. Relations between brain network activation and analgesic effect induced by low vs. high frequency electrical acupoint stimulation in different subjects: a functional magnetic resonance imaging study. Brain Res. 2003; 982: 168-178.

22. Hsu SS, Hu MH, Wang YH, et al. Dose-response relation between neuromuscular electrical stimulation and upper-extremity function in patients with stroke. Stroke. 2010; 41: 821-824.

23. Hernández ED, Galeano CP, Barbosa NE, et al. Intra- and interrater reliability of Fugl-Meyer assessment of upper extremity in stroke. J Rehabil Med. 2019; 51: 652-659.

24. Fan E, Ciesla ND, Truong AD, et al. Inter-rater reliability of manual muscle strength testing in ICU survivors and simulated patients. Intensive Care Med. 2010; 36: 1038-1043.

25. Ansari NN, Naghdi S, Mashayekhi M, et al. Intra-rater reliability of the Modified Ashworth Scale (MMAS) in the assessment of upperlimb muscle spasticity. Neurorehabilitation. 2012; 31: 215-222.

26. Duffy L, Gajree S, Langhorne P, et al. Reliability (inter-rater agreement) of the Barthel Index for assessment of stroke survivors: systematic review and meta-analysis. Stroke. 2013; 44: 462-468.

27. Woytowicz EJ, Rietschel JC, Goodman RN, et al. Determining levels of upper extremity movement impairment by applying a cluster analysis to the Fugl-Meyer assessment of the upper extremity in chronic stroke. Arch Phys Med Rehabil. 2017; 98: 456-462.

28. Yang A, Wu HM, Tang JL, Xu L, Yang M, Liu GJ. Acupuncture for stroke rehabilitation. Cochrane Database Syst Rev. 2016; 2016: CD004131. DOI: 10.1002/14651858.CD004131.pub3

29. Laufer Y, Elboim-Gabyzon M. Does sensory transcutaneous electrical stimulation enhance motor recovery following a stroke? A systematic review. Neurorehabil Neural Repair. 2011; 25: 799-809.

30. Ridding MC, Brouwer B, Miles TS, Pitcher JB, Thompson PD. Changes in muscle responses to stimulation of the motor cortex induced by peripheral nerve stimulation in human subjects. Exp Brain Res. 2000; 131: 135-143.

31. Chi YL, Zhang WL, Yang F, et al. Transcutaneous electrical acupoint stimulation for improving postoperative recovery, reducing stress and inflammatory responses in elderly patients undergoing knee surgery. Am J Chin Med. 2019; 47: 1445-1458.

32. Dirks ML, Wall BT, Snijders T, et al. Neuromuscular electrical stimulation prevents muscle disuse atrophy during leg immobilization in humans. Acta Physiol (Oxf). 2014; 210: 628-641.

33. Hu L, Klein JD, Hassounah F, et al. Low-frequency electrical stimulation attenuates muscle atrophy in CKD—a potential treatment strategy. J Am Soc Nephrol. 2015; 26: 626-635.

34. Jiang Y, Hao Y, Zhang Y, et al. Thirty minute transcutaneous electric acupoint stimulation modulates resting state brain activities: a perfusion and BOLD fMRI study. Brain Res. 2012; 1457: 13-25. 35. Qiu X, Zhong X, Zhang H. Applied research on the combination of weighted network and supervised learning in acupoints compatibility. J Healthc Eng. 2021; 2021: 4699420.

36. Guo X, Cheng B. Clinical effects of acupuncture for stroke patients recovery. J Healthc Eng. 2022; 2022: 9962421. DOI: 10.1155/2022/9962421

37. Ishida A, Kobayashi K, Ueda Y, et al. Dynamic interaction between cortico-brainstem pathways during training-induced recovery in stroke model rats. J Neurosci. 2019; 39: 7306-7320. DOI: 10.1523/JNEUROSCI.0649-19.2019

38. Venketasubramanian N, Moorakonda RB, Lu Q, et al. Frequency and clinical impact of serious adverse events on post-stroke recovery with NeuroAiD (MLC601) versus pla cebo: the Chinese medicine NeuroAiD efficacy on stroke recovery study. Cerebrovasc Dis. 2020; 49: 192-199. DOI: 10.1159/000506070

39. Chen S, Wang H, Xu H, et al. Electroacupuncture promotes axonal regrowth by attenuating the myelin-associated inhibitors-induced RhoA/ROCK pathway in cerebral ischemia/reperfusion rats. Brain Res. 2020; 1748: 147075. DOI: 10.1016/j.brainres.2020.147075

40. Ia A, Mn B, Ta C, et al. Acupuncture therapy in trigeminal neuralgia: an integrative literature review. Rev Int Acupuntura. 2020; 14: 111-116. DOI: 10.1016/j.acu.2020.08.002

41. Qyt A, Ran L, Kza B, et al. Can acupuncture therapy reduce preoperative anxiety? A systematic review and meta-analysis. J Integr Med. 2020; 19 (1): 20-28. DOI: 10.1016/j.joim.2020.10.007

42. Martin CS, Deverman SE, Norvell DC, et al. Randomized trial of acupuncture with antiemetics for reducing postoperative nausea in children. Acta Anaesthesiol Scand. 2019; 63: 292-297. DOI: 10.1111/aas.13288

43. Baldo AP, Tardiff JC, Schwartz SD. Mechanochemical function of myosin II: investigation into the recovery stroke and ATP hydrolysis. J Phys Chem B. 2020; 124 (45): 10014-10023. DOI: 10.1021/acs.jpcb.0c05762

44. Yu P, Wang Y, Yuan J, et al. Observation for the effect of rTMS combined with magnetic stimulation at Neiguan (PC6) and Sanyinjiao (SP6) points on limb function after stroke: a study protocol. Medicine (Baltimore). 2020; 99 (38): e22207. DOI: 10.1097/MD.0000000000022207

45. Abduqodirova MB, Khodjibekova YM, Abduqodirov EI. Com prehensive assessment of ultrasound capabilities in diagnosing upper limb tunnel neuropathies. The Bulletin of Contemporary Clinical Medicine. 2025; 18 (2): 7-11. DOI: 10.20969/VSKM.2025.18(2).7-11

46. Khasanov AI, Baykhodjaeva EB, Atavullaev MJ, et al. Pre diction of maxillofacial complications in post-COVID-19 patients, using magnetic resonance imaging. The Bulletin of Contemporary Clinical Medicine. 2025; 18 (2): 75-81. DOI: 10.20969/VSKM.2025.18(2).75-81

47. Jiang T, Wu M, Zhang Z, et al. Electroacupuncture attenuated cerebral ischemic injury and neuroinflammation through α7nAChR-mediated inhibition of NLRP3 inflammasome in stroke rats. Mol Med. 2019; 25 (1): 9. DOI: 10.1186/s10020-019-0091-4

48. Yao S, Liu Y, Cui S, et al. Effect of different frequencies of electroacupuncture on post-stroke dysphagia in mice. J Mol Neurosci. 2020; 70 (11): 1871-1879. DOI: 10.1007/s12031-020-01580-1

49. Du HR, Gong HS. The hand as a homunculus – a perspective from hand acupuncture therapy. J Hand Surg Asian Pac Vol. 2020; 25 (2): 251-255. DOI: 10.1142/S2424835520970012

50. Raffaele S, Gelosa P, Bonfanti E, et al. Microglial vesicles improve post-stroke recovery by preventing immune cell senescence and favoring oligodendrogenesis. Mol Ther. 2021; 29 (4): 1439-1458. DOI: 10.1016/j.ymthe.2020.12.009

 

 

PRACTICAL EXPERIENCE

УДК 616.367-007.27

DOI: 10.2 0969/VSKM.2026.19(5).163-169

PDF download Endoscopic management of choledocholithiasis in altered anatomy and topography of the major duodenal papilla: From technical limitations to functional outcomes

Ilyas M. Saifutdinov1,2

1 Interregional Clinical Diagnostic Center, 12a Karbyshev str., 420089 Kazan, Russia

2 Kazan State Medical Academy – Branch of the Russian Medical Academy of Postgraduate Education, 36 Butlerov str., 420012 Kazan, Russia

Abstract. Introduction. Despite advances in endoscopy, current classifications of complex choledocholithiasis do not recognize the absence of classical visual landmarks of the major duodenal papilla as an independent factor of difficulty. This condition represents a technical barrier for standard cannulation techniques and may be misinterpreted as a contraindication for minimally invasive treatment. The presented clinical case demonstrates a unique scenario of complete absence of mucosal landmarks around the major duodenal papilla orifice in a patient with atypical papilla location. Aim. To evaluate the efficacy and safety of our stepwise protocol for endoscopic retrograde access while preserving the sphincter of Oddi function in patients with altered anatomy and topography of the major duodenal papilla. Materials and Methods. We describe a unique clinical case of an 83-year-old male patient with “functionally invisible” major duodenal papilla characterized by the absence of the longitudinal fold of the intramural common bile duct, the first transverse fold of the duodenum, and biliary flow. Despite these challenges, we successfully applied our patented stepwise papillotomy technique (Patent RF No. 2644307). Results and Discussion. A successful staged endoscopic lithoextraction was performed over two hospitalizations. Four months after papillotomy, during an outpatient duodenoscopy, full anatomical and functional integrity of the sphincter of Oddi was confirmed: the cannulation catheter was surrounded by muscular tissue (no free play), with a coefficient of preservation of the intra-mural common bile duct (Kα) ≥ 70%. Complete clinical remission of mechanical jaundice and cholangitis was achieved. Conclusions. Our findings demonstrate that modern endoscopic technologies can achieve a functional outcome even when classic visual landmarks are absent. We propose introducing “functionally invisible” major duodenal papilla as a new complexity factor into the existing classification systems, which would help standardize management strategies and avoid unnecessary open surgery.

Keywords: choledocholithiasis, functionally invisible major duodenal papilla, endoscopic retrograde cholangiopancreatography, sphincter of Oddi.

For reference: Sayfutdinov IM, Endoscopic management of choledocholithiasis in altered anatomy and topography of the major duodenal papilla: From technical limitations to functional outcomes. The Bulletin of Contemporary Clinical Medicine. 2026; 19(5):163-169. DOI: 10.20969/VSKM.2026.19(5).163-169.

REFERENCES

1. Ардасенов Т. Б., Будзинский С. А., Никонов А. А. Возможности эндоскопических вмешательств в лечении сложных форм холедохолитиаза // Вестник Российского государственного медиц инского университета. – 2010. – № S. – С. 77–78. Ardasenov TB, Budzinskiy SA, Nikonov AA. Vozmozhnosti endoskopicheskikh vmeshatel’stv v lechenii slozhnykh form kholekholelitiaza [Possibilities of endoscopic interventions in the treatment of complex forms of choledocholithiasis]. Vestnik Rossiyskogo gosudarstvennogo meditsinskogo universiteta [Bulletin of the Russian State Medical University]. 2010;(S):77-78. (In Russ.)

2. Будзинский С.А., Шаповальянц С.Г ., Федоров Е.Д. и др. Роль баллонной дилатации области дозированной эндоскопической папиллосфинктеротомии в лечении пациентов со  «сложным» холедохолитиазом // Эндоскопическая хирургия. – 2020. – Т. 26, № 4. – С. 12–21. Budzinskiy SA, Shapoval’yants SG, Fedorov ED, et al. Rol’ ballonnoy dilatatsii oblasti dozirovannoy endoskopicheskoy papillosfinkterotomii v lechenii patsientov so «slozhnym» kholedokholitiazom [Role of balloon dilation after limited endoscopic papillosphincterotomy in patients with difficult bile duct stones]. Endoskopicheskaya khirurgiya [Endoscopic Surgery]. 2020;26(4):12-21. (In Russ.) DOI: 10.17116/endoskop20202604112

3. Kedia P, Tarnasky PR. Endoscopic Management of Complex Biliary Stone Disease. Gastrointest Endosc Clin N Am. 2019;29(2):257-275. DOI: 10.1016/j.giec.2018.11.004

4. Ki HS, Park CH, Jun CH, Park SY, Kim HS, Choi SK, Rew JS. Feasibility of cap-assisted endoscopic retrograde cholangiopancreatography in patients with altered gastrointestinal anatomy. Gut Liver. 2015;9(1):109-112. DOI: 10.5009/gnl13447

5. Wang L, Wang L, Huang N, Li T. Comparison between different advanced cannulation techniques for difficult biliary cannulation: a systematic review with a meta-analysis. Frontiers in Medicine. 2024;11:1344644. DOI: 10.3389/fmed.2024.1344644

6. Sevinç B, Karahan O. The Role Safety Steps in Success and Complication Rate of Endoscopic Retrograde Cholangiopancreatography. Surg Laparosc Endosc Percutan Tech. 2017;27(4):233-236. DOI: 10.1097/SLE.0000000000000427

7. Семенцов К.В., Савченков Д.К., Медведева А.В., Кошелев Т.Е., Гаврикова Е.А. Особенности эндоскопических ретроградных операций на билиарном тракте у пациентов с хирургически изменённой анатомией (состояние после гастрэктомии, резекции желудка по Бильрот-II) // Хирургия: Журнал им. Н.И. Пирогова. – 2025. – № 2. – С. 37–43. Sementsov KV, Savchenkov DK, Medvedeva AV, Koshelev TE, Gavrikova EA. Osobennosti endoskopicheskikh retrogradnykh operatsiy na biliarnom trakte u patsientov s khirurgicheski izmenennoy anatomiyey (sostoyaniye posle gastrektomii, rezektsii zheludka po Bil’rotu-II) [Features of endoscopic retrograde operations on the biliary tract in patients with surgically altered  anatomy (post-gastrectomy state, Billroth II resection)]. Khirurgiya. Zhurnal im. N.I. Pirogova [Pirogov Journal of Surgery]. 2025;(2):37-43. (In Russ.)

8. Chen X, Wang F, Liu J, Tao WH, Zhang Z, Cao TT, Fang J, Zhao Q. Risk factors for adverse events associated with endoscopic retrograde cholangiopancreatography in patients with surgically altered anatomy: a retrospective study. BMC Gastroenterol. 2021;21(1):448. DOI:10.1186/s12876-021-02031-w

9. Park TY, Kang JS, Song TJ, Lee SS, Lee H, Choi JS, Kim HJ, Jang JW. Outcomes of ERCP in Billroth II gastrectomy patients. Gastrointest Endosc. 2016;83(6):1193-1201. PMID: 26546981. DOI: 10.1016/j.gie.2015.10.036

10. Alkarboly T, Gharib DT, Salih KM, et al. Ectopic papilla of Vater in the pylorus presenting with cholangitis: A case report with literature review. International Journal of Surgery Case Reports. 2022;93:106887. DOI: 10.1016/j.ijscr.2022.106887

11. Способ эндоскопического лечения холедохолитиаза и профилактики постманипуляционных осложнений: патент 2644307 Рос. Федерация / И. М. Сайфутдинов [и др.]; заявитель и патентообладатель ГАУЗ МКДЦ. – № 2016145943/14; заявл. 21.11.2016; опубл. 08.02.2018, Бюл. № 4. – 11 с. Saifutdinov IM, Krasilnikov DM, Chugunov AN, Slavin LE, Panasyuk MV. Sposob endoskopicheskogo lecheniya kholedokholitiaza i profilaktiki postmanipulyatsionnykh oslozhneniy: patent 2644307 Ros. Federatsiya. No. 2016145943/14; zayavl. 21.11.2016; opubl. 08.02.2018, Byul. No. 4. [Method for endoscopic treatment of choledocholithiasis and prevention of post-procedural complications: patent 2644307 Russia. No. 2016145943/14]. 11 p. (In Russ.)

12. Сайфутдинов И.М., Красильников Д.М., Чугунов А.Н., Славин Л.Е., Панасюк М.В. Комплексная инструментальная оценка отдалённых результатов транспапиллярных вмешательств у пациентов с холедохолитиазом // Казанский медицинский журнал. – 2025. – Режим доступа: online first. Saifutdinov IM, Krasilnikov DM, Chugunov AN, Slavin LE, Panasyuk MV. Kompleksnaya instrumental’naya otsenka otdalennykh rezul’tatov transpapillyarnykh vmeshatel’stv u patsientov s kholekholelitiazom [Comprehensive instrumental assessment of long-term outcomes of transpapillary interventions in patients with choledocholithiasis]. Kazanskiy meditsinskiy zhurnal [Kazan Medical Journal]. 2025. Available at: online first. (In Russ.) DOI:10.17816/KMJ627110

13. Коваленко В.В., Денисов С.Д., Шестерина Е.К. Развитие большого сосочка двенадцатиперстной кишки человека в эмбриогенезе // Медицинские новости. – 2019. – № 2. – С. 72–76. Kovalenko VV, Denisov SD, Shesterina EK. Razvitiye bol’sho go sosochka dvenadtsatiperstnoy kishki cheloveka v embriogeneze [Development of the major duodenal papilla in human embryogenesis]. Meditsinskiye novosti [Medical News]. 2019;(2):72-76. (In Russ.)

14. Коваленко В.В., Денисов С.Д., Любецкая А.П. Вариантная анатомия большого сосочка двенадцатиперстной кишки человека // Медицинский журнал. – 2016. – № 4. – С. 105–109. Kovalenko VV, Denisov SD, Lyubetskaya AP. Variantnaya anatomiya bol’shogo sosochka dvenadtsatiperstnoy kishki cheloveka [Variant anatomy of the major duodenal papilla in humans]. Meditsinskiy zhurnal [Medical Journal]. 2016;(4):105-109. (In Russ.)

15. Khan A, Ahmad SQ, Akhtar TS, et al. Relationship of difficult endoscopic retrograde cholangiopancreatography cannulation and visual characteristics of papilla. JGH Open. 2024;8(12):e70045. DOI:10.1002/jgh3.70045